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 Abstract  VI 
Abstract 
 
Allograft acceptance in solid organ transplantation might not be determined by mechanisms 
unique to the tolerant state but rather by the balance between the effector and regulatory 
immune response. In consequence, this quantitative view of tolerance implies the existence 
of marginal states, wherein regulatory responses are just insufficient to prevent rejection, or 
in which regulatory responses are just sufficient to prevent rejection but are readily disturbed. 
The presence of low-dose immunosuppression might be supportive in both scenarios and 
thus, allograft acceptance is promoted. This work aims to formally show that marginal states 
of allograft acceptance under low-dose immunosuppression exist and are dependent on 
regulation. Thus, a low-dose Tacrolimus monotherapy was combined with a weak regulation-
inducing protocol in the fully mismatched BALB/c-to-C57BL/6 skin transplantation model.  
 
Orally administered Tacrolimus in doses of 150 mg per kg food was therapeutic and 
prevented allograft rejection when administered before or at the time of transplantation. 
Tacrolimus at 75 mg/kg proved subtherapeutic when administered in monotherapy.  The 
combination of costimulatory blockade with anti-CD154 antibody and a donor-specific 
transfusion (DST) led to moderate prolongation of allograft survival. The combination of anti-
CD154 + DST and Tacrolimus at 75 mg/kg was not more effective than anti-CD154 + DST 
treatment alone, when Tacrolimus therapy was started 7 days prior to transplantation. 
However, when Tacrolimus was introduced seven days post transplantation, a remarkable 
synergism between the induction therapy and the low-dose immunosuppression could be 
observed and allograft survival was significantly enhanced. This finding was supported by in 
vitro T reg suppression assays, where effector T cell division is additionally suppressed in the 
presence of low doses of Tacrolimus.  
 
In line with our hypothesis, it was further demonstrated that in the model of low-dose 
Tacrolimus in combination with weak-regulation induction, allograft acceptance can be 
broken. This was done by 1) withdrawal of immunosuppression, 2) enhancing the effector 
response and 3) disrupting the regulatory response. Thus, it was proven that stable 
immunosuppression in marginal states of allograft acceptance depends upon the balance of 
regulatory and effector responses.  
 
The findings of this work have far-reaching implications for patient management, 
interpretation of immunomonitoring studies and clinical tolerance-induction studies. 
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Zusammenfassung 
Die Akzeptanz eines Transplantats wird möglicherweise nicht durch einzigartige 
Toleranzmechanismen bestimmt, sondern vielmehr durch die Bilanz aus der Effektorantwort 
und der regulatorischen Immunantwort. Diese quantitative Ansicht der Toleranz umfasst 
auch die Existenz von Grenzfällen, wobei die regulatorische Immunantwort gerade nicht 
ausreicht, um die Transplantasabstoßung zu verhindern; oder wobei die regulatorische 
Immunantwort zwar gerade eben ausreicht, die Abstoßung zu verhindern, aber ohne 
weiteres gestört werden kann. Die Gegenwart von niedrig dosierter Immunsuppression kann 
in beiden Szenarien unterstützend wirken und dadurch möglicherweise die Akzeptanz des 
Transplantats vorantreiben. Mit dieser Arbeit soll formell gezeigt werden, dass diese 
Grenzfälle der Transplantatsakzeptanz unter Therapie mit niedrig dosierten 
Immunsuppressiva existieren und dass sie auf Regulation angewiesen sind. Dazu wurde 
eine niedrigdosierte Tacrolimus-Monotherapie mit einen schwach-regulationsinduzierendem 
Protokoll kombiniert und dies im BALB/c-auf-C57BL/6-Hauttransplantationsmodel mit 
vollständiger Gewebemerksmals-Inkompatibilität  angewandt.  
 
Oral verabreichtes Tacrolimus in Dosen zu 150 mg pro kg Futter hatte therapeutische 
Wirkung und verhinderte die Transplantatsabstoßung, wenn die Therapie vor, oder zum 
Zeitpunkt der Transplantation gestartet wurde. Als Monotherapeutikum hatte Tacrolimus in 
Dosen zu 75 mg pro kg Futter keine therapeutische Wirkung. Die Kombination aus 
Kostimulationsblockade mit dem anti-CD154 Antikörper und einer donorspezifischen 
Transfusion (DST) führte zu einer moderaten Verlängerung des Transplantatüberlebens. Die 
Kombination aus der Behandlung anti-CD154 + DST mit 75 mg/kg Tacrolimus zeigte sich 
nicht effektiver als die Behandlung mit anti-CD154 + DST alleine, wenn die 
Tacrolimustherapie sieben Tage vor der Transplantation gestartet wurde. Wenn hingegen die 
Tacrolimustherapie erst sieben Tage nach der Transplantation gestartet wurde, konnte ein 
bemerkenswerter Synergismus zwischen der regulationsinduzierenden Behandlung und der 
niedrig dosierten Immunsuppressionstherapie beobachtet werden, wobei das 
Transplantatüberleben signifikant verbessert wurde. Diese Erkenntnis wurde durch in vitro T 
reg Suppressionsassays bestätigt, wo eine zusätzliche Suppression der Effektor-T-
Zellantwort in Anwesenheit von niedrig dosiertem Tacrolimus beobachtet wurde.  
 
In Übereinstimmung mit unserer Hypothese konnten des Weiteren gezeigt werden, dass die 
Transplantatsakzeptanz im Modell der Kombination von niedrig dosiertem Tacrolimus mit 
einer schwachen Regulationsinduktion zerstört werden kann. Dies geschah durch: 1) Entzug 
der immunusppressiven Therapie, 2) Verstärkung der Effektorantwort oder 3) Abbruch der 
regulatorischen Immunantwort. Damit konnte gezeigt werden, dass die stabile 
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Immunsuppression in oben beschriebenen Grenzfällen der Transplantatsakzeptanz von der 
Bilanz aus der Effektorantwort und der regulatorischen Immunantwort abhängt. 
 
Die Erkenntnisse, die im Rahmen dieser Arbeit gewonnen wurden, haben weitreichende 
Auswirkungen auf das Patientenmanagement, die Interpretation von Studien zur Definierung 
von Biomarkern und klinischen Studien zur Induktion von Toleranz gegenüber dem 
Transplantat. 
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1 Introduction 
1.1 Transplantation – an overview 
Almost 60 years ago, the first successful human kidney transplantation was performed in 
Boston by Joseph E. Murray and colleagues. This event was preceded by the work of half a 
century. Not only did the surgical techniques have to be established in order to transfer 
tissue or organs, but also unforeseen rejection of the grafts between different individuals had 
to be overcome. By transplanting between identical twins, Murray could bypass the latter 
problem. It was the work of several researchers that explained the rejection of grafts. Already 
in 1912, it was described by Georg Schöne that a second set skin transplant fails more 
rapidly than the original rejected one. James B. Murphy showed two years later that lymphoid 
cells were responsible for the destruction of (tumour -) grafts. The same conclusion was 
drawn by Leo Loeb 20 years later, based upon his rat skin transplant model [1]. Sir Peter B. 
Medawar, the “father of transplantation” [2], showed in the mid-1940s with controlled and 
precise experiments on rabbits that skin graft rejection was an immunologic reaction [3]. 
Snell and Gorer identified the major histocompatibility complex (MHC), the genetically 
encoded information responsible for the graft rejection [4]. Strategies to reduce the 
recipients’ immune response were developed in the following years in order to overcome 
rejection. The combination of refined operation techniques and immunosuppressive 
treatment opened the door for transplantation as a widely spread therapy for organ failure 
and dysfunction.   
 
Transplantation is the only curative therapy for end-stage organ failure. This includes end-
stage heart failure [5], end-stage renal disease [6], end-stage liver disease [7] and diabetes 
with end-stage renal failure [8]. By end of June 2013, over 10,000 patients in Germany alone 
were registered on the Eurotransplant waiting list for solid organ transplantation. During the 
first half of the year 2013, a total of 1,622 solid organ transplants have been performed in 
German transplant centres [9]. Despite being a widely-spread live-saving therapy, long-term 
transplant outcomes are not satisfactory and transplantation remains an experimental field.  
 
 
1.2 Terms in transplantation 
Transplantation in general is the transfer of cells, tissue or organs from a donor to a recipient. 
In autotransplantation, the donor himself is also the recipient; this for example may be the 
case in skin transplantation to treat burn. If the recipient is another individual than the donor, 
the term allotransplantation is used. Here we discriminate three different possibilities: 
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Syngeneic transplantation describes the transfer of cells, tissue or organs (then called 
syngraft or isograft) between genetically identical individuals, in humans, this only refers to 
transplantation between monozygotic twins. Allogeneic transplantation (of an allograft or 
homograft) is the transfer of cells, tissue or organs between genetically distinct members of 
the same species. Xenotransplantation is the term used for the transfer of a xenograft 
between members of two different species.  
 
1.3 Basic concepts 
1.3.1 T cell activation 
1.3.1.1 TCR signalling  
In the 1980’s, the structure of the antigen receptor on T cells was characterised [10,11]. The 
αβ-T cell receptor (TCR) consists of an α and a β chain, that form a heterodimer. The αβ 
heterodimer forms a TCR complex with the noncovalently associated CD3 and ζ proteins 
upon binding MHC–peptide complexes [12] (Figure 1).  
 
                                               
ZAP70
NFAT AP1
DAG MAPK
IL-2
TCR:CD3:ζ
complex
CN
NFkB
PLC-γ
CD4/
CD8
Lck
ERK
PKC
 
Figure 1: Activation of T cells, adapted from Janeway’s Immunobiology [275] 
 
The CD3 and ζ chains contain ITAMs (immunoglobulin receptor family tyrosine-based 
activation motif) that are essential for the intracellular signalling. The TCR complex clusters 
with a co-receptor (either CD4 or CD8), thus, the co-receptor associated protein tyrosine 
kinase Lck phosphorylates the ITAMs in the CD3 and ζ chains. This leads to binding and 
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activation of the intracellular protein tyrosine kinase ZAP-70, which phosphorylates several 
other cytoplasmic molecules, including LAT (Linker for Activation of T-Cells) and  SLP-76 
[13]. Thus, several signalling pathways are activated, such as MAP – kinase pathways, a 
PLCγ1-calcium - dependent pathway and a Diacylglycerol (DAG) – pathway. These 
pathways lead to activation of Extracellular-signal Regulated kinases (ERK) or Janus kinase 
(JAK), Calcineurin (CN) and enzyme protein kinase C (PKC), respectively. This leads to the 
activation of transcription factors such as NF-AT, NFκB or AP-1. These factors are 
responsible for the expression of genes required for proliferation, differentiation and effector 
functions of  T cells [14,15].                                       
1.3.1.2 Costimulation 
For a functional T cell response, a second activation signal, besides TCR ligation, is 
necessary. This is transduced by so-called costimulatory molecules [15]. Costimulatory 
molecules can be grouped into the CD28/B7 family and the tumour necrosis factor (TNF) 
family. CD28 binds to the B7 molecules CD80 and CD86 on antigen – presenting cells 
(APCs) [16]. CD28 signalling pathways via phosphatidylinositol 3-kinase (PI3K) amplify TCR 
signalling pathways [15],  and blocking the CD28 signalling whilst TCR signalling is present 
leads to anergy [17]. The inducible costimulatory molecule (ICOS) is a CD28 homolog that 
binds to B7h and seems to be important in effector cell differentiation [18]. The CD28/B7 
family also includes negative costimulatory (i.e. coinhibitory) molecules such as CTLA and 
PD-L1. Both have been described as part of the suppressive mechanism of regulatory T cells 
[19,20]. Members of the TNF / TNFR – family of costimulatory molecules are, amongst 
others, CD40L (CD154), OX40, 4-1BB (CD137) and GITR. Since costimulatory molecules of 
the TNF – family are in general expressed upon activation, they may play a role in effector 
and memory responses rather than in naïve T cell responses [18]. Blockade of different 
costimulatory pathways in animal models of transplantation has been proven to be 
successful in prolongation of allograft survival [21]. Further, antibodies against costimulatory 
moleculed are in use or, considered to be, in the clinic. 
 
1.3.2 T cell specification 
The vast majority of T cells express the αβ-TCR. These cells comprise two lineages which 
are defined by their ability to bind distinct major histocompatibility complexes (MHC). They 
express either the MHC-class I – binding protein CD8 or the MHC-class II – binding protein 
CD4. With regard to their functional task within the immune response, they are also referred 
to as cytotoxic CD8+ cells, and helper or regulatory CD4+ cells [22]. A T cell that has not yet 
encountered antigen is called “naïve”; after activation, T cells proliferate and can differentiate 
into effector T cells. CD8+ cells can differentiate into cytotoxic lymphocytes (CTL) which 
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mainly kill infected cells and contribute in allograft rejection. There are several distinct 
subsets of effector CD4+ cells, mainly TH1, TH2 and TH17 helper T cells and regulatory T cells 
(T reg). Differentiation into a distinct subset occurs in response to the present cytokine milieu 
and involves both transcriptional activation and epigenetic modification of target genes [23] 
(Figure 2). Each of these subsets has a special cytokine profile and expresses specific 
transcription factors [24].  
 
                         
Th0
Naive CD4+ T cell
T reg
TGF-β, RA
Th17
TGF-β, IL-6, IL-23
Th1
IL-12, 
IL-2
Th2
IL-4,  
IL-2
Tbet
STAT-1 
STAT-4
GATA-3
STAT-5
FoxP3 ,STAT-5 RORγt, STAT-3
IL-10, TGF-β IL-17, IL-21, IL-22
IFN-γ, 
TNF
IL-4, 
IL-5, 
IL-13
 
Figure 2 T cell polarisation 
 
 
During the last years, there is increasing evidence that the differentiation into different T cell 
subsets is not terminal. In in vitro and in vivo studies, a T cell plasticity within and between 
the helper and regulatory cell subsets could be shown [23].  
                             
1.4 Allorecognition 
The underlying genetic basis of graft rejection after allogeneic transplantation (or 
allotransplantation) was studied in the 1940s by Snell and Gorer. Using congenic inbred 
mouse strains, one region in the genome could be identified that was responsible for 
rejection of an allograft, the major histocompatibility locus, named H-2. Later it was found 
that the locus consists of multiple genes; therefore it was named major histocompatibility 
complex (MHC) [4]. The MHC in human was called human leukocyte antigen (HLA). The 
genes of the MHC code for the antigen-presenting MHC molecules, of which there are two 
classes: MHC class I and class II; respectively. There is also a third class of MHC genes 
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(MHC class III) that encode complement proteins or cytokines such as TNFα, but not all are 
involved in immune funtions. The MHC class I and II molecules serve the same process, 
which is antigen presentation to T cells. Without processed antigen being presented to them 
in MHC context (together with costimulation), T cells cannot be activated.  MHC class I 
molecules present antigenic peptides of intracellular origin to CD8+ T cells, whereas CD4+ T 
cells recognize exogenous antigens presented on MHC class II molecules (Figure 3).  
 
                              
Ag
ER
Cytosol
MHC Class I
ER
MHC Class II
Ag
 
Figure 3 Major histocompatibility complex: antigen presentation, adapted from Janeway’s Immunobiology [275] 
 
Every nucleated cell type expresses MHC class I molecules, but the expression of MHC 
class II molecules is generally limited to antigen-presenting cells (APC), though it can be 
induced in other cells such as endothelial cells or fibroblasts [25]. 
 
The ability of individual organisms to discriminate self- from non-self-antigens is known as 
allorecognition. It describes the process of recipient cells recognizing foreign antigen 
presented on a MHC, as it inevitably happens in allo- and xenotransplantation. During 
development in the thymus, T cells undergo positive and negative selection. T cells that bind 
with too high affinity to self-MHC, or do not bind to self-MHC will be deleted. The T cell 
repertoire is then tolerant towards self-antigens, but recognizes non-self antigens. So far, 
three different pathways of allorecognition have been described: 1) direct, 2) indirect and 3) 
semidirect allorecognition.  
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1.4.1 Direct Allorecognition  
The process of recipient T cells recognizing antigen presented via intact donor MHC on 
donor APC (here: dDC) is termed direct allorecognition (Figure 4).  
 
                                         
dDC
T cell help
CD4
CD8
 
Figure 4 Direct allorecognition 
 
 
Two theories have been brought up to explain the underlying mechanisms of the interaction 
between host T cell receptor (TCR) and donor MHC: the “high determinant density” model 
and the model of “multiple binary complexes” [26,27]. Briefly, the former theory holds it that 
the T cells can directly recognize the allogeneic MHC itself and not only peptides bound to 
the MHC [26-28]. In consequence, the density of ligands for alloreactive T cells is very high 
in opposition to the density of peptide-specific ligands. Therefore, T cells with low-affinity 
receptors are also able to respond to foreign MHC, which leads to the high incidence of 
alloreactivity observed. The second theory of “multiple binary complexes” suggests that the 
complex of a variety of bound peptides together with an allogeneic MHC is recognized by 
alloreactive T cells. Subsequently, a single MHC molecule can stimulate many different 
alloreactive T cells [29,30]. Both theories are not mutually exclusive and may account for the 
high incidence (up to 7%) of alloreactive T cells described in the literature [31]. It has been 
proposed that in the case of structurally different MHC molecules between donor and 
recipient, the alloreactivity is directed against the MHC itself (“high determinant density”), 
whereas the alloreactivity against the peptides in an allogeneic MHC complex (“multiple 
binary complexes”) may be predominant when the MHC molecules do not differ substantially 
[32].  
 
Experimental proof of the participation of direct allorecognition in rejection has been given by 
depleting the graft of donor APC prior to transplantation. This leads to prolonged allograft 
survival [33], yet is eventually not sufficient to prevent rejection (see below). Since the intact 
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donor APC that must be present in the graft and host to elicit direct allorecognition, will be 
eliminated by the host’s immune response, the contribution of this pathway is temporarily 
limited.  
 
1.4.2 Indirect Allorecognition  
T cells can also recognize donor histocompatibility antigen that is processed and presented 
by self-MHC (here: rDC) molecules; which is referred to as the indirect pathway of 
allorecognition (Figure 5).  
 
                             
dDC
rDC
Antigen
CD4
 
Figure 5 Indirect allorecognition 
 
The processing of peptides derived from donor MHC molecules is a common event [34,35]. 
This occurs when apoptotic donor cells are taken up by host antigen-presenting cells. 
Additionally, the peptides can be shed from the surface of donor cells (here, a dDC is shown 
as an example). The existence of an indirect way of alloantigen presentation came into focus 
in a rat transplantation model. Here, after depletion of passenger donor APC in the graft, 
rejection did eventually occur [36]. The importance of this second pathway of allorecognition 
was demonstrated by Auchincloss et al. in a skin transplantation model. CD8+- depleted mice 
without MHC class I molecules were able to reject a MHC class II deficient skin graft via a 
CD4+ response. Since CD4+ cells do not interact with MHC class I molecules (the remaining 
MHC class in the graft), the donor antigens must have been presented by host MHC class II 
[37].  
 
This aforementioned data proves the sufficiency of an indirect allorecognition to cause graft 
rejection in the absence of direct allorecognition. Host dendritic cells are constantly trafficking 
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in the body and also in the graft itself, which expresses donor MHC molecules. Therefore, 
indirect allorecognition that can occur every time after transplantation may mount an immune 
response leading to rejection. Thus, the indirect pathway is probably the dominant way of 
allorecognition in the long term. 
1.4.3 Semi-direct Allorecognition  
Experimental data indicated that T cells with indirect allospecifity can amplify or suppress T 
cells with direct allospecifity [38-40]. This phenomenon has been first explained by a four- 
cell, unlinked, model: CD4+ helper or suppressor T cells interact via the indirect pathway with 
recipient DC, whereas CD8+ cells directly recognize donor cells. Work of several groups 
showed the ability of DC to acquire intact MHC molecules from other cells in vitro, which was 
then further investigated by Herrera in vivo [41]. A third pathway of allorecognition was 
described then, the semi-direct allorecognition (Figure 6).  
 
                
dDC
rDC
Antigen
2
CD4
CD8
T cell help
1
 
Figure 6 Semidirect allorecognition 
 
Semi-direct allorecognition refers to direct pathway T cells recognizing intact, allogeneic 
MHC:peptide complexes that have been transferred from donor cells to recipients DC and 
are presented on their surface. Additionally, indirect pathway can recognize donor peptides 
that were internalised and are presented via the MHC class II on the same DC. 
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1.5 Rejection 
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Figure 7 Rejection of an allograft 
 
1.5.1 Hyperacute rejection 
Hyperacute graft rejection occurs usually within minutes after transplantation, when 
preformed recipient antibodies bind to donor endothelial ABO or major histocompatibility 
(MHC) antigens. This can activate the complement cascade or mediate antibody-dependent 
cellular toxicity (ADCC), leading to damage of endothelial cells, culminating in intra-vascular 
thrombosis and tissue injury [42,43]. Hyperacute rejection inevitably leads to allograft loss, 
but occurs nowadays rarely due to pre-transplant bloodtyping and T cell crossmatch testing 
[44]. Hyperacute rejection also prevents interspecies transplantation (Xenotransplantation). 
 
1.5.2 Acute rejection 
Acute rejection occurs usually within days or weeks after transplantation. Even when the 
recipient receives immunosuppressive treatment, acute rejection episodes can occur 
repeatedly. Acute rejection can be cellularly (lymphocytes) or humorally (antibody) mediated. 
Every transplantation leads inevitably to tissue damage and thus to activation of the innate 
immune system. Innate immune cells such as neutrophils, macrophages and natural-killer 
cells (NK cells) express pattern recognition receptors (PRR) which recognize damage-
associated molecular pattern molecules (DAMP) [45,46]. This antigen-independent 
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inflammatory response can promote further injury, e.g. caused by the production of tissue-
damaging molecules such as reactive oxygen species (ROS) or nitric oxide (NO) [47]. The 
cells of the innate immune system produce cytokines, such as IFNγ, IL-6 or IL-12, leading to 
the activation of the adaptive immune system [48,49]. Work by Chalasani et al. indicated that 
the innate immune response towards the graft is necessary for an effective adaptive, 
antigen- dependent, immunity [50]. Dendritic cells (DCs) are considered to be the link 
between innate and adaptive immunity [51]. Immature DCs traffick through non-inflamed 
tissues, but exert immunogenic effects, when they receive a maturation signal. This can be 
provided by DAMPs following transplantation. Activated DCs migrate to the lymphoid tissue, 
presenting antigen to T cells, stimulating the adaptive antigen response [52]. There is also 
data demonstrating the influence of chemoattractants from neutrophils and macrophages on 
the optimal recruitment of T cells to the allograft [53].  
 
Among the infiltrating cells in an acutely rejected allograft, T cells indeed build up the largest 
population [54,55]. Based mainly on experience from animal experiments, acute rejection is 
seen predominantly as a T cell mediated process. Athymic or neonatally thymectomized 
mice fail to reject MHC-mismatched skin grafts unless reconstituted with T cells from 
untreated syngeneic wildtype mice, after which the transplants will be rejected rapidly. T cells 
contribute to graft rejection in various ways after activation [56,57]. The release of 
proinflammatory cytokines (IL-1, IFNγ, TNF) triggers further graft infiltration by macrophages, 
monocytes, eosinophils and others, which promotes additional antigen-independent 
cytotoxicity. But also T cells, mostly MHC class I restricted CD8+ T cells, can secrete 
cytotoxic molecules thus inducing apoptosis of the target cells. Cytotoxic T cells lyse target 
cells via two distinct mechanisms, the perforin/granzyme pathway or the Fas/FasL pathway 
[58]. It could be shown that CD4+ T cells, but not CD8+ T cells are essentially required to 
initiate rejection of an allograft [59]. CD4+ T cells, mostly TH1 helper cells, mediate delayed-
type hypersensitivity responses (DTH) in an antigen-specific manner [60].  
 
Activated CD4+-T cells can also provide B cell help by cytokine production and expression of 
costimulatory molecules. B cells can act as APC for T cells, secrete inflammatory cytokines / 
chemokines and produce alloantibodies [61,62]. B cell infiltration was reported in acute 
rejection episodes of human kidney, liver and heart [61,63-65]. Studies on B cell-deficient 
µMT mice were performed, showing that B cells and antibodies are not required for acute 
rejection [66-68]. However, there is data indicating a significant role of B cells in acute 
rejection. Impaired indirect alloantigen presentation by B cells was followed by reduced 
antibody production and CD4+-T cell division in murine cardiac transplantation [61]. Depletion 
of B cells using the anti-CD19 or anti-CD20 antibodies aggravated or ameliorated rejection 
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depending on the organ transplanted and the intensity of the rejection [69]. Further, 
antibodies produced by B cells can induce complement and therefore lysis of graft cells. If 
the Fc receptor on NK cells or macrophages recognizes antibodies, this can lead to antibody 
mediated cellular cytotoxicity (ADCC) mounting in apoptosis of the graft cells. The 
aforementioned effector mechanisms of cytotoxicity, DTH, Lysis and ADCC will then lead to 
a rapid rejection of the transplanted tissue.  
 
1.5.3 Chronic Rejection 
Chronic rejection refers to chronic allograft injury mediated by immunologic factors in 
contrast to other mechanisms such as drugs, ageing or infection. The chronically rejecting 
organ displays vasculopathy with distinct histologic injury depending on the type of solid 
organ [70,71], leading to diminished function and eventually loss of the organ. In general, 
chronic rejection is influenced by both alloantigen-dependent and alloantigen-independent 
mechanisms [70]. A rat kidney-retransplantation model established by Tullius et al. [72] 
demonstrated that early immunohistological changes in the chronic rejected allograft during 
the first 12 weeks are predominantly antigen-dependent and can be reversed by 
retransplantation back to the donor strain. In later retransplanted isografts, fibrotic injury 
continued to progress and even isografts did display immunohistological alterations similar to 
chronic rejection [73], indicating that late events in chronic rejection are antigen-independent. 
 
Grafts undergoing chronic rejection display perivascular inflammation and fibrosis [74,75]. 
The pathognomonic lesion in chronic rejection is obliterative arteriopathy (OA), caused by 
fibrointimal hyperplasia [71]. The initial damage of endothelium and exposure of collagen 
causes repair mechanism involving fibrin and other clotting proteins and platelets [70,71,76]. 
Various factors such as platelet activating factors (PAF), platelet-derived growth factor 
(PDGF), tumour necrosis factor (TNF), leukotrienes and thromboxane are released, which 
can also lead to induced proliferation and migration of smooth muscle cells (SMC) [76-78]. 
The endothelial activation comes together with the upregulation of MHC II and adhesion 
molecules, supporting the infiltration of leukocytes [79-82]. The microscopic picture in the 
initial stage in rodents shows that monocytes/macrophages and T cells are predominant, but 
also eosinophils, plasma cells, DCs, B cells and mast cells were found [75,76,83-86]. T cells 
and macrophages build the arterial inflammatory response, with the lymphocytes attached to 
the intima and the macrophages permeating adventitia, media and intima of the vessel 
[71,79,86,87].  At this stage, cytokines such as tissue growth factor beta (TGF-β),  interferon-
γ (IFN γ), IL-1 and tumour necrosis factor (TNF) are expressed in the graft, as well as the 
chemoattractants RANTES (CCL5) and monocyte chemotactic protein-1 (MCP-1) [83,84,88]. 
This leads to further attraction of macrophages/monocytes and T cells, that in turn produce 
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more cytokines and chemoattractants. PDGF, released by endothelial cells, SMC, platelets 
and activated macrophages, and TNF, released predominantly by activated macrophages, 
stimulate the proliferation of SMC and their release of extracellular matrix proteins [76,89,90]. 
TGFβ activates extracellular matrix deposition and is expressed in grafts undergoing chronic 
rejection [70,91,92]. It has been demonstrated that TGFβ contributes to fibrosis, e.g. by 
upregulating connective tissue growth factor (CTGF) in fibroblasts and SMC, which has 
mitogenic effects on fibroblasts [93,94]. Häyry [95] communicates following hypothesis that is 
supported by many data including the above mentioned: SMC replicate in autocrine or 
paracrine response to the cytokines and growth factors. Extracellular matrix expressing 
metalloproteinases and proteolytic enzymes contribute to the migration of SMC to the intima, 
where they start remodelling the vascular wall. This leads to arterial narrowing and occlusion 
of small vessels, followed by damage of the surrounding tissue due to ischemia and fibrotic 
changes.      
 
1.6 Regulatory immune cells in Transplantation  
Whenever there is an activation of the immune system, i.e. an inflammatory process, there is 
also a regulatory response to control inflammation and thus prevent the host organism from 
damage. This is also true in transplantation. Indeed, the immune cell populations leading to 
rejection of an allograft also harbour regulatory cells that can suppress the effector response. 
These specialised cells either underwent selection processes for regulatory function or were 
driven into a regulatory phenotype on site (of the allograft). Other mechanisms to regulate 
the immune response are: ignorance, anergy and deletion [96]. Ignorance simply refers to T 
cells ignoring antigen, either because T cells cannot enter the sites where the antigens are 
expressed (immuno-priviledged sites) or because the antigen signal does not overcome the 
threshold to lead to a T cell response. T cells can also be rendered anergic, i.e. non-
responding to further stimulation. This happens when the TCR is stimulated without 
adequate costimulation and signalling through alternative receptors occurs. Deletion of T 
cells does not only take place in the thymus (central deletion), but also in the periphery. 
Antigen-reactive T cells can be depleted by activation-induced cell death (AICD) upon 
restimulation of the TCR with signalling through other receptors such as Fas. This might 
occur in CD8+ T cells that are activated without CD4+ T cell – help [96,97].  
  
In their ground-breaking publication in 1953, Billingham, Brent and Medawar already 
suggested that leukocytes able to suppress allospecific immune responses do exist [98]. 
Since then, different regulatory cell populations have been reported, such as regulatory T 
cells, B cells and macrophages, tolerogenic DCs and myeloid-derived suppressor cells 
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(MDSCs). The presence of these cells in a transplant recipient can promote acceptance of 
the allograft.  
 
1.6.1 Regulatory T cells  
Various T cell populations with regulatory function in transplantation have been discovered, 
including CD4+, CD8+ and CD4-CD8- regulatory T cells (Figure 8).  
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Figure 8 Regulatory T cell subsets 
 
1.6.1.1 CD4+ regulatory T cells 
Naturally occurring, thymus-derived  CD4+ regulatory T cells (T regs) form a self-renewing, 
actively dividing and differentiated population and maintain tolerance in the periphery, mainly 
against self-antigens [97]. They are characterised as CD4+CD25+FoxP3+ cells, as well as the 
population of induced T regs. In mice, FoxP3 is expressed exclusively on T cells and it is 
necessarily and sufficiently responsible for suppressive function in CD4+ T regs [99-101]. In 
addition, T regs constitutively express high levels of the costimulatory molecule 
glucocorticoid-induced tumor necrosis factor receptor (GITR) [102]. GITR is described to 
enhance proliferation of both T regs and effector T cells [103]. Altogether, induction of GITR 
signalling has been shown to abrogate T reg suppression [104].  
 
FoxP3+ T regs highly express both PD-1 (programmed death receptor) and PD-L1 
(programmed death receptor – ligand 1), a major coinhibitory receptor - ligand team [105]. 
PD-L1 was found to have a major role in the induction and maintenance of induced T regs, 
thus promoting tolerance [20]. Induced T regs are CD4+ T cells that inducibly express FoxP3 
and differentiate after encountering antigen in a tolerogenic microenvironment, thus are 
converted from potential effector T cells. Both naturally occurring and induced T regs can 
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respond to alloantigens in a graft-protecting way. Thymus-derived T reg might be 
predominantly present in the initial period after transplantation, later, induced T regs probably 
play a more important role [106,107].  
 
T regs (thymus-derived and induced) suppress proliferation and / or activation of naïve and 
memory CD4+ and CD8+ effector T cells, B cells, and the function of NK cells, macrophages 
and DCs [108,109]. They can exert their effects via cell-contact dependent mechanisms. Via 
binding of the cytotoxic T lymphocyte antigen 4 (CTLA4), a receptor constitutively expressed 
on T regs, to the costimulatory molecules CD80 and CD86 on DCs, their activity can be 
inhibited [110]. Further, this can induce the production of the enzyme indoleamine 2,3-
dioxygenase (IDO) by DCs, which, due to tryptophan deprivation, leads to attenuated T cell 
proliferation [108]. T regs themselves produce cytokines such as IL-10 and TGFβ. 
Interleukin-10 is an anti-inflammatory cytokine produced by many cells of the adaptive and 
innate immune system. In in vivo models of inflammatory bowel disease and transplantation, 
blockade or absence of IL-10 prevents T reg – mediated regulation [111,112]. TGFβ is a 
cytokine that is important for the development of induced T regs and in fact might be 
produced in part in an autocrine fashion [113]. It can be also expressed on the cell surface of 
activated T regs. TGFβ produced by T regs can inhibit the activation of effector T cells [114]. 
Another, more recently described, mechanism of suppression by T regs could be by IL-35 
secretion [115]. However, the roles of these cytokines as suppressor mechanism is not 
completely clear, since in vitro data is often controversial [116]. Other mechanisms that have 
been described are cytotoxic activity of T regs via granzyme B and perforin [117] or 
apoptosis – inducement due to IL-2 depriviation [118].  
 
In addition to T regs (thymus-derived and induced), other CD4+ regulatory T cells have been 
described, such as TR1 cells. These are distinct peripherally induced regulatory T cells that 
are negative for FoxP3 - expression, develop in response to IL-10 and can secrete IL-10 and 
TGFβ [119]. Further, TGFβ – producing TH3 cells have been described [116]. 
 
1.6.1.2 CD8+ regulatory T cells 
CD8+CD28- have been described in human kidney transplant patients after leukocyte 
depletion treatment. They use cell contact mechanisms to inhibit T cell activation via APCs  
and seem to be a distinct subset from a IL-10-producing CD8+ T cell population [107]. The 
latter can be generated in vitro and can inhibit T cell responses through IL-10.  
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1.6.1.3 CD4-CD8- regulatory T cells 
Cells that express CD3 and the αβ-TCR, but neither CD4 nor CD8 (or the NK cell marker 
NK1.1) are so-called double-negative T cells. This immunosuppressive population has been 
first described in a mouse skin transplantation model, where graft survival could be 
enhanced. The suppressive mechanism shown was cell-contact - and Fas – dependent 
killing of CD8+ cytotoxic T cells [120]. This cell population has also been described in animal 
models of diabetes and graft-versus-host-disease and could be isolated from human blood. 
In further experiments, double-negative regulatory T cells also had suppressive effects on 
CD4+ T cells, B cells, and APCs [121]. 
 
1.6.2 Regulatory B cells  
B cells in transplantation may have more than an antibody-producing role. Regulatory B cells 
secreting IL-10 have been described as immunosuppressive in models of autoimmunity such 
as experimental autoimmune encephalomyelitis (EAE), IBD, arthritis and diabetes [122]. 
Further, they were also detectable in human patients [123]. B regs have been described to 
induce populations of regulatory T cells in animal models of colitis and EAE [124]. CD40 and 
CD80/86 engagement is necessary for the establishment and/or function of B regs [125]. In a 
mouse transplantation model, hindered IL-10 production of regulatory B cells does not 
interfere with tolerance induction. It rather is suggested to be dependent on direct interaction 
between B cells and target cells [126]. In human kidney transplant patients after CD52 – 
(lymphocyte / monocyte) depletion, the repopulating B cells had B reg and transitional B cell 
phenotypes [127]. Transitional B cells are poor costimulators and thus may lead to T cell 
unresponsiveness [128]. Interestingly, the presence of naïve and transitional B cells after 
transplantation is associated with a positive outcome and a B cell gene signature was 
described in immunosuppressive-free patients with maintained graft function (operationally 
tolerant). Such B cell related gene markers were Cd20, Ms4-a1 and Fcrl1 [129,130]. 
 
1.6.3 Regulatory macrophages 
Macrophages are activated quickly upon tissue damage as it occurs in transplantation, as 
already mentioned earlier. But macrophages do not only promote graft damage, they can 
also contribute in wound healing. Macrophages are often classified into two groups, the 
classically activated M1 – macrophages and the alternatively activated M2 – macrophages 
[131]. Further, regulatory macrophages have been described. Genome microarray studies on 
M regs induced in vitro from mouse and human monocytes show that these macrophages 
have a gene expression profile different from M1 and M2 polarised macrophages 
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[132](Hutchinson, unpublished data). Markers for these mouse M regs are typical 
macrophage – markers such as CD11b, F4/80, CD68 and CD14. Further these M regs 
express only intermediate levels of MHC II and low levels of costimulatory molecules CD80, 
CD86 and CD40. Further, they express PD-L1 and CD11c [132]. A variety of different stimuli 
has been shown to induce suppressive function of macrophages. Amongst these are M-CSF, 
IL-10, vitamin D, IFNγ, immune complexes and repetitive TLR stimulation, reviewed in [133]. 
Thus, no unique phenotype can be described for suppressor macrophages. IL-10 secretion 
may be one mode of action of regulatory macrophages [134]. Further, production of iNOS in 
mouse M regs or IDO in human M regs, has been described [132](Hutchinson, unpublished 
data). By these means, M regs may directly inhibit activation and proliferation of effector T 
cells. In addition, this leads to a microenvironment that can promote induction of regulatory T 
cells (Walter, unpublished data). M regs have already been used as cell therapy in kidney 
transplant patients [135], and interestingly, these two patients are maintained on additional 
immunosuppressive therapy at unexpectedly low doses. 
 
1.6.4 Tolerogenic DCs 
Mature dendritic cells can efficiently activate T cells and improve memory T cell responses. 
In steady state conditions, DC found in the peripheral lymphoid tissue are not fully mature. In 
order to achieve immunity, the antigen needs to be coadministered with a maturation 
stimulus [136]. If the antigen is delivered without a maturation signal, the immature DCs will 
engage T cells, but this lead to unresponsiveness [137]. It has also been shown that injection 
of ex vivo antigen.pulsed DC under the absence of maturation signals leads to 
downregulation of the immune response and induction of T regs [138]. Further, DCs might 
promote tolerance in response to tolerogenic signals such as IL-10 and TGFβ or to signals 
coming from T regs [109,139]. As already mentioned previously, IDO is one of the 
mechanism by which tolerogenic DCs can suppress T cell responses [139]. In addition, 
tolerogenic DCs inhibit T cells via IL-10 or heme oxygenase 1 (HO-1) [140,141]. Immature 
myeloid tolerogenic DCs can promote allograft acceptance in solid organ transplantations 
[142]. It has also been described that the population of plasmacytoid DCs (pDCs) which 
express more PD-L1 correlate with increased numbers of T regs in liver transplant patients 
[143].  This induction of T regs by pDCs has also been observed in animal models of 
transplantation [144].  
 
1.6.5 Myeloid - derived suppressor cells (MDSCs) 
MDSCs are a heterogeneous population of myeloid progenitor cells present in tissues during 
inflammation. They were first described in cancer patients, and now their 
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immunosuppressive function has been acknowledged in other diseases and transplantation     
[145]. Several subsets of MDSCs have been defined in both human and mouse. Common 
phenotypical markers of mouse MDSC subsets are expression of CD11b and Gr1 [146]. 
Activated T cells, stromal cells and, in cancer, tumour cells produce factors such as 
macrophage–colony stimulating factor (M-CSF), granulocyte-macrophage-CSF (GM-CSF), 
IL-6 or prostaglandins that regulate expansion and activation of MDSCs [146]. Upon 
activation, MDSCs can inhibit T and B cell responses by production of iNOS and arginase 1 
[147,148]. Release of reactive oxygen species (ROS) is also part of the suppressive function 
of MDSCs [145]. In a murine skin transplantation model, MDSCs producing IL-10 and HO-1 
did prolong allograft survival  [149]. It has been shown that MDSCs can induce T regs [150] 
and in murine islet transplantation, this enhancement is mediated by expression of PD-L1 
[151].    
 
1.7 Immunosuppressive treatment in Transplantation 
1.7.1 Overview 
The first drugs successfully used to prevent acute rejection in transplantation between non-
identical individuals were steroids (cortisone) and Azathioprine, a chemotherapy drug found 
to be effective in kidney transplantation in the early 1960s [152]. Azathioprine inhibits de 
novo purine synthesis and has an anti-proliferative effect on T and B lymphocytes [153]. The 
immunosuppressive therapy in transplantation could be expanded years later when the 
calcineurin-inhibitor Cyclosporine was introduced in the clinic in 1978 [154]. Thus, the one 
year survival time of an allograft increased dramatically [155]. In the following, more 
immunosuppressive drugs have been introduced into transplantation. In 1982, the type 2 
isoform inosine 5'-monophosphate dehydrogenase (IMPDH) inhibitor mycophenolate mofetil 
(MMF) was developed. Studies showed that MMF is, in contrast to Azathioprine, more 
lymphocyte-specific and more effective in preventing graft rejection [156,157]. Thus, and 
because it is effective in combination with other immunosuppressants, MMF has largely 
replaced Azathioprine in the clinic [158].  
 
In 1986, a new calcineurin-inhibitor (CNI) called Tacrolimus, was discovered and found to be 
more potent than Cyclosporine. The mechanisms of action of CNI will be discussed below. In 
1989, the immunosuppressive properties of Rapamycin (Sirolimus), a microbial product with 
structural similarity to Tacrolimus, were further tested in transplantation models [159]. 
Rapamycin binds the same protein as Tacrolimus, but does not inhibit calcineurin. It acts on 
the mammalian target of Rapamycin (mTOR), thus leads to cell-cycle arrest in T cells [160].  
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In general, immunosuppressive therapy includes glucocorticoids and small-molecule 
immunosuppressive drugs as the drugs mentioned above. A third group are protein 
immunosuppressive drugs including fusion proteins such as CTLA-4-Ig, depleting antibodies 
and non-depleting antibodies [158].  
 
Antibodies as induction therapy have been used since the early 1980’s. Anti-Thymocyte 
globulin (ATG) and Campath-1H (Alemtuzumab) are widely used antibodies depleting T and 
B cells (and the latter to a lesser extend NK cells, monocytes and macrophages). Basiliximab 
is a non-depleting anti-IL2R antibody inhibiting lymphocyte proliferation. Further protein 
immunsuppressive drugs are developed (e.g. non-depleting CD40L antibodies ASKP1240 or 
4D11) or in use (e.g. CTLA4-Ig) for blockade of the costimulatory CD40/CD40L or the 
CD28/CD80/CD86 pathways [21].  
 
The common therapy protocol in transplantation includes an antibody such as Basiliximab 
with higher doses of CNI in the induction phase with an additional anti-proliferative drug 
(MMF) and tapered steroids. The maintenance phase then is based mostly on the CNI, with 
possible addition of MMF or Rapamycin to reduce CNI doses and toxicity [161,162]. Since 
CNIs as Cyclosporine and Tacrolimus are the basis of current standard immunosuppressive 
therapy, they will be described in more detail [162].    
 
 
1.7.2 Calcineurin Inhibitors 
1.7.2.1 Cyclosporine (CsA) 
Cyclosporine is a fungal metabolite discovered in a screening program for 
immunosuppressive agents in 1972 [154]. Cyclosporine is a calcineurin-inhibitor that inhibits 
T cell proliferation and was introduced in the clinic by Sir Roy Calne six years later [163]. 
Since then, it has been used in transplantation and is in use until now. Its mechanism of 
action will be described below in context with another CNI. 
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1.7.2.2 Tacrolimus (FK-506) 
Tacrolimus is a macrolide lactone (C44H69NO12) that could first be isolated from Streptomyces 
tsukubaensis – cultures in Japan in the mid-1980’s (Figure 9) [164]. 
                                            
                 Figure 9 Chemical structure of Tacrolimus. Source: www.medlibrary.com 
  
Various animal studies followed to further evaluate the immunosuppressive and anti-
lymphocytic effects and soon, Tacrolimus was given to acutely rejecting transplant patients 
as “rescue” therapy. In 1990, a liver transplant study started, using Tacrolimus as first-line 
therapy [165]. Subsequently, Tacrolimus has been widely used in solid organ and bone 
marrow transplantation. The drug has been described as being up to 100-fold more potent in 
in vitro suppression assays than the CNI Cyclosporine [166]. Further, it was shown that 
Tacrolimus has suppressive effects on T cells without affecting myeloid cells at the same 
concentrations [167].  
 
Activation of a T cell via engagement of the TCR results in activation of the calcium – 
calcineurin - NF-AT – pathway. Once Tacrolimus has entered the cell, it binds to the 
abundant FK506-binding protein FKBP-12, which is a cytosolic immunophilin. The FKBP-
FK506 complex then competitively binds to calcineurin, a Ca2+ / calmodulin-dependent 
proteine phosphatase enzyme [168], and thus the calcium-dependent signal transduction 
pathway in T cells is interrupted (see Figure 10). Without Calcineurin, the cytosolic subunit of 
the nuclear factor of activated T cells (NF-ATc) will not be dephosporylated, thus the 
translocation to the nucleus is blocked. Therefore, NF-ATc cannot form a complex with the 
nuclear component of the nuclear factor of activated T cells (NF-ATn), which is necessary for 
promoter-binding of the IL-2 gene und subsequent production of IL-2 [169], a crucial cytokine 
for T cell activation. Also, further genes regulated through NF-AT are affected by calcineurin-
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inhibitors, such as IL-4, IFNγ or Fas-ligand [170]. By inhibition of calcineurin with Tacrolimus, 
the activation, differentiation and proliferation of naïve and memory effector CD4+ and CD8+ 
T cells is effectively suppressed [171,172]. In its mode of action, Cyclosporine is similar to 
Tacrolimus. The correspondent immunophilin for Cyclosporine is Cyclophilin A, the formed 
complex can also bind calcineurin with the above described consequences. In comparator 
studies, evidence was found that Tacrolimus is superior to Cyclosporine treatment regarding 
acute rejection episodes and graft loss [173,174].  
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                 Figure 10 Effector mechanims of Tacrolimus 
  
 
1.7.3 CNI toxicity – a trade off? 
The short-term graft survival could be strikingly improved by the use of calcineurin inhibitors.  
Yet, the long-term outcome did not change much [175], due to further problems arising by 
numerous adverse drug-related effects. The toxic effects of both Tacrolimus and 
Cyclosporine are described similar: Nephrotoxicity and chronic kidney damage, neurotoxicity, 
disturbances of glucose metabolism and susceptibility to malignancy have been associated 
with both treatments [176,177]. Both MMF and Rapamycin in combination alone or together 
with either Tacrolimus or Cyclosporine were subject of various studies in order to spare / 
minimise the CNI doses. Late conversion from CNI-MMF treatment to a combination of MMF 
and Rapamycin did not improve renal function, in fact it was harmful to kidney transplant 
patients with already impaired renal function. An early conversion results only in an initial 
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better renal function. Additionally, also Rapamycin has adverse effects such as proteinuria, 
bone marrow suppression and, of note after an operative procedure, impaired wound healing 
[178]. In the Efficacy Limiting Toxicity Elimination (ELITE)-Symphony study [161], graft 
survival and acute rejection episodes with de novo Rapamycin in combination with MMF 
were worse than with the Tacrolimus-MMF treatment. Further, treatment with low-dose 
Tacrolimus (3-7 ng/ml) in combination with MMF had the best outcome (renal function and 
graft survival) compared to normal or low-dose Cyclosporine in combination with MMF [178]. 
Disregarding the low-dose use, the general toxicity profiles of Tacrolimus, Cyclosporine and 
Rapamycin were found to be retained, but by minimising the doses of CNI in stable renal 
transplant patients, impaired renal function can be improved [179,180].      
 
1.7.4 Pharmacokinetics 
Immunosuppressive drugs have variable pharmacokinetics in the individual patient. Thus, 
drug monitoring is important to achieve optimal efficient dosages to exert therapeutic effects 
with minimised side effects. A method used widely in the clinic is the measurement of trough 
levels (C0), i.e. the concentration immediately before intake of a new dose of the 
administered drug.  
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 Figure 11 Concepts in drug monitoring (compare [[107,181]) 
 
After the intake, there is an initial absorption phase where drug levels then reach a peak 
(maximum concentration Cmax) until the concentration then falls off to Cmin. The total drug 
exposure between two doses is the area under the concentration-time curve (AUC). To 
determine the AUC, the drug concentration should be measured at several different time 
points to create a 12 hour pharmacokinetic profile [181]. This is not feasible in the clinic for 
every patient. Thus, measurement of Tacrolimus C0 - trough levels, often reported as 
correlated with AUC [182-185], was recommended in 2009 by the KDIGO clinical practice 
guideline [186]. Nonetheless, there are studies reporting that other time points such as C2 or 
C4 correlate better with the AUC [182,183], though the relevance of this in regard to acute 
rejection episodes remains unclear. Important for the clinic is the fact that the differences in 
the maximum concentration Cmax do not affect graft survival time, if the AUC stays the same 
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[181,187]. In fact, Tacrolimus Cmax seems to correlate with the incidence of certain adverse 
effects [188,189]. So patients should receive Tacrolimus treatment that guarantees a certain 
AUC to avoid acute rejection, but does not lead to strong peak concentrations in order to 
reduce unnecessary adverse effects. 
 
1.8 Tolerance - inducing strategies 
1.8.1 Costimulatory blockade with anti-CD154 in animal models 
1.8.1.1 Effects of anti-CD154  
Treatment with anti-CD154 antibody to block the CD40/CD154 pathway of costimulation 
showed graft survival prolongation effects in various models. This has been reported in 
different species (mouse, rat, non-human primate) and organs (islet, skin, heart, or kidney) 
[190-195]. Yet, in a full mismatch murine skin transplant model, anti-CD154 therapy alone 
has been reported as non-sufficient to prolong allograft survival [195].  
 
The mode of action of anti-CD154 blockade has been extensively examined in mouse solid 
organ transplant models. In a multiple minor mismatch model of murine skin transplantation, 
(B10.BR to CBA/Ca), anti-CD154 antibody induced antigen-specific tolerance in CD4+ T 
cells. For this, however, the CD8+ effector response had to be controlled, which was done by 
either thymectomy or depletion with an anti-CD8+ antibody prior to transplantation. When 
anti-CD154 antibody was given alone, this resulted in significantly prolonged, yet not 
indefinite graft survival in this minor mismatch model, despite a delay in the CD8+ cell-
mediated rejection could be observed. It was further demonstrated that the induced CD4+ 
cells were capable of linked suppression, since donor × third party F1 grafts were accepted 
in mice tolerised with anti-CD154 and thymectomy [194]. The same group showed in further 
experiments that the tolerance achieved in their multiple minor mismatch model of anti-
CD154 following CD8+ depletion is infectious, i.e. imposed on naïve CD 4+ T cells [196]. It 
was concluded that the impact of anti-CD154 antibody cannot be explained only by its ability 
to cause activation-induced cell death (AICD) of effector CD4+ or CD8+ T cells. Rather, anti-
CD154 led to generation of a regulatory CD4+ T cell population that is responsible for the 
tolerance observed.  
 
Ferrer et al. demonstrated that CD154 blockade caused late modest conversion of donor-
reactive FoxP3- CD4+ T cells into induced FoxP3+ T regs in a transgenic mouse model. It 
was further shown that the injection of anti-CD154 could delay the expansion of donor-
reactive CD8+ T cells [197].   
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1.8.1.2 Combined treatment of anti-CD154 + DST 
As it has been described by different groups, the administration of a donor-specific 
transfusion (DST) in combination with anti-CD154 treatment enhances the graft survival 
prolongation effect [198-201]. Yet, whilst in cardiac, islet, or minor mismatch skin transplant 
models the administration of a DST under costimulatory blockade is sufficient to induce 
permanent graft survival [200,202], in the B/c-to-B/6 full mismatch skin transplant model it is 
not. The Rossini group reports skin graft survival in this stringent model for ~50 days [195].  
 
This group could show that only the combination of anti-CD154 and DST resulted in the rapid 
activation and subsequent deletion of alloreactive CD8+ T cells in a transgenic mouse model 
[203]. These results were later confirmed by Ferrer et al. who additionally showed, as 
mentioned above, that anti-CD154 blockade induces FoxP3+ T reg in the periphery. The 
increase in the frequency of graft-specific T regs was further enhanced by the combination of 
anti-CD154 + DST [197]. Further work of other groups on the effect of combined treatment of 
anti-CD154 and DST demonstrated that transgenic CD4+ T cells were not depleted, but this 
treatment induced hyporesponsiveness of the alloreactive CD4+ T cells [199,204]. Recent 
experiments in a B/c-to-B/6 skin transplant model indicated that administration of anti-CD154 
+ DST attenuates antigen-specific T cells responses by skewing CD8+ T cells towards short-
lived effector cells [205]. 
 
1.8.2 Clinically applied strategies  
Despite steady progress in the field of transplantation during the last decades, leading to 
reduction of acute rejection; transplant recipients still have a lower quality of life and a lower 
life expectancy compared to the general population. This is mainly due to maintenance 
immunosuppressive therapy [206]. Additionally, even with immunosuppressive treatment, 
long-term graft survival has not been improved substantially. In fact, the adverse effects of 
immunosuppression, especially Calcineurin-Inhibitors, contribute to this effect [207]. 
Therefore, much effort has been made to achieve immunosuppression withdrawal. How can 
this be done? 
 
In the early 1990s, Thomas Starzl et al. reported five liver-transplanted patients that had 
stopped taking immunosuppressive drugs for 5 up to 13 years, but had normal liver functions 
[208]. This long-term drug-free acceptance of an allograft without signs of chronic rejection is 
described as operational tolerance in transplantation [209]. Additionally, the patient should be 
fully immunocompetent, and the tolerance should be antigen-specific. Further, the absence 
of a donor-specific response measurable by donor-specific antibodies (DSA) in transplanted 
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patients has been described [210]. In the clinic, the term operational tolerance is used, since 
it could not been proven that it is true tolerance. This is, as defined by animal experiments, a 
transferable and dominant regulation [211]. In the following, more patients, mostly due to 
noncompliance, have been found to accept their graft without immunosuppression. It has 
become an important goal to deliberately induce tolerance towards the allograft in transplant 
patients.  
 
Tolerance induction through haematopoietic chimerism in pre-immune rodent models has 
been done for 60 years now [98]. Translation of numerous successful small animal protocols 
to large animals and humans came with various difficulties. So far, allograft tolerance in 
human renal transplantation could be induced only in combination with haematopoietic 
chimerism [212]. But this does not come easily, the preparative treatments are harsh and the 
therapy is not without side effects such as graft-versus-host-disease (GvHD). The risk of 
developing GvHD, a disease that can be fatal and life-threatening, in the context of 
transplantation may not be warranted.  
 
Induction therapy, i.e. high intensity of immunosuppression at the time of transplantation; that 
is tapered in the following is the conventional approach to minimise immunosuppression, 
especially CNIs. These strategies, also including lymphodepletional antibodies and other 
biologics, did not lead to operational tolerance in patients, where immunosuppressive drugs 
could be withdrawn definitely. Yet, the doses could be reduced, albeit not to a level where 
the adverse effects would not occur [213].  
 
Operational tolerance and thus withdrawal of all immunosuppression seems extremely 
difficult to achieve for all transplant patients. A more imminently achievable goal might be the 
induction of a recipient regulatory response that allows minimisation of maintenance 
immunosuppression. This can be described as partial (or “prope”) tolerance, a state of the 
immunological regulation of the recipient that is just insufficient to prevent rejection over a 
certain time. Here, by very low doses of immunosuppression, this state could be supported to 
promote long-term allograft survival, without raising adverse effects and toxicity [214].  
 
 
 
 
 Introduction  25 
1.9 Tolerance – a balance? 
There are two general ways to explain tolerance in transplantation. One that might be called 
a qualitative account of transplant tolerance holds it that tolerance is a unique state that is 
entirely distinct from states of rejection or stable immunosuppression. There are several 
possible mechanisms discussed that can lead to this tolerance, e.g. the presence of antigen-
specific regulatory T-cell populations in tolerant patients as opposed to patients that will 
undergo rejection. Another mechanism could be the total clonal deletion or complete anergy 
of effector cells in tolerant patients. It is thinkable that the allograft has become an immuno-
priviledged site in tolerant patients; therefore effector cells do not have physical access to the 
graft. Another concept in transplantation immunology proposed by Stockinger et al. [215] 
holds it that in an organism there are several niches that can be populated by effector cells or 
regulatory cells. In consequence, in tolerant patients these niches would be predominantly 
filled by regulatory cells in contrast to the population by effector cells in rejecting patients.  
 
In contrast to this “qualitative view”, tolerance and rejection might be seen as resulting from 
the quantitative balance between effector and regulatory response. Consequently, tolerance 
occurs if the regulatory response predominates whereas rejection will take place if the 
regulatory response is exceeded by effector cells. We can imagine that such a balance does 
not result in a black & white - picture, it rather suggests different degrees of stability. Further, 
this quantitative account implies the existence of marginal conditions, wherein neither 
regulation nor effector responses predominate. This could be the explanation for following 
situations: 1) The effector cells marginally exceed the regulatory cells, leading to a weak 
rejection that can be controlled by low doses of immunosuppression. 2) The regulatory 
response marginally exceeds the effector response, leading to an unstable state that can be 
supported in favour of regulation by low doses of immunosuppression. 
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2 Aim 
The aim of this work was to give formal proof that marginal states of allograft acceptance do 
exist. As described above, the existence of marginal conditions, wherein neither regulatory 
nor effector responses predominate might explain certain observations in the clinic. Further, 
these states may influence immunosuppressive treatment of transplant patients and, 
eventually, the tolerance-inducing therapies. Yet, so far, no experimental model of such 
states exists. Therefore, a low-dose Tacrolimus monotherapy in C57BL/6 – mice and a weak 
tolerance-inducing protocol in the BALB/c-to-C57BL/6 skin transplantation model was 
established in this project. Both treatments were then combined to answer the question 
whether low-dose Tacrolimus therapy can support the allograft survival in mice treated with a 
weak tolerance-inducing protocol. Further, it was crucial to show that neither treatment alone 
did lead to comparable graft survival and that the disruption of either immunosuppression or 
regulation would lead to rejection of the allograft.  
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3 Materials and Methods 
3.1 Materials 
3.1.1 Instrumentation 
Item Manufacturer Headquarters 
Safety cabinet DIN 12950 Clean Air/Telstar Woerden Netherlands 
Centrifuge 5417C Eppendorf Hamburg, Germany 
FACS Canto II Becton, Dickinson & Company (BD) 
Franklin Lakes, NJ, 
USA 
LED cold-light source KL1500 Schott Mainz, Germany 
Light Cycler 480 Roche Basel, Switzerland 
Megafuge 1.0R Heraeus Instruments Hanau, Germany 
Microscope M651 Leica Wetzlar, Germany 
Microscope SMZ168 Motic Wetzlar, Germany 
Mikrotom  SLEE Mainz, Germany 
NanoDrop 2000c Thermo Fischer Scientific Waltham, MA, USA 
pipetus® pipetting controller Hirschmann Laborgeräte Eberstadt, Germany 
Precision microplate reader Molecular Devices Sunnyvale, CA, USA 
Steam cooker DG2438 Severin Elektrogeräte GmbH Sundern, Germany 
Thermal Pad Model  SHOR-LINE Kansas City, KS, USA 
Thermal cycler PTC-200  MJ Research Inc.  St.Bruno, QC, Canada 
Zeiss Axio Observer Z1 microscope Zeiss Jena, Germany 
3.1.2 Consumables 
Item Manufacturer Headquarters 
Capilliaries with Na- Hep. 9UL Hirschmann Laborgeräte Eberstadt, Germany 
cell culture plates, different sizes Corning Corning, NY, USA 
Cell Strainer 70 µm or 100 µm BD Falcon 
Franklin Lakes, NJ, 
USA 
Cover slides Carl Roth Karlsruhe, Germany 
EDTA Tubes/ Probengefäß 1,3 ml 
K3E Sarstedt Nürnbrecht, Germany 
Embedding cassettes Carl Roth Karlsruhe, Germany 
FACS Tubes for flow cytometry Sarstedt Nürnbrecht, Germany 
Falcon tubes Greiner Bio One 
Frickenhausen, 
Germany 
MACS columns (MS, LD, LS) Miltenyi Biotec  
Bergisch Gladbach, 
Germany 
MACS Pre- Separation Filters 30 µm Miltenyi Biotec  
Bergisch Gladbach, 
Germany 
Lightcycler 480 Multiwell Plate 96 Roche Basel, Switzerland 
Pipette tips 1ml Corning Corning, NY, USA 
Pipette tips 250 µl Sarstedt Nürnbrecht, Germany 
Pipette tips, with filter, different sizes  Biozym 
Hessisch Oldendorf, 
Germany 
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Pipette tips10 µl Starlab Hamburg, Germany 
Qia-shredder columns Qiagen Venlo, Netherlands 
Reaction tube 2 ml + 0,5 ml Eppendorf Hamburg, Germany 
Serological pipettes Corning Corning, NY, USA 
Steriflip/ Stericup-Unit Merck Millipore Darmstadt, Germany 
Super Frost Plus Microscope Slides Thermo Fischer Scientific Waltham, MA, USA 
3.1.3 Operation consumables 
Item Manufacturer Headquarters 
Bepanthen ointment for eyes  B. Braun Melsungen, Germany 
Cannulaes, different sizes 
Becton, Dickinson&Company 
(BD) 
Franklin Lakes, NJ, 
USA 
Depilation creme asid® med ASID BONZ Herrenberg, Germany 
Feather disposable scalpell No.11 
Feather Safety Razor Co., 
Ltd. Osaka, Japan 
Forceps BD331R and BD215R Aesculap / B. Braun Melsungen, Germany 
Forceps Dumont #5 FST Heidelberg, Germany 
Gauze swabs Hartmann 
Heidenheim, 
Germany 
Medical tape 3M™ Durapore™ 3M St. Paul, MN, USA 
Mepitel™ wound contact layers Mölnlycke Health Care  Gothenburg, Sweden 
Needle holder FD241R Aesculap / B. Braun Melsungen, Germany 
Scissors BC 110R Aesculap / B. Braun Melsungen, Germany 
Suture thread 4-0 Prolene  
Johnson & Johnson Medical 
GmbH 
New Brunswick, NJ, 
USA 
Suture thread 5-0 Sofsilk  
Johnson & Johnson Medical 
GmbH 
New Brunswick, NJ, 
USA 
Suture thread 7-0 Ethilon 
Johnson & Johnson Medical 
GmbH 
New Brunswick, NJ, 
USA 
Syringes, different sizes 
Becton, Dickinson&Company 
(BD) 
Franklin Lakes, NJ, 
USA 
3.1.4 Reagents 
Item Manufacturer Headquarters 
2- Mercaptoethanol, 55 mM in DPBS GIBCO / Life technologies Carlsbad, CA, USA 
2-Propanol Merck Darmstadt, Germany 
7-AAD Becton, Dickinson&Company (BD) 
Franklin Lakes, NJ, 
USA 
ACK Lysis Buffer GIBCO / Life technologies Carlsbad, CA, USA 
Albumine Bovine Fraction Sol 7,5% Sigma Aldrich St. Louis, MO, USA 
Anti- Biotin- Microbeads Miltenyi Biotec  
Bergisch Gladbach, 
Germany 
Aquatex Merck Darmstadt, Germany 
Atropinsulfat 0,5 mg/ml B. Braun Melsungen, Germany 
Biocoll Separating Solution Biochrom / Merck Darmstadt, Germany 
BSA Solution 7,5% Sigma Aldrich St. Louis, MO, USA 
CD45.2- Biotin, mouse Miltenyi Biotec  Bergisch Gladbach, Germany 
Citrate buffer pH 6.0 Zytomed Systems  Berlin, Germany 
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DAB+ Substrate Chromogen System DAKO Hamburg, Germany 
DEPC Treated water VWR Radnor, PA, USA 
Detection Reagent 1 GIBCO / Life technologies Carlsbad, CA, USA 
Detection Reagent 2 GIBCO / Life technologies Carlsbad, CA, USA 
Diphtheria Toxin Sigma Aldrich St. Louis, MO, USA 
DMSO Sigma Aldrich St. Louis, MO, USA 
DNA Zap (Solution 1 + 2) Ambion / Life technologies Carlsbad, CA, USA 
Dulbecco's PBS Sigma Aldrich St. Louis, MO, USA 
ECL Plus WB Detection System GIBCO / Life technologies Carlsbad, CA, USA 
EDTA solution 0,5 M, Ultra Pure GIBCO / Life technologies Carlsbad, CA, USA 
Eosin Y solution  Sigma Aldrich St. Louis, MO, USA 
Ethanol Merck  Darmstadt, Germany 
FcR Blocking Reagent mouse Miltenyi Biotec  
Bergisch Gladbach, 
Germany 
Fetal Calf Serum (FCS) Sigma Aldrich St. Louis, MO, USA 
Fixable Viability Dye eF506 eBioscience San Diego, CD, USA 
Flourescent Mounting Medium DAKO Hamburg, Germany 
Foxp3 Fixation/Permeabilization 
Concentrate  eBioscience San Diego, CD, USA 
Foxp3 Fixation/Permeabilization 
Diluent eBioscience San Diego, CD, USA 
Foxp3 Perm Buffer 10x eBioscience San Diego, CD, USA 
Glucose 5% B.Braun Melsungen, Germany 
Glutamax 100x  GIBCO / Life technologies Carlsbad, CA, USA 
Goatserum Sigma Aldrich St. Louis, MO, USA 
H2O2 solution, 30% University Regensburg Regensburg, Germany 
Heparin Na  25000 I.E. Rotexmedica Amt Trittau, Germany 
IC Fixation Buffer eBioscience San Diego, CD, USA 
Isoflurane Baxter Baxter Deerfield, IL, USA 
Ketamin WDT Garbsen, BRD 
Liquid DAB+ Substrate Chromogen 
System DAKO Hamburg, Germany 
Mayer's Hemalum solution  Carl Roth Karlsruhe, Germany 
MEM Non-essential Aminoacids100x GIBCO / Life technologies Carlsbad, CA, USA 
NaCl 0,9% B.Braun Melsungen, Germany 
Paraformaldehyd - solution 
(PFA)<5% Pathology Deptartment UKR Regensburg, Germany 
Penicillin/Streptamycin Invitrogen / Life technologies Carlsbad, CA, USA 
Periodic Acid solution  Merck  Darmstadt, Germany 
Roti®-Histokit  Carl Roth Karlsruhe, Germany 
Roti®-Histol  Carl Roth Karlsruhe, Germany 
RPMI 1640 medium  GIBCO / Life technologies Carlsbad, CA, USA 
Schiff reagent  Merck  Darmstadt, Germany 
SensiTek HRP ScyTek Laboratories  Utah, UT, USA 
Sodium Pyruvat 100 mM, 100x GIBCO / Life technologies Carlsbad, CA, USA 
SuperScript® III First-Strand-
Synthesis SuperMix Invitrogen/ Life technologies Carlsbad, CA, USA 
Sybr® Green Dye Invitrogen/ Life technologies Carlsbad, CA, USA 
 Materials and Methods  30 
Tacrolimus (FK-506), >99% purity LC-Laboratories Woburn, MA, USA 
Tacrolimus (FK-506), >99% purity biorbyt Cambridge, UK 
Tacrolimus (Prograf) 5mg/ml 
solution Astellas Chuo, Japan 
Tacrolimus food produced by SSNIFF Soest, Germany 
TMB Substrate Reagent Set Sarstedt Nürnbrecht, Germany 
Trypan Blue Sol. 0,4% Sigma Aldrich St. Louis, MO, USA 
Tween 20 Sigma Aldrich St. Louis, MO, USA 
Vybrant CFDA SE Cell Tracer Kit Molecular Probes / Life technologies Carlsbad, CA, USA 
Xylazin Bernburg AG Bernburg, Germany 
 
3.1.5 Kits 
Item Manufacturer Headquarters 
CD4+CD25+ Regulatory T Cell 
Isolation Kit, mouse Miltenyi Biotec  
Bergisch Gladbach, 
Germany 
Epidermis dissociation kit, mouse Miltenyi Biotec  
Bergisch Gladbach, 
Germany 
FlowCytomix Mouse 
Th1/Th2/Th17/Th22 13 plex kit eBioscience San Diego, CA, USA 
IFNγ Quantikine ELISA kit, mouse R&D Systems Minneapolis, MN, USA 
Pan T cell isolation kit II, mouse Miltenyi Biotec  Bergisch Gladbach, Germany 
RNeasy Plus mini kit  Qiagen Venlo, Netherlands 
T reg expansion kit, mouse Miltenyi Biotec  
Bergisch Gladbach, 
Germany 
 
3.1.6 Antibodies 
3.1.6.1 For injection 
See 1.2.1.10, Application of antibodies 
3.1.6.2 For Histology 
Antibody Fluorochrome Clone Isotype Manufacturer 
anti-mouse FoxP3 purified FJK-16s rat IgG2a, κ eBioscience 
rat IgG2a, κ purified eBR2a 
 
eBioscience 
goat-anti Rat IgG1 Fab2-B Biotin     Santa Cruz 
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3.1.6.3 For FACS 
Antibody Fluorochrome Clone Isotype Manufacturer 
anti-mouse B220 V450 RA3-6B2 rat IgG2a, κ 
BD 
biosciences 
anti-mouse CD115 APC AFS98 rat IgG2a, κ eBioscience 
anti-mouse CD11b eF450 M1/70 rat IgG2b, κ eBioscience 
anti-mouse CD11b V450 M1/70 rat IgG2b, κ 
BD 
biosciences 
anti-mouse CD11b APC M1/70 rat IgG2b, κ eBioscience 
anti-mouse CD11c PE HL3 aH IgG1 
BD 
biosciences 
anti-mouse CD11c APC-eF780 N418 aH IgG eBioscience 
anti-mouse CD137 APC 17B5-1H1 hamster IgG2 
Miltenyi 
Biotec 
anti-mouse CD138 APC 281-2 rat IgG2a, κ 
BD 
biosciences 
anti-mouse CD19 FITC 1D3 rat IgG2a, κ 
BD 
biosciences 
anti-mouse CD19 AF647 1D3 rat IgG2a, κ eBioscience 
anti-mouse CD19 APC-H7 1D3 rat IgG2a, κ 
BD 
biosciences 
anti-mouse CD21/35 PE-Cy 7 8D9 rat IgG2a, λ eBioscience 
anti-mouse CD23 FITC B3B4 rat IgG2a, κ eBioscience 
anti-mouse CD25 PE PC61 rat IgG1, λ1 
BD 
biosciences 
anti-mouse CD25 APC 3C7 rat IgG2b, κ 
BD 
biosciences 
anti-mouse CD27 APC-eF780 LG.7F9 aH IgG eBioscience 
anti-mouse CD274 PE MIH5 rat IgG2a, λ eBioscience 
anti-mouse CD279 FITC J43 aH IgG eBioscience 
anti-mouse CD28 PE 37.51 sH IgG2, λ1 
BD 
biosciences 
anti-mouse CD314 PE CX5 rat IgG1, κ eBioscience 
anti-mouse CD3e PE-Cy 7 145-2C11 aH IgG eBioscience 
anti-mouse CD4 PerCP-Cy 5.5 RM4-5 rat IgG2a, κ 
BD 
biosciences 
anti-mouse CD4 PE-Cy 7 RM4-5 rat IgG2a, κ 
BD 
biosciences 
anti-mouse CD4 APC GK1.5 rat IgG2b, κ eBioscience 
anti-mouse CD4 APC-H7 GK1.5 rat IgG2b, κ eBioscience 
anti-mouse CD44 FITC IM7 rat IgG2b, κ eBioscience 
anti-mouse CD45.2 PerCP-Cy 5.5 104 mouse IgG2a, κ 
BD 
biosciences 
anti-mouse CD49b V450 DX5 rat IgM, κ 
BD 
biosciences 
anti-mouse CD62L APC MEL-14 rat IgG2a, κ eBioscience 
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anti-mouse CD8a V450 53-6.7 rat IgG2a, κ 
BD 
biosciences 
anti-mouse CD90.2 FITC 53-2.1 rat IgG2a, κ eBioscience 
anti-mouse CD93 PE AA4.1 rat IgG2b, κ eBioscience 
anti-mouse F4/80 PE-Cy 7 BM8 rat IgG2a, κ eBioscience 
anti-mouse FoxP3 FITC FJK-16s rat IgG2a, κ eBioscience 
anti-mouse FoxP3 APC FJK-16s rat IgG2a, κ eBioscience 
anti-mouse GR-1 PerCP-Cy 5.5 RB6-8C5 rat IgG2b, κ eBioscience 
anti-mouse IgG FITC     eBioscience 
anti-mouse IgM APC II/41 rat IgG2b, κ eBioscience 
anti-mouse Ly6C FITC AL-21 rat IgM, κ 
BD 
biosciences 
anti-mouse Ly6G PE 1A8 rat IgG2a, κ 
BD 
biosciences 
anti-mouse MHC I 
(H-2Kb) FITC AF6-88.5 rat IgG2a, κ 
BD 
biosciences 
anti-mouse MHC I 
(H-2Kb) PE-Cy 7 AF6-88.5 mouse IgG2a, κ eBioscience 
anti-mouse MHC I 
(H-2Kd) APC SF1-1.1.1 mouse IgG2a, κ eBioscience 
anti-mouse MHC I 
(H-2Kd) eF450 SF1-1.1.1 mouse IgG2a, κ eBioscience 
anti-mouse MHC II PE M5/114.15.2 rat IgG2b, κ eBioscience 
anti-mouse NK1.1 PerCP-Cy 5.5 PK136 mouse IgG2a, κ eBioscience 
anti-mouse Siglec H PerCP-eF710 440c rat IgG2b, κ eBioscience 
anti-mouse TCRγδ APC GL-3 aH IgG eBioscience 
 
 
Isotype control Fluorochrome Clone Manufacturer 
rat IgG2a, κ AF647   BD 
hamster IgG2,κ APC B81-3 BD 
rat IgG2a, κ APC   eBioscience 
rat IgG2a, κ APC eBR2a eBioscience 
rat IgG2b, κ APC A95-1 BD 
aH IgG FITC eBIO299Arm eBioscience 
rat IgG2a, κ FITC eBR2a eBioscience 
rat IgG2b, κ FITC A95-1 BD 
rat IgM, κ FITC R4-22 BD 
aH IgG PE eBIO299Arm eBioscience 
rat IgG1, κ PE   eBioscience 
rat IgG1, λ1 PE A110-1 BD 
rat IgG2a, κ PE   eBioscience 
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rat IgG2b, κ PE   eBioscience 
sH IgG2, λ1 PE   eBioscience 
aH IgG1,κ PE-Cy 7   BD 
rat IgG2a, κ PE-Cy 7   eBioscience 
rat IgG2a, λ PE-Cy 7 eBR2a eBioscience 
mouse IgG2a, κ PerCP-Cy 5.5 G155-178 BD 
rat IgG2a, κ PerCP-Cy 5.5   BD 
rat IgG2b, κ PerCP-Cy 5.5   eBioscience 
 
 
3.1.7 Buffers and solutions 
MACS-Buffer: 0.5% BSA 
 2 mM EDTA 
  in PBS 
   
  
sterile filter, store cold 
   
   
supplemented 
medium: 43 ml RPMI 
 
5 ml FCS 
 
0.5 ml Penicillin/Streptamycin 
 
0.5 ml Glutamax 
 
0.5 ml Non-essential Amino Acids 
 
0.5 ml Sodium Pyruvate 
 
0.1 ml 2- Mercaptoethanol 
 
  
 
 sterile filter, store cold 
   
   
T-TBS (10x): 24.2 g TRIS base  
 80 g NaCl  
  add ddH2O to 1l   
  adjust pH to 7.58  
   
  dilute in  ddH2O for 1x T-TBS 
 
 
3.1.8 Primers 
All primers were QuaniTect primers ordered from Qiagen. 
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3.1.8.1 Housekeeping genes 
gene a.k.a. order no name 
Gapdh  QT01658692 glyceraldehyde-3-phosphate dehydrogenase 
Hprt  QT00166768 hypoxanthine guanine phosphoribosyl transferase 
Ppia  QT00247709 peptidylprolyl isomerase A 
Rn18s  QT02448075 18S ribosomal RNA 
Tbp  QT00198443 TATA-box binding protein 
 
 
3.1.8.2 Genes of interest 
gene a.k.a. order no name 
Ccr2  QT02276813 chemokine (C-C motif) receptor 2 
Cd200  QT00145817 CD200 antigen 
Cd79b  QT00243663 CD79B antigen 
Col1a  QT00162204 collagen, type I, alpha 1 
Cxcl10  QT00093436 chemokine (C-X-C motif) ligand 10 
Ebi3  QT00155596 Epstein-Barr virus induced gene 3 
Fcrl1  QT02249912 Fc receptor-like 1 
Fcrlb  QT01539006 Fc receptor-like B 
Foxp3  QT00138369 forkhead box P3 
Grem1  QT01039983 gremlin 1 
Gzmb  QT00114590 granzyme B 
Hmmr  QT00127505 hyaluronan mediated motility receptor (RHAMM) 
Hmox1  QT00159915 heme oxygenase (decycling) 1 
Hs3st1  QT02257283 heparan sulfate (glucosamine) 3-O-sulfotransferase 1 
Ido1  QT00103936 indoleamine 2,3-dioxygenase 1 
Ifng  QT01038821 interferon gamma 
Il13ra2  QT00176162 interleukin 13 receptor, alpha 2 
Inos  QT00100275 nitric oxide synthase 2, inducible 
Lag3  QT00113197 lymphocyte-activation gene 3 
Man1a  QT00132034 mannosidase 1, alpha 
Ms4a1 CD20 QT01058330 membrane-spanning 4-domains, subfamily A, member 1 
Nav3  QT01050133 neuron navigator 3 
Pdcd1 PD-1 QT00111111 programmed cell death 1 
Pdcdlg1 PD-L1 QT00148617 Programmed cell death 1 ligand 1 
Pdgfa  QT00197610 platelet derived growth factor, alpha 
Pnoc  QT00102480 prepronociceptin 
 Materials and Methods  35 
Sh2d1b1  QT01049195 SH2 domain protein 1B1 
Sh2d1b2  QT00522221 SH2 domain protein 1B2 
Slc8a1  QT01044862 solute carrier family 8, member 1 
Tcaim Gm1129 QT00281771 T cell activation inhibitor, mitochondrial 
Tcl1  QT00103530 T cell lymphoma breakpoint 1 
Tgfb1  QT00145250 transforming growth factor, beta 1 
Tlr5  QT02328221 toll-like receptor 5 
Tmem176b TORID QT00198037 transmembrane protein 176B 
Tnfrsf4 OX40 QT00109151 tumor necrosis factor receptor superfamily, member 4 
Trem1  QT00153979 triggering receptor expressed on myeloid cells 1 
Trem2  QT00157969 triggering receptor expressed on myeloid cells 2 
 
3.1.9 Software 
Apart from the conventional software (e.g. Microsoft office) following software programs were 
used:   
software application 
Axio Vision LE Zeiss microscope software 
BD FACSDiva 6.0 Flow cytometry data 
Flow Jo 7.6.5 Flow cytometry data 
Genecluster 3.0 Cluster analysis qPCR data 
Gpower 3.1 Statistical planning 
GraphPad Prism 4 Various graphs and statistics 
Java Tree Cluster analysis qPCR data 
LightCycler® 480 Software, Version 1.5 qPCR data 
Reference Manager 11 Compilation of references 
SigmaPlot 11.0 Kaplan-Meier survival curves 
SoftMax Pro ELISA data generation 
 
3.1.10 Mice 
C57BL/6J, BALB/cAnNCrl, C3H and Rag1-/- (B6.129S7-Rag1tm1Mom/J) mice were 
purchased from Charles River or The Jackson Laboratory. FoxP3-GFP-DTR mice were bred 
in house and were provided by Prof. Dr. Stefan Fichtner-Feigl. 
 
In general, male mice of 18-20 g (6-8 weeks of age) were used for experiments. Exceptions 
(for sex) are female C57BL/6J mice in the male-to-female minor antigen mismatch model 
and FoxP3-GFP-DTR mice, where male and female mice were used to increase group sizes. 
Here, treatment and control groups were mixed for sex to ensure comparability.  
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3.2 Methods  
3.2.1 Methods involving mice 
Animal experiments were approved by the local authorities (AZ: 54-2532.1-15/12 and 54-
2532.1-06/13). 
 
3.2.1.1 Treatment of mice 
In general, mice from one cage were randomised for treatment in order to have accurately 
matched control groups. If this was not done for certain treatments, data from an historical 
control group was used as reference, which is indicated in the respective figure legend. 
 
3.2.1.2 Skin-Transplantation 
Donor mice were euthanized by CO2 asphyxiation. Tail skin was removed with a ventral anto-
posterior cut and placed in ice-cold sterile PBS for a maximum of 3 hrs. Tail skin from one 
donor was sufficient for 5 - 6 skin grafts. In some cases, the spleen was then removed to 
prepare a single cell suspension for the donor specific transfusion (DST).   
 
Recipient mice were anaesthetised with a mixture of 3.6 mg Xylazine, 27.3 mg Ketamine in 
1000 µl 0.9% NaCl at 40 µl per 10 gram bodyweight. Once in narcosis, the back of the 
recipient was shaved and depilated using depilatory cream. Mice were placed on a warming 
plate (37°C) to avoid cooling and the back skin was swabbed with medicinal Isopropanol. 
Then the upper layers of the skin were removed to obtain a square of ~1 cm in diameter, 
leaving the subcutis with the blood supplying vessels intact. Sterile 0.9% NaCl-solution 
(prewarmed to 37°C) was used to keep the tissue wet and elastic. From the donor tail, a 
size-matching full-thickness piece was trimmed and placed on the wound bed, carefully 
avoiding overlapping. The graft was fixed in all four edges using a single interrupted suture 
with a 7.0 suture thread and covered with sterile Mepitel® wound dressing and a piece of 
sterile gauze swab. Subsequently, the mice were wrapped in medical adhesive tape and kept 
warm until wake-up. The bandages were removed 7 days post-transplantation.  
 
3.2.1.3 Graft monitoring 
After transplantation, skin grafts were monitored for signs of rejection. This was initially done 
daily, then twice per week. In case of signs of rejection, grafts were monitored in shorter time 
intervals. Skin grafts were examined for thickening, signs of inflammation, haemorrhagic 
spots or scarring. Grafts with less than 20% viable, intact tissue were considered as rejected.  
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3.2.1.4 Donor specific transfusion 
The donor spleen was meshed under sterile conditions (laminar flow cabinet) using a 100 µl 
nylon mesh and the plunger of a 2ml syringe. The cell-suspension was washed with sterile 
PBS and centrifuged (250g, 4°C, 5 min, standard). The supernatant was aspirated and for 
Erythrocyte-lysis, the pellet was resuspended with 3 ml sterile ACK buffer and then 
immediately centrifuged. After aspirating the supernatant, the cells were washed twice with 
10 ml sterile PBS. The cell number was adjusted to 20 x 106 cells / ml, per ml 12.5 µl Heparin 
(60 U) were added to avoid cell coagulation. Recipient mice (prior to transplantation) were 
placed in a fixation chamber and the tail veins expanded by placing the tail in warm water 
(ca. 45°C). Using a 1 ml syringe with a 273/4 gauge needle, 250 µl of the cell suspension (i.e. 
5 x 106 cells) were injected i.v. in a lateral tail vein. Bleeding was stopped by compression 
with a sterile gauze swab. Immediately after releasing the mice from the fixation chamber, 
they received an i.p. injection of anti-CD154 antibody in 200 µl PBS. Mice were allowed to sit 
for at least 1h before proceeding to skin transplantation. 
 
3.2.1.5 Retransplantation 
3.2.1.5.1 Donor 
On d50 post-transplantation, some mice with an intact graft were anaesthetised with a 
mixture of 3.6 mg Xylazine, 27.3 mg Ketamine in 1000 µl 0,9% NaCl at 40 µl per 10 gram 
bodyweight. After careful shaving of the surrounding area, the graft was cut out and trimmed 
before placing in ice-cold PBS for a maximum of 5 min. The donor was killed afterwards by 
cervical dislocation and organs and blood were removed for analysis. 
3.2.1.5.2 Recipient 
The recipients were prepared for skin transplantation as described above. The wound bed for 
the transplant was prepared regarding the exact size of the donor tissue. The intact graft was 
retransplanted without attached tissue of the first recipient. The following approach was done 
as described above. 
 
3.2.1.6 Effector cells from sensitised mice 
To obtain sensitised effector T cells against BALB/c – antigen, C57BL/6 – recipients received 
one BALB/c – transplant on d0. Seven days later, recipient mice were set on 75 mg/kg 
Tacrolimus – food. On d21, after completed rejection of the first allograft, recipients received 
a second BALB/c – transplant under continuation of the food. After successful rejection of the 
second allograft, mice were sacrificed on d37 and spleens were harvested. T cells were 
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sorted as described elsewhere (see below, Pan T cell isolation kit II). After sorting, cells were 
resuspended at 40 x 106 cells / ml with 12.5 µl Heparin (60 U), and 250 µl (i.e. 10 x 106 cells) 
were injected i.v. in a lateral tail vein. 
 
3.2.1.7 Transfer of LN cells  
Graft-draining lymph nodes (axilliary, inguinal) from allografted mice treated with anti-CD154 
+ DST +Tac-75 or Tac-100 were removed on d50. T cells were individually per mouse sorted 
as described elsewhere (see below, Pan T cell Isolation Kit II). After sorting, cells were 
resuspended at 4 x 106 cells / ml with 12.5 µl Heparin (60 U), and 250 µl (i.e. 1 x 106 cells) 
were injected i.v. in a lateral tail vein of a Rag1-/- mouse.  
 
3.2.1.8 Splenectomy 
For spleen removal, mice were anaesthetised as described before. Once in narcosis, mice 
were placed right-laterally on a 37°C warming plate and on the left side a small area below 
the ribcage was shaved and swabbed aseptically. A small incision in this hair-free area of 1 – 
1.5 cm was made to access the abdomen. The spleen was exteriorised and placed carefully 
on a sterile gauze swab next to the incision. The splenic artery and veins were then ligated, 
cut, and the spleen removed. The peritoneum, abdominal muscle and skin are then sutured 
performing the single interrupted suture technique with a 4.0 Prolene suture thread. 
 
3.2.1.9 Thymectomy 
Thymectomised mice were ordered at Jackson Laboratory, USA. Mice were thymectomised 
at 4 - 6 weeks of age, when already a certain repertoire of mature T cells has been formed. 
Littermates of these mice were left untreated. After 1 week, mice were shipped to the animal 
housing facilities in Regensburg and after a further recreation time of 1 week, mice were 
transplanted. 
 
3.2.1.10 Application of antibodies 
Antibodies or Isotype controls were injected i.p. in sterile PBS in an end-volume of 200 µl / 
injection/ mouse. Doses were given as indicated in the table below. All antibodies and 
Isotype controls were ordered from BioXcell, MA, USA.  
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Antibody / Fusion 
protein Clone Dose  Days (relative to STx on d0) 
anti-mouse CD134L RM134L 0.5 mg/day 0, 2, 4, 8 
anti-mouse CD154 MR-1 0.5 mg/day 0, 1, 3, 6  
anti-mouse CD25 PC-61.5.3 1 mg/day 50, 53, 56, 59 
anti-mouse GITR DTA-1 1 mg/day 50, 53, 56, 59 
anti-mouse IL10R 1B1.3A 0.5 mg/day 50, 52, 54, 56, 58, 60, 62, 64 
anti-mouse PD-L1 10F.9G2 0.25-0.5 mg/day 50, 52, 54, 56, 58, 60, 62, 64 
anti-mouse TGFβ 1D11.16.8 1 mg/day 50, 52, 54, 56, 58, 60, 62, 64 
CTLA4-Ig (hum/hum)  0.5 mg/day 1, 3 
    
    
Isotype control  Dose 
 
HRPN rat IgG1 0.5-1 mg/day as control for aIL10R / aCD25 
LTF2 rat IgG2b 0.25-1 mg/day as control for aGITR/ aPD-L1 
MOPC21 mouse IgG1 1 mg/day as control for aTGFβ 
 
 
3.2.1.11 Application of Tacrolimus therapy 
Tacrolimus was given at doses of 25 mg, 50 mg, 75 mg, 100 mg and 150 mg per kg food. 
For this, the required amounts of Tacrolimus (FK-506) were shipped to the food supplying 
company SSNIFF, where pellets including the desired dose were produced. Thus, the 
Tacrolimus-powder was incorporated into the pellets. To discriminate medicinal food from 
normal mouse food, the pellets were dyed with light green color. The mice were provided 
with Tacrolimus food ad libitum by members of our working group.  Additionally to the food, a 
bolus dose of 1 mg/kg bodyweight of Tacrolimus (Prograf®) in 5% glucose solution was 
administered i.p. on the day of food change and two consecutive days. For this, the stock 
solution of 5 mg/ml Tacrolimus (Prograf®) was diluted 1:25 with the glucose solution 
(working solution: 200 µg/ml) and 5 µl/ g body weight were injected. 
 
3.2.1.12 Application of Diphtheria toxin 
Under sterile conditions, lyophilized Diphtheria toxin was reconstituted with 1 ml sterile PBS 
to achieve a stock solution of 1 mg/ml. For further dilution, a small aliquot was withdrawn 
from the vial using a syringe and transferred to a 1.5 ml test tube. The amount of substance 
was determined with a 200 µl pipette and subsequently diluted 1:10 with sterile PBS (e.g. for 
a 50 µl aliquot, 450 µl PBS were added). This 1:10 dilution was then transferred to a 50 ml  
Falcon tube and diluted 1:40 with sterile PBS to achieve a final concentration of 2.5 ng/µl. 
Mice were injected i.p. with 10 µl = 25 ng/ gram bodyweight (i.e. 25 µg/kg bodyweight) every 
other day for a total of six injections.   
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3.2.1.13 Toxicology 
Measurements were performed by the Institute for Clinical Chemistry and Laboratory 
Medicine, University Hospital of Regensburg.  
 
3.2.1.13.1 Tacrolimus 
Serum-levels of Tacrolimus in mice were measured by LC-MS/MS in EDTA-blood. For this, 
mice were bled at indicated time points retro-bulbary under a brief Isoflurane-narcosis. Per 
analysis, 100 – 200 µl blood was taken. 
 
3.2.1.13.2 Creatinine  
Serum-levels of Creatinine were measured in the serum of heparinised blood by photometric 
analysis. Mice were bled retro-bulbary on d50 to collect 150 µl blood. Serum was obtained by 
Clinical Chemistry.  
 
3.2.2 Molecular biology 
3.2.2.1 RNA isolation  
Single cell suspensions were pelleted and lysed by addition of 350 µL of RLT buffer 
supplemented with 1% (v/v) 99% 2-mercaptoethanol. For whole-organ qPCR analysis, whole 
organs were removed, wrapped in aluminium foil, snap-frozen in liquid N2 and smashed (in 
the foil) between two metal blocks. The crushed organs were then lysed with 350 µl 
supplemented RA1 buffer and vortexed vigorously. Subsequently, the tissue samples were 
applied on a Qia-shredder column and centrifuged for 2 min at high speed (20,000 rcf). The 
cell lysates were stored at -80°C until RNA extraction. RNA was eluted in 30µL ddH2O. RNA 
was isolated using the RNeasy Plus mini kit from Qiagen and the protocol “Purification of 
Total RNA from animal Cells“. Throughout the handling with cells, RNA, and cDNA 
contaminations with nucleases were avoided using RNaseZap® and nuclease free filter-tips.  
 
3.2.2.2 cDNA synthesis 
First-strand cDNA synthesis from total RNA samples was done using the SuperScript® III 
First-Strand-Synthesis SuperMix according to the manufacturer’s protocol.  
The RNA was used in the highest concentration possible in the case of very low RNA yields 
due to limited numbers of cells, especially for skin samples. Thus, RNA concentration of the 
samples was measured with a NanoDrop spectrophotometer. Since 6 µl is the maximum 
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amount that can be used in the protocol, this volume was used for the sample with the lowest 
RNA concentration. RNA of the corresponding samples was diluted accordingly with RNAse / 
DNAse free H2O.  
 
For first-strand cDNA synthesis, the components (see below) were combined in a 0.2 ml 
reaction tube and incubated for 5 min in a thermal cycler at 65°C. 
 
                                 
component amount
up to 5 µg total RNA max. 6 µl
50µM oligo(dT) primer 1 µl
Annealing Buffer 1 µl
RNAse / DNAse free water fill to 8 µl
  
 
After incubation, the tubes were immediately placed on ice for 2 min and quickly spun down. 
Then, the following reagents were added to the tubes:     
             
                           
comp onent amount
2x First-S trand Reaction mix 10 µ l
SuperScript III  / RnaseOUT Enzym e Mix 2 µ l
 
 
This was followed by short vortexing and spinning before samples were incubated for 50 min 
at 50°C in a thermal cycler. The reaction was terminated by a 5 min incubation step at 85°C. 
Tubes were then chilled on ice for 10 min and then stored at -20°C until further processing.   
 
 
3.2.2.3 Quantitative real-time PCR 
The quantitative polymerase chain reaction (qPCR) can be used to quantify a selected 
polynucleotide sequence by amplifying its concentration to a level at which an accurate 
detection can be made [200,201]. 
 
This level is the so-called crossing point (CP) which is defined as the number of PCR cycles  
necessary to detect the first reliable fluorescence signal from the dye Sybr Green added to 
the reaction. PCR amplifies the targeted nucleic acid in the sample and this amplification is 
considered to be exponentially in the most progressive phase. The fluorescent dye SYBR 
Green will bind to the minor groove of double-stranded DNA. The fluorescence is greatly 
enhanced upon DNA-binding [202].The resulting DNA-dye-complex absorbs blue light (λmax 
= 488 nm) and emits green light (λmax = 522 nm).  
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3.2.2.3.1 Quantitative real-time PCR setup 
If necessary, cDNA was diluted 1 to 5 with nuclease-free water. Master mixes per primer for 
the target and the housekeeper genes listed above were prepared as a multiple of the 
reagent volumes shown below: 
                              
component amount
10x Primer (Quantitect) 2.5 µl
QuantiTect SYBR Green PCR Kit 12.5 µl
cDNA 2 µl
ddH2O 8 µl
 
 
Each cDNA sample was assayed in three technical replicates. 25 µl of the mastermix were 
transferred into real-time PCR 96-well plates. 
 
The PCR was performed on a Roche Lightcycler 480 as follows: First, during a pre-
incubation time of 15 min at 95°C, the FastStart Taq DNA polymerase is activated. Then, 40 
amplification cycles follow (temperature targets see below). 
 
                                             
Target °C hold step
94 15s denaturation 
55 30s annealing
72 30s elongation
  
 
At the end of the 40 amplification cycles amplicons were melted for 5 s at 95°C followed by 
an annealing step for 1 min at 65°C. Melting curve analysis was performed by stepwise 
heating-up of the sample until 97°C. The fluorescence signal decreases slowly until the 
melting temperature of the amplicon is reached. Then, a strong decline of the fluorescence 
signal will be detectable. The derivative function of the melting curve will display a peak at 
the melting point of the amplicon. If more than one peak is present, this indicates 
contaminating DNA or primer-dimers.   
 
3.2.2.3.2 Analysis of qPCR data 
Statistics, qPCR: 
RT-PCR data was normalized against a set of 5 stable housekeeping genes (18S-rRNA, 
GAPDH, TBP, PPIA, Actb. For RT-PCR a nonparametric Mann-Whitney test was conducted 
on a per-gene basis for pairwise comparisons between the clinical groups. Gene-wise 
multiple testing adjustments were performed using the Holm-Bonferroni correction [203]. A 
statistical criterion for identification of differentially expressed genes adjusted P < 0.05. 
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Clustering analysis for the dLN qPCR data was done by Dr.Dr. J. Hutchinson (Department of 
Experimental surgery, University Hospital of Regensburg) 
3.2.2.4 IFNγ -ELISA 
The principle of the enzyme-linked immunosorbent assay (ELISA) method is the antibody-
based antigen detection. A commercially available ELISA kit based on the sandwich ELISA 
principle was used to measure IFNγ-production. The kit was used following the 
manufacturer’s instructions for cell culture supernatants. Test samples were analysed in 
duplicates. For analysis, a linear regression line was plotted using the mean values of the 
duplicates of the standard curve. On the basis of the equation of this regression line with the 
mean OD of the sample duplicates as x-value, the amount of IFNγ was calculated. OD 
values below the OD values of the highest dilution of the standard were not considered. 
Appropriate conduction of the ELISA was checked with the internal control of the kit, which 
was conducted every time.  
 
3.2.3 Cell biological methods 
3.2.3.1 Determination of cell numbers  
Cells in single cell suspensions were counted using a Neubauer haemocytometer. For this, 
cells were diluted 1 to 10 (v/v) with trypan blue and 10 µL of the mixture were placed in the 
space between the haemocytometer and the cover slip. If dilution was required, cells were 
diluted 1 to 10 (v/v) with PBS prior to dilution with trypan blue.  Cell concentrations in the 
sample were calculated according to Formula 1. The mean value of four independent areas 
containing 50 to 100 cells counted was calculated in order to minimise the counting error. 
 
factordilution
chamberofvolume
chamberoneincountedcellsofnumber
cellsofionConcentrat ×=  
Formula 1 Calculation of cell numbers using Neubauer haemocytometer 
 
 
3.2.3.2 Preparation of single cell suspension 
3.2.3.2.1 Spleen and LN 
The spleen and / or dLN (axilliary, inguinal) were removed and stored in cold PBS on ice for 
a maximum of 30 min. Then, organs were mashed using a 100 µm cell strainer and a 2 ml 
BD Discardit II syringe plunger, if required, under sterile conditions. Cells were then 
pelletised (5 min, 270 rcf, 4°C) and the supernatant (SN) discarded. If necessary, 
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Erythrocyte-lysis was performed using 3 ml ACK-Buffer, resuspended cells were immediately 
spun down and the SN aspirated. If Erythrocyte-lysis was not necessary, or after the lysis, 
cells were washed twice with 10 ml PBS and then used for further procedures. 
 
3.2.3.3 MACS sorting 
Sorting cells using the Miltenyi MACS-system was performed according to the 
manufacturer’s manual. In detail, cell separation procedures are described below. 
 
3.2.3.3.1 CD4+CD25+ T reg Kit (Miltenyi) 
Single spleen cells were counted, pelletised and resuspended in 40 µl ice-cold MACS-Buffer 
per 107 cells. Then, 10 µl Biotin-Antibody Cocktail per 107 cells were added and cells were 
incubated for 10 min in the refrigerator at 4°C. Subsequently, 30 µl ice-cold MACS-Buffer, 20 
µl anti-Biotin beads and 10 µl of CD25-PE antibody per 107 cells were added, followed by an 
incubation time of 15 min in the refrigerator at 4°C. Afterwards, cells were washed with 1 ml 
ice-cold MACS-Buffer per 107 cells, pelletised and the SN was discarded. The pellet was 
resuspended in 500 µl ice-cold MACS-Buffer. A MACS LD-column was placed in the MACS 
separator magnet and rinsed with 2 ml ice-cold MACS-Buffer, the flow-through was 
discarded. The labeled cells were then applied through a MACS-filter on the LD column, 
saving the flow-through (representing the CD4+ cells) in a 15 ml Falcon tube. The column 
was washed twice with 2 ml ice-cold MACS-Buffer, saving the flow-through in the tube 
containing the CD4+ cells. These were then centrifuged, the SN discarded and the cells 
resuspended in 90 µl ice-cold MACS-Buffer. Further, 10 µl Anti-PE- MicroBeads were added, 
then the cells were incubated for 15 min in the refrigerator at 4°C. After washing the cells 
with 1 ml ice-cold MACS-Buffer per 107 cells, the cells were pelletised and the SN was 
discarded. The pellet was resuspended in 500 µl ice-cold MACS-Buffer. A MACS MS-column 
was placed in the MACS separator magnet and rinsed with 500 µl ice-cold MACS-Buffer, the 
flow-through was discarded. The labeled cells were then applied on the MS column and 
magnetically sorted. The flow-through was saved in a 15 ml- Falcon, representing the 
CD4+CD25- fraction. The column was washed thrice with 500 µl ice-cold MACS-Buffer, 
saving the flow-through in the CD4+CD25- -tube. The column was placed on a fresh 15 ml 
Falcon tube. Then, 1 ml ice-cold MACS-Buffer was applied to flush the column with the 
provided plunger into the tube, which elutes the CD4+ CD25+ cells. To further increase the 
purity of the CD4+CD25+ -population, these cells were applied on a second MS-column and 
magnetically separated. The cell populations were kept in buffer on ice until further handling.  
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3.2.3.3.2 CD45.2 Sort 
Single cell suspensions from spleen, dLN and skin were counted, pelletised and 
resuspended in 100 µl ice-cold MACS-Buffer per 107 cells. Additionally, 10 µl CD45.2 Biotin-
antibody per 107 cells were pipetted to the cells, which were then incubated for 10 min in the 
refrigerator at 4°C. Then, cells were washed with 10 ml ice-cold MACS-Buffer, pelletised and 
the SN was discarded. Now, cells were resuspended in 80 µl ice-cold MACS-Buffer per 107 
cells and 20 µl anti-Biotin beads per 107 cells were added, followed by an incubation time of 
15 min in the refrigerator at 4°C. Afterwards, cells were washed with 10 ml ice-cold MACS-
Buffer, pelletised and the SN was discarded. The pellet was resuspended in 500 µl ice-cold 
MACS-Buffer. Magnetic separation was performed with the autoMACS™ Pro Separator as 
indicated in the manufacturer’s manual using the program “Possel-s” to collect the CD45.2+ 
cell fraction. This program was chosen to achieve highest possible yield especially of the skin 
samples. 
 
3.2.3.3.3 Pan T cell isolation kit II (Miltenyi) 
Single spleen cells were counted, pelletised and resuspended in 40 µl ice-cold MACS-Buffer 
per 107 cells. Then, 10 µl Biotin-Antibody Cocktail per 107 cells were added and cells were 
incubated for 10 min in the refrigerator at 4°C. Further, 30 µl ice-cold MACS-Buffer and 20 µl 
anti-Biotin beads per 107 cells were added, followed by an incubation time of 15 min in the 
refrigerator at 4°C. Afterwards, cells were washed with 10 ml ice-cold MACS-Buffer, 
pelletised and the SN was discarded. The pellet was resuspended in 500 µl ice-cold MACS-
Buffer. Magnetic separation was performed with the autoMACS™ Pro Separator as indicated 
in the manufacturer’s manual using the program “Deplete” to collect the unlabelled T cell 
fraction containing CD4+ and CD8+ T cells  . 
 
After all sorts, purity FACS stains were performed. 
 
3.2.3.4 Suppression Assay 
After MACS-sorting, CD4+CD25- cells were put into culture in flat-bottom 96-well plates at 1 x 
105 cells per well together with aCD3/aCD28 coated beads in a total of 250 µl volume of 
supplemented cell media. For suppression assays, 1 x 105 CD4+CD25+ cells per well were 
added, the volume of beads was increased accordingly, the final volume of cells and 
reagents in media was maintained as 250 µl. Tacrolimus was added at final concentrations of 
0.25, 0.5, 1, 1.5 and 2 ng/ml. Cells were incubated for exactly 48h at 37°C with 5% CO2. 
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After incubation, the supernatants were harvested into 1.5 ml reaction tubes on ice and spun 
down at 300g to pellet cells. Then, the supernatant was transferred to a fresh 1.5 ml reaction 
tube and frozen at -20°C until further processing. 
 
3.2.3.5 Suppression Assay – CFSE 
Briefly, the setup for the culture was as described above.  
 
However, MACS-sorting of the cells was modified: the CD4+ cell fraction was stained with 
CFDA-SE and cells were rested overnight in supplemented medium in 6-well plates (max 7 x 
106 cells / well). On the next day, CD4+ cells were labelled with CD25-PE and then further 
processed as described above in the respective section. 
 
After 48h-incubation at 37°C with 5% CO2, the supernatants were harvested as described 
above. Further, the wells were rinsed with PBS to obtain the cultured T cells. These were 
pooled together with the pellet of the supernatant harvest and then stained for FACS 
analysis. 
 
3.2.3.6 CFSE-labelling 
Cells to be labelled with CFSE were adjusted with pre-warmed PBS (i.e. 37°C) to 10 x 106 
cells / ml. The CFSE stock aliquots (0.5 mM) were diluted 1:125 with pre-warmed PBS to 
obtain a 4 µM CFSE-working solution. This was then mixed 1:1 with the cells, resulting in a 
final concentration of CFSE of 2 µM. The suspension was incubated for 15 min at 37°C in the 
water bath in the dark. The reaction was abrogated by adding FCS at 10% of the final 
volume. Cells were then spun down (300 g, 10 min, RT) and SN was discarded. The pellet 
was resuspended in supplemented medium, cells were plated in a 6-well-plate and 
recovered over night at 37°C in the incubator. 
 
3.2.3.7 FACS staining  
All flow cytometric analysis (fluorescence-activated cell sorting, FACS) were measured using 
BD Canto II. The used antibodies with the respective fluorescence conjugates are listed 
above. If not stated otherwise, all steps were done on ice. When sufficient material was 
available, 1 x 106 cells were dispensed into FACS tubes, otherwise as much cells as possible 
were used. After a wash with 1 ml PBS and a centrifugation step (300 g, 5 min, 4°C) the 
supernatants were either aspirated or discarded. This will be referred to as “wash step” in 
this work and can be performed with different buffers. In the following, the pellet was 
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resuspended in 1 ml PBS and 1 µl eF506 Viability Dye was added to the tubes, which were 
then vortexed and incubated in the dark on ice for 30 min. After that cells were washed twice 
with PBS and resuspended in 100 µl FACS buffer containing 10 µl mouse FcR blocking 
reagent and incubated on ice for 30 min. Master mixes of the antibodies desired for each 
staining were prepared according to the dilutions listed above. After another wash with FACS 
Buffer, the master mix (max. 70 µl) was added. The tubes were vortexed briefly and 
incubated on ice in the dark for 30 min. This was followed by two wash steps. If no 
intracellular staining was required, then 200 µl FACS Buffer were added to each tube and 
cells were stored at 4°C in the dark until analysis, but for not more than 3 h. In the case of 
FoxP3 – staining, cells were resuspended instead in 1 ml Fix/Perm solution and incubated 
for 30 min – max. 18 h in the refrigerator. Subsequently, cells were washed with 2 ml Perm 
Buffer. 90 µl Perm Buffer and 10 µl mouse FcR blocking reagent were added to the cells. 
After 15 min incubation, 10 µl of the FoxP3-antibody-working solution were pipetted per tube 
and cells were incubated for 30 min on ice. Cells were washed twice with Perm Buffer, then 
200 µl FACS buffer were added and cells were stored in the refrigerator until analysis for a 
maximum of 24 h.   
 
FACS-Panels used:  
 
Laser detection 405 488 633 
Fluorochrome 
V450 / 
eF450 V500 FITC PE 
PerCP Cy 5.5 
/ PerCPeF710  PE-Cy7 APC 
APC-eF780 / 
APC-H7 
         
T cell 
                
  
CD8a viability dye CD44 CD28 CD4 CD3e CD62L CD27 
T reg 
                
  
CD8a viability dye FoxP3 CD25 CD4 CD3e CD137 CD27 
B cell 
              
  
  
B220 viability dye CD23 CD93 CD4 CD21/35 CD138 CD19 
NK/NKT 
                
  
CD49b viability dye CD19 CD314 NK1.1 CD3e TCRgd CD27 
DC 
        
  
      
  
CD8a viability dye Ly6C MHC II Siglec H CD4 CD11b CD11c 
Macrophage/MDSC   
      
  
      
  
CD11b viability dye Ly6C Ly6G GR-1 F4/80 CD115 CD11c 
T reg II 
                
 (in vitro, CFSE) CD8a viability dye CFSE CD25 CD4 CD3e FoxP3 - 
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3.2.3.8 Crossmatch – FACS  
To measure donor-specific antibodies (DSA) and unspecific antibodies (NDSA), serum from 
treated mice was incubated with donor splenocytes (BALB/c) and splenocytes from self 
(C57BL/6). First, 2.5 x 105 BALB/c splenocytes were incubated together with 2.5 x 105 
C57BL/6 (B/6) splenocytes and 10% mouse FcR blocking reagent in 50 µl for 20 min on ice. 
Then, 50 µl serum - dilution was added per tube. Blank controls were treated accordingly, but 
no serum was added. For the standard curve, pooled sera from five sensitised mice were 
used. These have had rejected 2 consecutive BALB/c – skin grafts under 75 mg/kg 
Tacrolimus. The pooled sera were serially two-fold diluted in PBS, from a 1:10 dilution up to 
a 1:1280 dilution. As negative control, sera from naïve B/6 mice were used (NMS). The test 
sera from mice were used in a 1:40 dilution. Test-sera were done in duplicates, the standard-
curve sera, NMS sera and blanks in triplicates. The serum was incubated for 90 min on ice 
together with the cells. This was followed by three wash steps with FACS Buffer (see above). 
Further, 10 µl mouse FcR blocking reagent was added to the cells and incubated for 10 min 
on ice. Without washing, 10 µl anti-mouse IgG-FITC antibody working solution was added 
and incubated for 60 min on ice. After one wash step, 10 µl each of following anti-mouse 
antibody working solutions were pipetted into the tubes: IgM–APC, CD3-PE, H2Kd-eF450 
and H2Kb- PeCy7. Cells were incubated for 30 min on ice and then washed twice. Then 50 µl 
FACS buffer were added and samples were measured. 
 
3.2.3.8.1 Principle and Analysis of the Crossmatch FACS 
The flow cytometry crossmatch (FCXM) has been first decribed in 1983 [204] and has been 
used since then in clinics to measure anti-donor antibodies. The above described 
Crossmatch FACS follows the T cell FCXM in principle: Antibodies in the serum will bind to 
the splenocytes, the anti-mouse IgG antibody will bind to these antibodies (Figure 12).  
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+ serum
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fluorescence labeled
 
                                                  Figure 12 Principle of crossmatch FACS 
 
For the analysis using the FlowJo 7.6.5 software, a lymphocyte gate was set in the forward-
scatter / sideward-scatter plot. Using the signal for the CD3 and the H2Kd- antigen it was 
discriminated between B/c splenocytes (donor, H2Kd) or B/6 splenocytes (self, H2Kb). The 
PE-signal of the H2Kd positive and H2Kd negative population than shows the IgG response 
bound on B/c or B/6 cells. The mean fluorescence intensity (MFI) of the PE-signal was used 
for further analysis. A limit of detection was determined as mean MFI of the three NMS 
samples plus the threefold standard deviation (SD). Samples with a MFI below the limit of 
detection were considered as negative for IgG antibody.  The same applies for the APC-
signal of the IgM response.           
                 
3.2.4 Histology 
3.2.4.1 Paraffin-embedded samples 
Harvested skin grafts, kidneys or spleens were placed in embedding cassettes and put in 5% 
paraformaldehyde. Fixation of the tissue samples was done by Pathology Department, 
University Hospital of Regensburg. Finally, samples were stored in melted paraffin to ensure 
complete infiltration. For embedding, samples were placed in an embedding mold which was 
subsequently filled with melted paraffin. Skin samples were embedded standing upright. The 
paraffin blocks were cooled on a cooling plate and then stored at RT until sectioning.  
 
Sectioning was performed on a microtome. For this, the block was first trimmed to obtain an 
optimal cutting surface. Then, 4 µm sections were cut and transferred to a 50°C water bath. 
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After unfolding, sections were mounted on Superfrost Plus microscope slides and dried for 
24h at 37°C, before proceeding to immunohistochemistry and histology stains / reactions.   
 
3.2.4.2 Haematoxylin & Eosin staining 
To deparaffinise tissue samples, slides were placed in Roti®-Histol for 10 min, before 
rehydrating them in a graded alcohol series. Briefly, slides were placed for 10 min each in 
100%, 96% and 70% EtOH followed by 10 min ddH2O. Subsequently, sections were 
incubated for 7 min in Mayer's hemalum solution to stain nuclei and then washed for 15 min 
with lukewarm running tap water. To stain cytoplasm, slides were afterwards incubated for 3 
min in Eosin Y solution. This was followed by short washes in ddH2O and 70% EtOH, 90 sec 
in 96% EtOH and 150 sec in 100% EtOH. After a final incubation for at least 5 min in Roti®-
Histol, sections were mounted with Roti®-Histokit and coverslips and air dried before 
analysis with the Zeiss Axio Observer. 
 
3.2.4.3 PAS (Periodic-Acid-Schiff)-reaction  
Deparaffinisation and initial rehydration were done as described above. Sections were then 
incubated for 8 min in periodic acid solution, washed in running tap water and rinsed in 
ddH2O. This was followed by 15 min incubation with Schiff reagent to stain glycogen and 
polysaccharides, and a washing step for 5 min in running tap water. After rinsing in ddH2O, 
sections were counterstained in Mayer's hemalum solution and washed with lukewarm 
running tap water for 3 min to stain nuclei. This was followed by short washes in ddH2O and 
twice in 70% EtOH, 1 min in 96% EtOH and twice for 5 min in 100% EtOH. After a final 
incubation for 15 min in Roti®-Histol, sections were mounted with Roti®-Histokit and 
coverslips and air dried before analysis with the Zeiss Axio Observer. 
 
3.2.4.4 Masson-Trichrome Staining 
The Masson-Trichrome-Staining was performed in the Pathology Department, University 
Hospital of Regensburg.  
 
3.2.4.5 FoxP3 – Staining 
Deparaffinisation and initial rehydration of skin or spleen sections as staining control were 
done as described above. Then, sections were cooked for 20 min in citrate buffer in a steam 
cooker and then cooled down for 20 - 30 min at RT. This was followed by three washing 
steps in ddH2O for each 5 min and a 10 min incubation step in 3% H2O2 solution. Again, 
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sections were washed three times in ddH2O for each 5 min and then once in T-TBS for 5 
min. Sections were then shortly drained and blocked with 5% goat serum in T-TBS for 1h at 
RT in a wet chamber. Afterwards, the primary antibody (FoxP3 or corresponding Isotype 
control) were added in a 1:50 dilution in blocking serum and incubated over night at 4°C in a 
wet chamber. On the consecutive day, sections were washed three times in T-TBS for 5 min. 
Then, the secondary antibody (Goat anti- rat IgG1 Fab2-B, Biotin Conjugated) was added in 
a 1:100 dilution in blocking serum and incubated for 1h at RT in a wet chamber. This was 
followed by three washing steps in T-TBS for each 5 min and an incubation step for 30 min at 
RT with HRP reagent. After three more washes in T-TBS for 5 min each, sections were 
stained for 90s with DAB reagent, reaction was stopped in ddH2O. Counterstaining was done 
with Mayer's hemalum solution for 8 min and a washing step with lukewarm running tap 
water for 10 min to stain nuclei. Then sections were mounted with Aquatex and coverslips 
and air dried before analysis with the Zeiss Axio Observer. 
 
 
3.2.5 Statistics: 
Statistical tests were performed as indicated in the respective figure legend. 
For statistical analysis of qPCR data, refer to section 1.2.2.3.2. 
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4 Results 
4.1 Oral administration of Tacrolimus in mice 
In later experiments, the effect of Tacrolimus on skin allograft survival in marginal states of 
allograft acceptance was examined. Therefore, a subtherapeutic Tacrolimus therapy had to 
be established. For this, it was necessary to keep mice over many weeks on controllable 
serum levels of Tacrolimus, therefore a reliable dosing protocol had to be developed. This 
can be achieved by different ways, such as oral administration, repeated i.p. injections, 
implanting osmotic pumps or subcutaneous drug pellets. Over the recent years, our group 
has been working successfully with the oral administration of drugs. Considering this and the 
minor stress of this application route, specially produced food supplemented with desired 
doses of Tacrolimus was given as the daily diet ad libitum. Thus, food containing 50 mg, 75 
mg, 100 mg and 150 mg Tacrolimus per kilogram of food was fed to male C57BL/6 mice over 
a time span of 153 days and serum levels of Tacrolimus were measured. Since it was 
anticipated that additional bolus injections were necessary to quickly achieve measurable 
serum levels, mice received i.p. injections of Tacrolimus on three consecutive days starting 
on the day of drug food administration. The mean serum levels increased dose-dependently, 
mean Tacrolimus serum levels of 0.88 µg/l ± 0.2, 3.7 µg/l ± 1.4, 8.94 µg/l ± 5.42 and 22.04 
µg/l ± 11.2, respectively, were achieved (Figure 13).  
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Figure 13: Relationship between oral Tacrolimus administration and serum levels in C57BL/6 mice. B/6 
mice were set on food containing (a) 50 mg,(b) 75 mg,(c) 100 mg, or (d) 150 mg Tacrolimus per kilogram food. 
Mean serum levels of Tacrolimus are displayed in scatter plots.  
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 Over a time span of 10 weeks, clearly titratable serum levels could be distinguished. For 
example, on d20 after induction, mice treated with 50 mg, 75 mg, 100 mg and 150 mg per 
kilogram food had serum levels of 0.5 µg/l ± 0.4, 2.9 µg/l ± 0.59, 9.5 µg/l ± 3.4 and 15.6 µg/l ± 
6.6. However, there are fluctuations in the measured values throughout the groups, which led 
to an overlap in serum levels of mice fed with 75 mg/kg and 100 mg/kg Tacrolimus-food at 
the last four measurements starting on d83. These fluctuations might have occurred for 
several reasons, such as amount of ingested food shortly before bleeding or absorption of 
Tacrolimus in individual mice. Interestingly, the mean serum levels in mice receiving higher 
doses of 100 mg/kg or 150 mg/kg peaked early on d34 after induction of the drug therapy. 
This might correspond to toxicity effects of these doses. Taken together, it was shown that 
long-term treatment of mice with food at doses of 50 mg, 75 mg, 100 mg and 150 mg 
Tacrolimus per kilogram leads to titratable, dose-dependently increasing serum levels. 
 
4.2 Toxic effects of Tacrolimus administration 
Tacrolimus as immunosuppressive therapy is very effective in preventing acute rejection, yet 
it has many unwanted side effects, such as increased susceptibility to infection, 
malignancies, and nephrotoxicity [158]. Specifically, it was planned to investigate toxic 
effects of the established oral Tacrolimus administration. As a first read-out parameter, body 
weight of the mice treated with 50 mg, 75 mg, 100 mg and 150 mg Tacrolimus per kilogram 
food was determined (Figure 14). Whereas weight curves for mice fed with doses up to 100 
mg/kg show a similar course, mice treated with 150 mg/kg Tacrolimus displayed reduced 
weight gain after the first month of treatment (150 mg/kg vs. 50 mg/kg: p = 0.023; 150 mg/kg 
vs. 75 mg/kg: p = 0.068; 150 mg/kg vs. 100 mg/kg: p = 0.038).  
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Figure 14: Weight curve  in C57BL/6 mice during oral administration of Tacrolimus. Weight curves of mice 
from Figure13.  Mean body weight is displayed with SD.  
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The aforementioned Tacrolimus nephrotoxicity has been reported to be dependent on the 
dosing regimen and occurs in 17%- 44% of kidney transplant patients [221,222]. Increased 
serum creatinine is a consequence of loss of renal function though nephrotoxicity in humans 
and mice [223,224]. Serum creatinine was measured after 50 days of treatment in untreated 
mice and sentinel mice treated with 75 mg/kg, 100 mg/kg or 150 mg/kg Tacrolimus food 
(Figure 15). A trend towards higher levels of serum creatinine in mice receiving higher doses 
of Tacrolimus indicates mild (100 mg/kg) or enhanced (150 mg/kg) nephrotoxicity compared 
to no changes in mice treated with 75 mg/kg Tacrolimus.  
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Figure 15: Serum Creatinine levels in sentinel mice. C57BL/6 mice were treated with oral Tacrolimus at 75, 
100 and 150 mg/kg or left untreated. On d50, Serum Creatinine was measured. Scatter plots display mean and 
SD. The observed changes are statistically not significant (Student’s T-Test, pairwise comparison with untreated 
group).  
 
 
Chronic Calcineurin-Inhibitor (CNI) – induced nephrotoxicity is histopathologically 
characterised by hyaline arteriolopathy, interstitial fibrosis, and tubular atrophy, and occurring 
glomerular changes [224,225]. In order to examine CNI-induced nephrotoxicity, kidneys of 
mice treated with 50 mg, 75 mg, 100 mg and 150 mg Tacrolimus per kilogram food were 
removed after ~5 months (d150 –d153), H&E stained and histopathologically analysed. The 
analysis was done with the help of a pathologist, PD Dr. med. P. Rümmele (University 
Hospital of Regensburg). In none of the samples, regardless of the Tacrolimus treatment, 
CNI-typical damage was observed. However, in 3/4 kidneys from mice treated with 150 
mg/kg Tacrolimus, tubular necrosis and inclusion bodies were observed (Figure 16). 
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Treatment with Tacrolimus in high doses has been reported as a risk factor for polyoma virus 
(BKV, JCV and SV-40) infection, a major complication after renal transplantation that can 
also occur in native kidneys. The presence of inclusion bodies and tubular injury 
morphologically defines BKV nephropathy [226]. It is possible that the mice might have been 
subjected to virus-infection due to the immunosuppression with high doses of Tacrolimus. 
Therefore, histological sections of the kidneys from the presumably infected mice were 
tested for polyoma virus (SV-40), Adenovirus and Cytomegalovirus (tests and analysis were 
performed by the Department of Pathology). None of the stainings gave positive (i.e. specific) 
results. Taken together, kidney damage is observed in mice treated with therapeutic doses of 
Tacrolimus (150 mg/kg), whilst mice receiving low doses of Tacrolimus (75 mg/kg) do not 
show any signs for kidney damage. Thus, the dose of 75 mg Tacrolimus per kg food does 
not seem to be nephrotoxic after long-term treatment. 
 
 
 
 
 
Figure 16: Histopathological analysis of the 
kidneys after long-term Tacrolimus treatment. 
Kidneys from mice treated with 75 mg or 150 
mg/kg Tacrolimus for 153 days were stained with 
Hematoxylin & Eosin (H & E) and analysed for 
CNI-induced kidney damage. Example shows a 
section from (a) a 75 mg/kg treated mouse 
(representative) and (b,c) a 150 mg/kg mouse with 
detected inclusion bodies. Inclusion bodies are 
indicated with arrows.  
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4.3 Introducing Tacrolimus monotherapy into a skin 
transplantation model 
An experimental model of marginal states of allograft acceptance must reflect the balance 
between effector and regulatory response where neither is predominant. Therefore, a model 
had to be established where neither the low-dose Tacrolimus monotherapy nor the weak 
regulation inducing therapy alone lead to allograft survival comparable to true tolerance. With 
the following experiments it was determined what doses of Tacrolimus in the BALB/c-to-
C57BL/6- skin transplantation model did not prolong allograft survival, and were thus 
subtherapeutic. When Tacrolimus monotherapy was started seven days prior to 
transplantation, only doses of 100 and 150 mg/kg significantly prolonged allograft survival 
(Fig 17a: MST 100mg/kg or 150 mg/kg vs. Untreated: 13.1 ± 1.79 or 135 ± 0 days vs. 8.3 ± 
0.42 days; p = 0.003 or p < 0.001).  Tacrolimus food administered in doses of 25, 50, and 75 
mg per kg food did not have any effect on the allograft survival (MST: 8.7 ± 0.33, 9.1 ± 0.52 
and 8.3 ± 0.42, respectively). When Tacrolimus monotherapy was started on the day of 
transplantation, both 100 and 150 mg/kg doses prolonged allograft survival significantly 
compared to the untreated group (Fig 17b: MST: 12.2 ± 0.74 or 64 ± 4.14 days vs. 8.3 ± 0.42 
days; p = 0.003 or p = 0.001). Administration of Tacrolimus starting seven days post-
transplantation did not lead to significant prolongation of allograft survival in both doses of 75 
and 150 mg/kg (Fig 17c: MST: 11 ± 0.78 or 9.6 ± 0.6 days vs. 8.3 ± 0.42 days).  
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When given prior to or post transplantation, 75 mg/kg Tacrolimus had no observable effect, 
showing no significant prolongation of allograft survival in a BALB/c-to-C57BL/6 - skin 
Figure 17: Introducing Tacrolimus monotherapy 
in the full MHC mismatch model of skin 
transplantation B/c  B/6. Tacrolimus therapy 
starting on d-7 (a), d0 (b) or d+7 (c) at the indicated 
doses (mg/kg food).  
n =  number of animals per group. Kaplan-Meier-
Survival plot. Statistical analysis: Log-rank test, 
multiple comparisons with Holm-Sidak method 
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transplantation model. In contrast, 100 mg/kg doses led to a small, albeit significantly 
prolongation when administered prior to or at the time of transplantation. Started on d-7, 
Tacrolimus doses of 150 mg/kg had a pronounced significant effect on the allograft survival, 
therefore, this dose given at early time points is considered as therapeutic. 
 
4.4 Defining a weak regulation inducing therapy  
For the combination of a low-dose immunosuppression therapy with a weak regulation 
inducing therapy to establish a model of marginal states of allograft acceptance, it was 
necessary to define a weak regulation inducing therapy that alone would not lead to indefinite 
allograft survival comparable. Therefore, a model of strong regulation induction in the 
BALB/c-to-C57BL/6 – skin transplant combination was (B/c  B/6) established as a 
“standard”. The group of Li described the use of triple costimulatory blockade to induce 
tolerance in a mouse skin transplant model [227], in which anti-CD154 and anti-OX40L 
antibodies and the fusion protein CTLA4-Ig were administered for one week following 
transplantation. With this treatment in the strain combination of DBA/2-to-C57BL/6 ( DBA  
B/6), Li et al. observed survival of 100% grafts over 100 days [227]. 
 
Since Tacrolimus monotherapy had been established in C57BL/6 mice, Li’s protocol was 
applied in the B/c  B/6 – strain combination (MST vs. Untreated: 69.7 ± 11 vs. 8.3 ± 0.42 
days; p < 0.00001; Figure 18). Yet, this significant effect did not match the graft survival 
described by Li et al. Allograft survival of a specific organ varies between different donor-
recipient-strain combinations also in the stringent full MHC-mismatch model [228]. Hence, 
the triple costimulatory blockade was also used in a C57BL/6-to-BALB/c – strain combination 
(where BALB/c is the recipient, B/6  B/c) and in the strain combination of DBA/2-to-
C57BL/6 (DBA  B/6) that had been used in Li’s experiment. Briefly, triple costimulatory 
blockade in these strain combinations had a similar effect than in the B/c  B/6 – model. 
Mean survival times of 57.2 ± 25 vs. 8.5 ± 4.6 days; p < 0.001 (B/6  B/c) and 61.2 ± 25.4 
vs. 11.8 ± 1 days; p < 0.001 (DBA  B/6) were achieved (Figure 18).  
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 Figure 18: Triple costimulatory blockade in three strain combinations. Recipient mice were treated with 
anti-CD154, anti-OX40L and CTLA4-Ig (Triple costimulatory blockade) starting on the day of transplantation. ctrl: 
mice received PBS injections. n =  number of animals per group. Kaplan-Meier-Survival plot. Statistical analysis: 
Log-rank test 
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Triple costimulatory blockade reproducibly prolongs allograft survival in a fully MHC-
mismatched skin transplant model, yet, it does not lead to indefinite graft survival. 
Nonetheless, the B/c  B/6 – combination led to the most significant prolongation of graft 
survival. Thus, the mean survival time of skin graft in this combination will be used as the 
reference to define weak regulation-inducing protocols. 
 
In order to achieve this less prolonged graft survival, mice were treated with anti-CD154 
antibody alone or with anti-CD154 antibody in combination with a donor-specific transfusion 
(DST) of BALB/c-splenocytes. Treatment with only one component of the triple costimulatory 
blockade was considered to lead to a minor prolongation of the graft survival and in other 
transplantations models it has been shown to prolong allograft survival [194]. It is described 
in the literature that the combination of a costimulatory blockade with a DST enhances the 
prolongation effect [195].  As shown in Figure 19, the injections of anti-CD154 antibody on 
day 0, 1, 3 and 6 relative to skin transplantation lead to a MST of 21.8 ± 3.2 days, which is a 
significant prolongation of the allograft survival compared to untreated mice (p < 0.001). 
Treatment with the antibody in combination with a DST on the day of transplantation 
increases the graft survival time significantly (MST anti-CD154 + DST 40 ± 6; p < 0.001) and 
more profoundly than treatment with anti-CD154 alone (p = 0.003).  
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Yet, both treatment options did not result in the allograft survival prolongation achieved with 
the triple costimulatory blockade (anti-CD154 vs. triple costimulatory blockade: p < 0.001 and 
anti-CD154 + DST vs. triple costimulatory blockade: p = 0.018). Hence, both the treatment 
with anti-CD154 antibody alone or in combination with a DST is considered as weak 
regulation-inducing protocols. 
 
 
Figure 19: Treatment with anti-CD154 and DST is a weak regulation inducing protocol. Recipient mice 
were treated with anti-CD154 alone or in combination with DST, starting on the day of transplantation. n =  
number of animals per group. Kaplan-Meier-Survival plot. Statistical analysis: Log-rank test, multiple 
comparisons with Holm-Sidak method 
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4.5 Combination of low-dose Tacrolimus therapy with a weak 
regulation-inducing protocol  
After both low-dose Tacrolimus therapy and weak regulation-inducing protocols were 
established, these treatments were combined to build a model of marginal conditions in 
allograft acceptance. First, Tacrolimus in doses of 50 mg/kg in the food was adjoined to 
induction therapy with anti-CD154 antibody. By giving the Tacrolimus 7 days before 
transplantation measureable drug levels at the time of the surgery could be ensured (Figure 
13). When Tacrolimus therapy was introduced on d+7, interference of Tacrolimus with T reg 
induction should be avoided. Treatment with anti-CD154 has been shown to induce 
regulatory T cell responses [229] and it was assumed that this may play a role in this model. 
T regs are dependent on IL-2 and the expression of this cytokine is inhibited by Tacrolimus 
[170,230].  
 
Mice received Tacrolimus therapy starting either 7 days before or 7 days after skin 
transplantation. The antibody doses were administered as usual on d0, 1, 3 and 6 respective 
to the day of transplantation (d0). As shown in Figure 20a, allograft survival was not 
significantly different in mice treated with anti-CD154 and Tacrolimus at 50 mg/kg starting on 
d -7 and in mice with antibody-treatment alone (MST anti-CD154 + TAC-50 on d-7 vs. anti-
CD154 alone: 26.7 ± 6.7 vs. 21.8 ± 3.2 days; p = 0.81). The delayed introduction of 
Tacrolimus on d+7 had a significant further effect on prolongation of graft survival compared 
to antibody-treatment alone (MST anti-CD154 + TAC-50 on d+7 vs. anti-CD154 alone: 40.2 ± 
6.9 vs. 21.8 ± 3.2 days; p = 0.012). 
 
Further, the weak-regulation inducing protocol using anti-CD154 and DST was combined 
with Tacrolimus at 50 mg/kg on d-7 or d+7 relative to transplantation. Administration of 
Tacrolimus starting one week prior to transplantation did not have an additional graft survival 
prolonging effect (MST anti-CD154 + DST + TAC-50 on d-7 vs. anti-CD154 + DST: 35.7 ± 10 
vs. 40 ± 6 days; p = 0.65, Figure 20b). In contrast, the late induction of Tacrolimus treatment 
starting seven days post transplantation did enhance graft survival compared to treatment 
with anti-CD154 and DST (MST anti-CD154 + TAC-50 on d+7 vs. anti-CD154 + DST: 64.5 ± 
4.7 vs. 40 ± 6 days; p = 0.004).  
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Taking this difference in early and late Tacrolimus administration into account, it was 
presumed that the presence of immunosuppression at the time of treatment with anti-CD154 
+ DST does not have any additional beneficial effect on the induced regulation. Therefore, 
mice were treated with a DST together with a single dose of anti-CD154 either 28 or 14 days 
prior transplantation. Tacrolimus therapy was then induced on d -7 and mice were given the 
usual anti-CD154 treatment beginning on the day of transplantation. However, no effect on 
graft survival was observed when DST was advanced (MST anti-CD154 + DST (d-28) + 
TAC-50 on d-7 vs. anti-CD154 + DST (d-14) + TAC-50 on d-7 vs. anti-CD154 + DST + TAC-
50: 39.3 ± 10.3 vs. 35.2 ± 7.6 days vs. 35.7 ± 10 days, respectively; p = 0.82 and 0.72, 
Figure 20c). Thus, we conclude that the effect of Tacrolimus enhancing the prolongation of 
allograft survival caused by anti-CD154 + DST only occurs when Tacrolimus is introduced 
after the transplantation. 
 
The question arose whether Tacrolimus in higher doses would, in combination with the anti-
CD154 + DST protocol, lead to further prolonged allograft survival. Therefore, Tacrolimus 
food at 75 mg/kg was given starting on d -7 or d +7, together with anti-CD154 + DST 
treatment on the day of transplantation. As expected, the early induction of Tacrolimus at 75 
mg/kg did not have an effect on graft survival prolongation caused by anti-CD154 + DST 
treatment (MST anti-CD154 + TAC-75 on d-7 vs. anti-CD154 + DST: 25.8 ± 14.8 vs. 40 ± 6 
days; p = 0.35, Figure 20d). When Tacrolimus at 75 mg/kg was administered starting one 
Figure 20: Low-dose Tacrolimus therapy combined with a weak regulation inducing protocol does 
significantly prolong allograft survival. Recipient mice were treated with anti-CD154 alone or in combination 
with  DST; this was combined with Tacrolimus therapy starting on d-7 or d7. n =  number of animals per group. 
Kaplan-Meier-Survival plot. Statistical analysis: Log-rank test, multiple comparisons with Holm-Sidak method 
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week after transplantation, allograft survival was significantly prolonged (MST anti-CD154 + 
TAC-75 on d+7 vs. anti-CD154 + DST: 76.4 ± 3.7 vs. 40 ± 6 days; p < 0.001).  
To summarise, Tacrolimus monotherapy combined with either anti-CD154 or anti-CD154 + 
DST significantly prolongs allograft survival, when the drug is administered 7 days after 
tolerance induction and transplantation. Graft survival is superior when regulation is induced 
by the combination of anti-CD154 treatment with a DST. 
 
4.6 Dose-dependent effect of Tacrolimus and two modes of action 
The weak regulation-inducing protocol based on anti-CD154 injections and DST was 
combined with subtherapeutic doses of Tacrolimus at 50, 75 and 100 mg/kg in the food, as 
shown in Figure 21. Thus, the allograft survival prolongation caused by anti-CD154 + DST 
treatment (MST 40 ± 6 days) was significantly increased in a dose-dependent effect to 64.5 ± 
4.7 days with the 50 mg/kg treatment (p = 0.035) and to 76.4 ± 3.7 days with 75 mg/kg 
Tacrolimus food (p < 0.001). When Tacrolimus was administered at 100 mg/kg food, the 
mean survival time was 134 ± 5.5 days. At d150, the experiment was stopped with over 50% 
of thus treated mice still had an intact allograft with no visible signs of rejection.  
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The data obtained with different doses of Tacrolimus is depicted in a dose-response plot in 
Figure 22. Thus, the data is separated into four groups: 1) Tacrolimus monotherapy started 
one week prior to transplantation, 2) on the day of transplantation, 3) one week after 
transplantation and 4) Tacrolimus therapy in combination with tolerance induction by anti-
Figure 21: Dose-dependency. Recipient mice were treated with anti-CD154 alone or in combination with  DST; 
this was combined with Tacrolimus therapy at doses of 50, 75 or 100 mg/kg food starting on d7. n =  number of 
animals per group. Kaplan-Meier-Survival plot.  Statistical analysis: Log-rank test, multiple comparisons with 
Holm-Sidak method 
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CD154 + DST. When started on the day of transplantation or one week prior, Tacrolimus 
monotherapy at 100 mg/kg leads to marginal prolongation of allograft survival, whereas 
doses of 150 mg/kg significantly prolonged graft survival (Figure 17). Interestingly, when 
Tacrolimus is administered on week post transplantation, synergism with the tolerance-
inducing therapy can be observed. More precisely, by combining low-doses of Tacrolimus 
with the tolerance inducing therapy, the achieved graft survival was comparable to that 
obtained with therapeutic doses (150 mg/kg) Tacrolimus.  
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Tacrolimus in this model shows two modes of action: The allograft survival prolongation 
effect of high doses of Tacrolimus at 150 mg/kg decreases drastically between the 
introduction at one week prior to transplantation to introduction one week post transplantation 
(Figure 23). In contrast to this, Tacrolimus at low doses in combination with tolerance 
induction leads to graft survival prolongation when it is introduced at the time of 
transplantation or up to 7 days later (MST induction on d0 vs. d+3 vs. d+7: 74.3 ± 2.7 vs. 
75.9 ± 1.7 days vs. 76.4 ± 3.7 days, respectively; p = 0.8 and 0.09).  
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Figure 22: Synergism.  Dose-response curves showing data obtained from mice treated with Tacrolimus in 
doses of 25, 50, 75, 100 or 150 mg/kg food at indicated time points, with or without combination with anti-CD154 
+ DST. 
Figure 23: Tacrolimus has two modes of action.  Immunosuppressive effect of Tacrolimus (treatment with 
Tacrolimus at 150 mg/kg food) and regulation supportive effect (treatment with anti-CD154 + DST and 
Tacrolimus at 75 mg/kg food). n = min. 4 per data point. Statistical analysis: Log-rank test 
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Taken together, when given at high doses and at early time points (preferably before 
transplantation), Tacrolimus is a general immunosuppressive drug. Surprisingly, Tacrolimus 
can also support regulation in this model, when it is given in low doses and at later time 
points (at the time of transplantation or up to one week later).  
 
 
4.7 Tacrolimus in low-doses relatively enhances suppression by    
T regs 
One possible explanation for enhanced regulation-dependent allograft survival under low-
dose Tacrolimus treatment is that T regs are less susceptible to suppression by low-dose 
Tacrolimus than effector T cells. This hypothesis was tested using in vitro suppression 
assays, where CD4+CD25- effector T cells (Teff) were cultured alone or 1:1 with CD4+CD25+ 
regulatory T cells (T reg) in the absence or presence of Tacrolimus at low doses (0.25 – 2 
ng/ml). Suppression of effector T cells by regulatory T cells was detected by measuring the 
expression of the proinflammatory cytokine IFNγ by ELISA.  
 
The addition of Tacrolimus alone led to dose-dependent suppression of the IFNγ expression 
(Figure 24). Addition of Tacrolimus to cocultures of Teffs and T regs led to significantly 
enhanced suppression of the IFNγ response compared to cocultured Teff and T reg without 
Tacrolimus (% of suppression: 0 ng/ml Tacrolimus vs. 0.25 ng/ml Tacrolimus: 50.8% ± 17.7 
vs. 85.5% ± 8.7, p = 0.0124). At doses of 0.5 ng/ml Tacrolimus, the suppression effect was 
further increased (% of suppression: 0 ng/ml Tacrolimus vs. 0.5 ng/ml Tacrolimus: 50.8% ± 
17.7 vs. 90.4% ± 4.5, p = 0.0049). When Tacrolimus doses were additionally increased, the 
IFNγ expression in the Teff-T reg-cocultures in some experiments was even suppressed 
towards the limit of detection.  
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These in vitro data show that Tacrolimus in low doses suppresses the IFNγ expression of 
effector T cells and disproportionately increases the suppressive effect of regulatory T cells 
in cocultures. If the low doses of Tacrolimus used in the in vitro assay did reflect the in vivo 
levels of Tacrolimus in the lymphoid tissue, the observed effect that low doses of Tacrolimus 
enhance suppression by T regs could account for the enhanced survival prolongation effect 
of subtherapeutic Tacrolimus observed in our in vivo model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: T reg Suppression assay. CD4+CD25- effector cells (Teff) were cultured either alone or in a 1:1 
ratio with CD4+CD25+ regulatory cells (T reg) under anti-CD3/anti-CD28 polyclonal stimulatory conditions and 
Tacrolimus addition as indicated. After 48h, supernatants were harvested and IFNγ was measured by ELISA. 
Mean and SD of 4 independent experiments are shown. The black and grey curve show the IFNγ production; 
the red line indicates percentage of suppression. Statistical analysis: pairwise comparison with 0 ng/ml 
Tacrolimus condition with Student’s T-Test (* p < 0.05, ** p < 0.01) 
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To facilitate readability, the treatment with anti-CD154 + DST + Tacrolimus at 75 mg/kg 
started on d+7 will be referred to as MD-75, where M stands for the anti-CD154 clone 
MR-1 and D for DST. 
 
4.8 Allograft acceptance vs. chronic rejection 
The previous experiments in mice treated with anti-CD154 + DST and Tac-75 (MD-75) 
indicated that regulation- and immunosuppression-dependent marginal states of allograft 
acceptance exist. However, despite a long-term acceptance of allografts in MD-75 mice, 
rejection eventually sets in at about 60 days (Figure 21). This late rejection raised the 
question whether the grafts were lost due to delayed acute rejection or chronic rejection. The 
features of acute and chronic rejection are not equal and can be distinguished by: 1) gross 
pathology, 2) histopathology and 3) molecular markers as detailed in the introduction. Thus, 
stable allografts from MD-75 mice at day 50 post transplantation were monitored for signs of 
acute or chronic rejection. As comparison for acute rejection, B/6 mice were transplanted 
with B/c allografts and received no further treatment. For chronic rejection control, a minor 
antigen (H-Y) mismatch model was used: B/6 female mice received a graft from B/6 male 
donors without additional treatment. 
 
MD-75 allografts undergoing rejection resemble acutely rejecting allografts in their 
macroscopic appearance (Figure 25). The sudden onset of acute rejection in B/c-to-B/6 
transplant recipients without further treatment (acute rejectors) on day 7 (± 1d) is mostly 
characterised by haemorrhagic, necrotic lesions in surrounding normal graft tissue with full 
hair growth. These necrotic lesions spread over the graft tissue until the peak of rejection on 
day 9 (± 1d), when the lesions often cover the complete graft tissue. In contrast to this, grafts 
in the chronic rejection model were rejected with much slower kinetics. Slowly progressing 
hair loss and scarring of the graft tissue were observed, whilst necrotic lesions did not occur.  
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Further, the grafts were examined microscopically. Analysis of H&E stained samples was 
done with the help of a pathologist, PD Dr. med. P. Rümmele (University Hospital of 
Regensburg). Acutely rejecting grafts were harvested when necrotic changes were 
macroscopically manifest, but before haemorrhagic lesions covered the whole graft tissue. In 
all samples, thickening of the skin in total and the epidermis in particular due to massive 
infiltration of inflammatory cells (mostly plasma cells and lymphocytes) was obvious (Figure 
26a). The skin structure was massively damaged with skin adnexal structures mostly 
destroyed. Polynuclear giant cells were detected; the inflammatory cell infiltrate caused 
apoptosis of keratinocytes, fibrinoid necrosis and partial epidermolysis.   
 
Skin grafts from a minor antigen mismatch model (male-to-female) were harvested upon 
detection of hair loss and scarring approximately one month post transplantation. These 
grafts underwent chronic rejection as microscopically characterised by manifest sclerosis and 
fibrosis (Figure 26b). The skin graft was thickened and the skin adnexal structures were 
dissolving. A minor cell infiltrate was present in the epidermis, which overlaid a belt of 
sclerosis. Underneath the sclerotic zone, an infiltration of inflammatory cells was present. 
This stratification is pathognomic for chronic rejection. 
 
Additionally, allografts from MD-75 mice on d50, when no signs of rejection were observed, 
were compared to syngeneic grafts (B/c to B/c) on d150 (Figure 26c + d). The syngeneic 
Figure 25: Macroscopic pathology of rejection. Both the onset (upper panel) and peak (lower panel) of 
rejection are shown. Left: Rejection in a B/c-to-B/6 skin transplant model without treatment (acute rejection). 
Middle:  Rejection in MD-75 mice. Right: Rejection in minor-mismatch (male-to-female) model (chronic 
rejection). Photos are representative. 
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grafts did not show any abnormalities except minimal infiltration of leukocytes in some 
samples, without any signs of fibrosis or destructive changes. MD-75 allografts on d50 
displayed intact skin adnexal structures (hair follicles, sebaceous glands) with an intact 
epidermis. Neither apoptosis nor necrosis was found. Yet, infiltration of leukocytes occurred 
and was mostly perivascular with single cells in the epidermis. This infiltrate was not 
connected with destruction of tissue, but rather seemed non-aggressive. Minor fibrosis or 
sclerosis were occasionally detected, but not in all samples. No stratification was detected, 
contradicting chronic rejection.  
 
To further address the initial question whether MD-75 mice undergo delayed acute or chronic 
rejection, a typical MD-75 skin graft was harvested during rejection for histology, when 
haemorrhagic spots were visible (Figure 26e). Microscopical analysis showed no fibrosis or 
sclerosis, but inflammatory destruction of rete pegs and adnexal structures. In the epidermis, 
inflammatory cells were detected, together with apoptosis and necrosis and beginning 
detachment of the epidermis. Thus, the features of an acute rejection process are manifest 
and the findings argue against chronic rejection taking place in MD-75 mice that reject after 
long-term acceptance.  
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The possibility of chronic rejection was additionally examined by molecular RT-PCR analysis. 
TGFβ is a fibrogenic cytokine and its elevated expression has been described in chronically 
rejecting skin grafts [231]. The expression of TGFβ in allogeneic grafts of MD-75 mice on d50 
Figure 26: Microscopic pathology of rejection. (a) Rejection in a B/c-to-B/6 skin transplant model without 
treatment (acute rejection, d7). (b) Rejection in minor-missmatch (male-to-female) model (chronic rejection, 
d31). (c) Syngeneic (B/c to B/c) (d150). (d) MD-75 graft (d50). (e) Rejection in a MD-75 mouse (d61). 
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without macroscopical signs of rejection was not significantly different from the expression in 
syngeneic MD-75 grafts. Moreover, the expression in both the syn- and allograft was 
significantly less than in chronic rejecting grafts (Figure 27: p = 0.016).  
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To summarise, macroscopical, microscopical and molecular analyses indicate that rejection 
that takes place in MD-75 mice after long-term acceptance of the allograft is consistent with 
delayed acute rejection rather then chronic rejection. 
 
4.9 Absence of donor-specific antibodies in MD-75 mice 
In clinical studies, operationally tolerant patients that are drug-free and have stable allograft 
function [209] have been reported as having no or only low amounts of donor-specific 
antibodies (DSA) [129,210]. Presence of DSA in turn might be correlated with rejection [232]. 
The flow cytometry crossmatch (FCXM) has been first described in 1983 [220] and has been 
used since then in clinics to measure anti-donor antibodies. A modification of a T cell FCXM 
was developed to measure anti-donor-antibodies in mice. Briefly, serum from sensitised mice 
(pooled) or mice treated with anti-CD154 + DST + 75 mg/kg Tacrolimus food (MD-75) was 
incubated with donor and recipient splenocytes. After washing away excess sera, 
fluorescence-labeled antibodies were used to capture target IgG and IgM antibodies bound 
to the splenocyte cell surface. Thus, both donor-specific and self-specific antibodies can be 
detected.  
 
For the analysis, first a lymphocyte gate was set in the forward-scatter / sideward-scatter plot 
(Figure 28, representative example). Using the fluorescence signal for the CD3 and the H2Kd 
antigen, it was discriminated between B/c splenocytes (donor, H2Kd) or B/6 splenocytes (self, 
Figure 27: TGFβ- RT-PCR in skin grafts. Syn- and allografts from MD-75 mice were pooled on d50 post 
transplantation; skins from mice undergoing chronic rejection were pooled at the peak of rejection. RNA was 
isolated from CD45.2+ leukocytes and levels of TGFβ were determined.  n = 4 (chronic) or 5 pools per group, (at 
least 2 grafts / pool) . Scatter plots show the mean and standard deviation. Statistical analysis: Mann-Whitney-
Test, two-tailed (*: p < 0.05 ns: p > 0.05). 
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H2Kb). As shown in the histogram plot, IgG antibody from sensitised mouse serum has 
bound to H2Kd positive B/c cells, thus indicating DSA. As expected, no IgG antibodies can be 
detected in serum from naïve B/6 mice (NMS), neither with specific nor self-specific binding 
capacities.  
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The serial two-fold dilution of the pooled sensitised mouse serum displays a dose-response 
curve for donor-specific IgG (Figure 29) and very low median fluorescence signals (MFI) for 
the H2Kb specific IgG response.  
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A limit of detection was defined as mean MFI of the NMS sera plus the threefold standard 
deviation. Samples with a MFI below the limit of detection were considered as negative for 
IgG antibody.  
 
Figure 28: Crossmatch gating strategy.   Gating strategy in one representative example is shown.  
Figure 30: Titration curve.  Anti-H2-Kd IgG  and anti-H2-Kb IgG response from serial two-fold dilution of serum 
from a sensitised mouse pool. Data points expressed as mean of triplicate MFI is displayed with the standard 
deviation. Curve analysis was done as a sigmoidal dose-response fit of data with 95% confidence intervall.  
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To further characterise our model of weak regulation in combination with low-dose 
Tacrolimus therapy, levels of DSA were determined in mice bearing the allogeneic transplant 
for 50 days. Both the IgG response against donor and self of these mice lies beneath the 
limit of detection (Figure 30a). Further, serum from mice with a syngeneic B/6 transplant and 
treatment with anti-CD154 + DST + Tacrolimus at 75 mg/kg was analysed. The donor-
specific IgG-response of both mice with allograft or syngraft was below the limit of detection 
(Figure 30b).   
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The absence of DSA is evidence that the treated mice do not have donor reactivity. This 
indicates that on d50 after transplantation, the mice are not undergoing acute rejection and 
probably also not undergoing chronic rejection.  
 
4.10  Genotypic characterisation of MD-75 mice with an allograft 
4.10.1 Gene expression profile in skin grafts 
In transplantation research, it is a focus to define biomarkers of tolerance, allowing 
identification of patients that are tolerant, or in line with the findings of this work, in marginal 
states of allograft acceptance. We have set up a panel of over 20 genes associated with 
states of tolerance or rejection (Section 3.1.8.2). The skin allografts of MD-75 mice were 
examined for the expression of these genes. Gene expression in MD-75 mice with a 
syngraft, mice treated with triple costimulatory blockade, mice undergoing acute and mice 
undergoing chronic rejection was measured as control. 
 
Skin grafts from either syn- or allografted MD-75 mice or mice treated with triple 
costimulatory blockade and 75 mg/kg Tacrolimus food were removed on d50 post 
Figure 30: Analysis of donor-specific antibodies in transplanted mice.  Limit of detection was defined as 
mean MFI of the NMS sera + 3x SD. Mean and standard deviation are shown in the scatter plots. (c) Anti-H2-Kd 
IgG  and anti-H2-Kb IgG response from allografted mice treated with anti-CD154 + DST + Tac-75 (n = 20). (d) 
Anti-H2-Kd IgG  response of allografted (n = 5) or syngrafted (n = 4) mice treated with anti-CD154 + DST + Tac-
75.  
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transplantation. In addition, skin grafts from acutely rejecting (untreated after transplantation) 
and chronically rejecting (male-to-female minor mismatch model) were removed on the peak 
of rejection. qPCR analysis of whole graft tissue of single grafts was performed, examining 
for the expression of the genes from our panel. However, only six genes of the panel 
(pdcdlg1, tmem176b, gm1129, man1a, cxcl10 and hmox) were reliably detectable (Figure 
31). 
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Figure 31: Gene profile of the skin graft. Groups: syn: MD-75 mice with syngraft. Allo: MD-75 mice with 
allograft. TT: mice treated with triple costimulatory blockade and 75 mg/kg Tacrolimus food. AR: Transplanted 
mice, untreated, acute rejection. CR: male-to-female minor mismatch transplantation, chronic rejection. qPCR 
analysis of whole single grafts on d50 (syn, allo, TT) or on the day of rejection (AR, CR). n = 4-6 per group. 
Scatter plots show mean with SD. Statistical analysis: pair-wise group comparison (Allo vs. Others) with Mann-
Whitney-Test and Holm-Bonferroni correction for multiple analysis. 
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gm1129, the tolerance-associated gene (TOAG-1), which encodes TCAIM (Figure 31a), 
which has been described as highly expressed during graft acceptance in mice heart and rat 
kidney transplant models, was not significantly different expressed in grafts of allografted 
MD-75 mice [233].  
 
Together with TOAG, also alpha-1, 2-mannosidase (man1a 1) was described in these 
models by the same group as being upregulated during induction therapy and graft 
acceptance and downregulated in the case of rejection. The expression of man1a 1 showed 
no significant differences in MD75 mice with an allograft compared to the control groups 
(Figure 31b).  
 
In human transplant studies, high intragraft expression of chemokine CXCL10 (IP-10) has 
been reported in conjunction with both acute and chronic rejection [234,235]. The cxcl10-
expression in MD-75 allografted mice was significantly higher than the expression in MD-75 
mice with a syngraft (p = 0.0043, Figure 31c), but not significantly different to the three other 
control groups.  
 
Heme-oxygenase 1 (hmox) is an enzyme, whose expression has been discussed 
controversially in the context of allograft acceptance and rejection [236].  In a mouse heart 
transplantation model using CD154 + DST to induce tolerance, intragraft expression of hmox 
was reported to have a protective effect, in other, rodent and human, models, hmox 
espression was upregulated during rejection [236,237]. In comparison to acutely rejecting 
allografts, hmox-expression was significantly reduced in MD-75 allografted mice (p = 
0.0079), which in addition did not show significantly altered hmox expression compared to 
syngrafted MD-75 mice, triple costimulatory blockade treated mice or mice undergoing 
chronic rejection (Figure 31d).  
 
Overexpression of tmem176b (tolerance-related and induced transcript, TORID) in the graft 
was first reported in a rat cardiac transplantation model [238]. Whilst the expression of 
tmem176b in MD-75 mice with an allograft was not significantly different from syngrafted MD-
75 mice, triple costimulatory blockade treated mice or mice undergoing chronic rejection, it 
was significantly decreased in comparison to acutely rejecting allografts (p = 0.0087; Figure 
31e).  
 
The last gene that came up in the qPCR analysis of whole skin grafts was pdcdlg1 (PD-L1). 
As already mentioned, PD-L1 has a role in the regulation and inhibition of the T cell 
response. Interestingly, the expression of pdcdlg1 is significantly upregulated in MD-75 mice 
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with an allograft compared to MD-75 mice with a syngraft (p = 0.0043). The upregulation in 
comparison the mice treated with triple costimulatory blockade is not significant; the 
expression in chronically rejecting grafts is comparable. Expression of pdcdlg1 is higher in 
mice undergoing acute rejection, yet, this is not significantly different from MD-75 mice with 
an allograft (Figure 31f). 
 
To summarise, none of the previously reported tolerance markers TOAG/TCAIM, TORID, 
alpha-1, 2-mannosidase or heme-oxygenase 1 was found to distinguish MD-75 mice with an 
allograft from neither MD-75 mice with a syngraft nor mice treated with triple costimulatory 
blockade. Yet, allografted MD-75 mice do express more CXCL-10, a chemoattractant for 
lymphocytes, and the inhibitory receptor ligand PD-L1. In conclusion, qPCR analysis of skin 
grafts of allograftes MD-75 mice shows a mixed picture. The expression of tolerance-related 
markers can be detected as well as markers for rejection, which is consisted with our 
hypothesis of marginal states and the balance between regulatory and effector responses. 
 
4.10.2 Gene expression profile in draining LN 
In order to obtain a more detailed gene expression profile of allograft acceptance in our 
model, the dLN were analysed for the expression of genes from our panel. Indeed, 22 of 
these genes associated with tolerance and rejection were reliably quantified by qPCR. In 
total, dLNs from 10 mice undergoing acute rejection, 10 mice undergoing chronic rejection, 5 
mice treated with triple costimulatory blockade and 75mg/kg Tacrolimus were analysed 
together with dLNs from 6 syngrafted MD-75 mice and 13 allografted MD-75 mice (Figure 
32). The data obtained from the qPCR is depicted as an unsupervised, hierachical cluster 
analysis. The acutely rejecting mice cluster all together, showing a consistent gene 
expression in the group. However, this is not the case for the other treatment groups. In 
general, single syngrafted MD-75 mice cluster next to single or grouped allografted MD-75 
mice. Chronically rejecting mice cluster partly together or with triple costimulatory treated 
mice. The gene profile of the dLN of allografted MD-75 mice is heterogenous within the 
group. Half of the mice in this group cluster directly together, while the other MD-75 mice are 
spread and found together with syngrafted MD-75 mice, triple costimulatory treated mice and 
some chronically rejecting mice.  
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In conclusion, a genetic profile unique to allografted MD-75 mice in the dLN could not be 
determined. This was also the case for syngrafted MD-75 mice, triple costimulatory treated 
mice and mice undergoing chronic rejection. Thus, the expression of the selected genes 
associated with states of tolerance or rejection in dLN cannot be used as a biomarker to 
determine the state of allograft acceptance in MD-75 mice. 
 
4.11  A model of marginal states of allograft acceptance 
So far, it could be shown that the addition of a low-dose Tacrolimus monotherapy to a weak 
regulation-inducing protocol synergistically prolongs allograft survival in allogeneic murine 
skin transplantation. It remains to be tested whether this experimental model is indeed 
reflecting marginal states of allograft acceptance, wherein neither the effector nor the 
regulatory response predominates. In these marginal states, a disturbance of either the 
regulation or the immunosuppression should tip the balance and lead to rejection of the graft. 
Thus, the same must apply for the experimental model of low-dose Tacrolimus and anti-
CD154 + DST. The balance in marginal states should be disturbed by 1) withdrawing 
immunosuppression, 2) enhancing the effector response or 3) disrupting the regulatory 
response. Therefore, this was tested in the experimental model. 
 
Figure 32: Gene profile of the dLN. syn: MD-75 mice with syngraft. Allo: MD-75 mice with allograft. TT: mice 
treated with triple costimulatory blockade and 75 mg/kg Tacrolimus food. AR: Transplanted mice, untreated, 
acute rejection. CR: male-to-female minor mismatch transplantation, chronic rejection. qPCR analysis of whole 
dLN (axilliary, inguinal) of single mice on d50 (syn, allo, TT) or on the day of rejection (AR, CR). Green shading 
indicates lower expression of a certain gene in comparison to the median of all samples, whereas red shading 
indicates higher expression. Grey boxes indicate missing data points. 
 Results  75 
4.11.1 Withdrawal of Immunosuppression leads to allograft rejection 
Unless stated otherwise, the experiments described below were in general performed with 
allografted mice treated with Tacrolimus food at 75 mg/kg (Tac-75) and anti-CD154 + DST, 
since the allograft survival was over 90% (i.e. 91.4%) on d50 post transplantation (i.e. d50).  
 
Withdrawal of the immunosuppressive treatment was done first to determine the effect on 
allograft survival. Tacrolimus food was switched to normal diet on d50, this led to significantly 
accelerated rejection of the allograft than in the control group, where Tacrolimus food was 
continued (Figure 33: MST withdrawal vs. continuation: 61.4 ± 1.5 vs. 74.8 ± 4.9 days, p = 
0.007).  
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4.11.2 Enhancing the effector response leads to allograft rejection 
To enhance the effector response, MD-75 mice were treated on d50 with 10 x 106  CD4+ and 
CD8+T cells from sensitised B/6 mice that had previously rejected two B/c allografts under 
Tac-75. Control mice received PBS only. Importantly, no other treatment modification was 
done, i.e. Tacrolimus food was continued. The injection of effector T cells  precipitated earlier 
rejection of the allograft in comparison to the control group (Figure 34: MST effector cell 
transfer vs. no transfer: 62.4 ± 2 vs. 76.8 ± 3.8 days, p = 0.007).  
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Figure 33: Withdrawal of immunosuppression.  On d50 post transplantation, Tacrolimus diet was continued 
or withdrawn in MD-75 mice. n =  number of animals per group. Kaplan-Meier-Survival plot.  Statistical analysis: 
Log-rank test 
  
Figure 34: Effector cell transfer.  On d50 post transplantation, MD-75 mice received i.v. 10 x 106 T cells from 
sensitised mice or PBS only . n =  number of animals per group. Kaplan-Meier-Survival plot. Statistical analysis: 
Log-rank test 
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The effector T cell transfer might be seen as a non-physiological challenge, so a second 
method to enhance the effector response was tested: A second skin transplant was applied 
to recipients on d50, which received either a skin graft from original donor (B/c) or from third 
party strain (C3H) (Figure 35). Mice that were challenged with a C3H graft rejected the 
original first graft (that is B/c origin) with similar kinetics than the MD-75 group that had not 
received any further treatment (MST challenge C3H vs. MD-75: 79.4 ± 4.4 vs. 82 ± 2.1 days, 
p = 0.81). However, mice that were challenged with a B/c graft rejected the first, original B/c 
graft significantly earlier than the MD-75 control group (MST challenge B/c vs. MD-75: 70.7 ± 
1.8 vs. 82 ± 2.1 days, p = 0.0014).  
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In addition, mice that were treated with anti-CD154 + DST + Tacrolimus food at 100 mg/kg 
(in the following: MD-100) received i.v. injections of 10 x 106 effector T cells on d50. At this 
time point, graft survival was 100%. Treatment with effector cells precipitated premature graft 
rejection also in the MD-100 group compared to the untreated MD-100 group (Figure 36: 
MST effector cell transfer vs. no transfer: 78.3 ± 6.5 vs. 134.1 ± 5.5 days, p < 0.001). 
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Figure 35: In vivo effector cell transfer.  On d50 post transplantation, MD-75 mice received a second 
transplant that was either B/c (donor) or C3H (third party). Allograft survival of the first allograft (B/c) in both 
groups is shown together with allograft survival of MD-75 mice that received no further treatment (historical 
control group). n =  number of animals per group. Kaplan-Meier-Survival plot. Statistical analysis: Log-rank test, 
multiple comparisons with Holm-Sidak method 
 
Figure 36: Effector cell transfer.  On d50 post transplantation, MD-100 mice received i.v. 10 x 106 T cells from 
the sensitised mice. As control group, allograft survival of MD-100 mice without further treatment is shown 
(historical control group). n =  number of animals per group. Kaplan-Meier-Survival plot. Statistical analysis: Log-
rank test 
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Taken together, these experiments show that enhancing the donor-specific effector response 
led to disturbance of marginal states and thus rejection of the allograft. 
4.11.3 Disrupting regulation leads to allograft rejection 
It follows from the above stated hypothesis that rejection caused by a disrupted regulatory 
response is another proof for having established an experimental model of marginal states. 
Therefore, MD-75 mice were treated on d50 post transplantation with antibodies against 
molecules that play a role in regulation in transplantation.  
 
Treatment with anti-PD-L1 antibody caused early rejection of the allograft compared to 
treatment with the isotype control antibody (Figure 37: MST aPD-L1 vs. Isotype: 65.9 ± 2.6 
vs. 76.4 ± 4.4 days, p = 0.045).  
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Further, treatment with anti-GITR antibody led to significantly earlier rejection compared to 
the corresponding isotype control group (Figure 38: MST aGITR vs. Isotype: 69 ± 5.6 vs. 
89.3 ± 6.6 days, p = 0.019). 
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Figure 38: Anti-GITR antibody. Starting on d50 post transplantation MD-75 mice received 4 injections of anti-
GITR antibody or isotype control. n =  number of animals per group. Kaplan-Meier-Survival plot. Statistical 
analysis: Log-rank test 
  
Figure 37: Anti-PD-L1 antibody Starting on d50 post transplantation MD-75 mice received 8 injections of anti-
PD-L1 antibody or isotype control. n =  number of animals per group. Kaplan-Meier-Survival plot. Statistical 
analysis: Log-rank test 
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The importance of PD-L1 and GITR in the allograft acceptance in this model implies the 
involvement of regulatory T cells. T regs are defined as CD4+CD25+FoxP3+ T cells and in 
mice, CD25 is a useful cell surface marker for T regs [109,239]. Therefore, it was planned to 
deplete T regs by an anti-CD25 antibody. This was done initially in wildtype C57BL/6 mice by 
administration of the depleting CD25 clone PC61 [240]. Flow cytometric analyses of spleen, 
LNs and peripheral blood showed significant reduction in relative numbers of FoxP3+ T cells 
of 44.6%, 49.1% and 55.5%, respectively (Figure 39).  
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When MD-75 mice were treated with the depleting anti-CD25 antibody, no effect on the 
allograft survival could be observed (Figure 40: MST anti-CD25 vs. Isotype: 92.5 ± 4.2 vs. 
93.5 ± 8.5 days, p = 0.41). Thus, it was concluded that not only CD4+CD25+  T regs were 
depleted, but also CD25+ activated effector T cells. 
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A second approach to determine whether FoxP3+ regulatory T cells are responsible for the 
regulation of the anti-donor response and thus allograft acceptance, was to use a genetically 
Figure 39: Depletion with anti-CD25. C57BL/6 mice were treated with 4 injections of anti-CD25 antibody 
(clone PC 61), isotype control or left untreated (animals per group: n = 6).  Mean percentage of FoxP3+ cells and 
standard deviation are shown. Statistical analysis: unpaired t-test, two-tailed (***: p < 0.0005, ns: p > 0.05). 
  
Figure 40: Anti-CD25 antibody. Starting on d50 post transplantation MD-75 mice received 4 injections of anti-
CD25 antibody (clone PC61) or isotype control. n =  number of animals per group. Kaplan-Meier-Survival plot. 
Statistical analysis: Log-rank test 
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modified mouse strain that allowed depletion of FoxP3+ cells. Briefly, these mice were 
generated by Rudensky’s group on a C57BL/6 background and carry the human diphtheria 
toxin receptor (DTR) fused to green fluorescent protein (GFP) sequences under the control 
of the FoxP3 promoter [241]. Thus, FoxP3+ T reg (not FoxP3- T cells) express both GFP and 
the DTR. By administration of diphtheria toxin (DTx) to these Foxp3-GFP-DTR mice, a 
transient and very specific depletion of FoxP3+ T reg can be achieved [241].  
 
Foxp3-GFP-DTR mice were treated with anti-CD154 + DST and Tacrolimus food at 75 mg/kg 
to induce allograft acceptance. The allograft survival was significantly different in these mice 
compared to wildtype C57BL/6 mice that were treated with anti-CD154 + DST and 
Tacrolimus food at 75 mg/kg at the same time as control group (Figure 41: MST Foxp3-GFP-
DTR vs. wildtype mice: 37.1 ± 10.8 vs. 75.5 ± 8.3 days, p = 0.027). These Foxp3-GFP-DTR 
mice had not received any DTx to deplete the FoxP3+ T reg.  
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This difference was an unexpected result since to our knowledge, no pathophysiological 
difference in these mice in any experiments has been observed. Measurement of Tacrolimus 
levels in the blood of non-transplanted Foxp3-GFP-DTR mice did not show different levels as 
would be expected in mice treated with 75 mg/kg Tacrolimus food (mean Tacrolimus level 
over 3 weeks after introduction: Foxp3-GFP-DTR  vs. C57BL/6 sentinel mice: 2.2 µg/l ± 0.5 
vs. 2.6 µg/l ± 0.5, p = 0.38). Thus, it was planned to induce allograft acceptance in our model 
by increasing the low-dose Tacrolimus in the Foxp3-GFP-DTR mice. Hence, they received 
anti-CD154 + DST and Tacrolimus in doses of 100 mg/kg. On d50 after transplantation, mice 
with an intact allograft (over 90%) were treated with i.p. injection of 25 ng/g bodyweight DTx 
or PBS as control. Injection of DTx did precipitate early rejection of the allograft in Foxp3-
GFP-DTR mice in comparison with PBS-treated Foxp3-GFP-DTR mice (Figure 42: MST DTx 
injection vs. PBS injection: 58.8 ± 0.9 vs. 111 ± 4.7 days, p < 0.001). 
Figure 41: Treatment with anti-CD154 + DST + Tac-75 in FoxP3-GFP-DTR mice. Together with wildtype B/6 
mice, FoxP3-GFP-DTR mice received a B/c transplant and were treated with anti-CD154 + DST + Tac-75 to 
induce allograft acceptance. No further treatment was done. n =  number of animals per group. Kaplan-Meier-
Survival plot. Statistical analysis: Log-rank test 
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In contrast, in wildtype C57BL76 mice treated with anti-CD154 + DST + Tac-100, the 
injection of 25 ng/g bodyweight DTx did not precipitate rejection (data not shown). The 
allograft survival in Foxp3-GFP-DTR mice treated with PBS was not significantly different 
from wildtype C57BL76 mice treated with anti-CD154 + DST + Tac-100. Therefore, it was 
shown that the specific depletion of T regs led to disruption of regulation in marginal states 
and thus allograft rejection.  
 
To further examine the importance of regulatory T cells in this model of allograft acceptance, 
their suppressive mechanisms were targeted. Injections with anti-IL10R antibody did not 
have an effect on allograft survival with reference to the isotype control treatment (Figure 43: 
MST aIL-10R vs. Isotype: 77.1 ± 2.4 vs. 78.8 ± 5.4 days, p = 0.6). 
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Figure 42: Treatment with anti-CD154 + DST + Tac-100 in FoxP3-GFP-DTR mice. FoxP3-GFP-DTR mice 
received a B/c transplant and were treated with anti-CD154 + DST + Tac-100 to induce allograft acceptance. On 
d50 post transplantation, mice randomisedly received i.p. injections of Diphtheria Toxin or PBS as control. n =  
number of animals per group. Kaplan-Meier-Survival plot. Statistical analysis: Log-rank test, multiple 
comparisons with Holm-Sidak method 
 
Figure 43: Anti-IL10R antibody. Starting on d50 post transplantation MD-75 mice received 4 injections of anti-
IL10R antibody or isotype control. n =  number of animals per group. Kaplan-Meier-Survival plot. Statistical 
analysis: Log-rank test 
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In contrast to this, injections of anti-TGFβ antibody, provoked rejection at significantly earlier 
time points than the Isotype control (Figure 44: MST aTGFβ vs. Isotype: 69 ± 1.4 vs. 81 ± 2.2 
days, p = 0.002).  
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Therefore, regulation in marginal states of allograft acceptance in MD-75 mice is dependent 
on peripheral T reg producing TGFβ rather then on IL-10 producing natural T reg.  
 
Taken together, the disruption of regulation in the experimental model by disturbing PD-L1, 
GITR and TGFβ pathways and by depleting FoxP3+ T regs leads to rejection of the allograft. 
It was therefore demonstrated that in the model of low dose Tacrolimus in combination with 
weak regulation induction, allograft acceptance can be broken. This was done by 1) 
withdrawal of immunosuppression, 2) enhancing the effector response or 3) disrupting the 
regulatory response. Thus, we are convinced that we have established an experimental 
model of marginal states of allograft acceptance.  
 
4.12  Location of regulatory and effector cell populations 
4.12.1 Regulators and effectors in spleen and dLN 
If our hypothesis is correct and there is a balance between regulatory and effector cells, then 
it should be possible to detect both regulatory and effector cells at the same anatomical sites. 
In MD-75 mice, the spleen was surgically removed 50 days post transplantation. Allograft 
survival in these animals was not affected significantly when compared to allograft survival of 
otherwise untreated MD-75 mice (Figure 45a: MST splenectomy d50 vs. MD-75: 77.3 ± 2.4 
vs. 81.9 ± 2.1 days, p = 0.16). This raised the question whether spleen was even necessary 
for the induction of allograft acceptance in mice treated with low-dose Tacrolimus and anti-
CD154 + DST induction. Thus, splenectomy was performed in C57BL/6 mice at d -7 pre-
transplant, then these mice and naïve control mice were treated with anti-CD154 + DST and 
Figure 44: Anti-TGFβ antibody. Starting on d50 post transplantation MD-75 mice received 4 injections of anti-
TGFβ antibody or isotype control. n =  number of animals per group. Kaplan-Meier-Survival plot. Statistical 
analysis: Log-rank test 
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Tacrolimus at 75 mg/kg. No significant difference was observed between the splenectomised 
and untreated groups (Figure 45b: MST splenectomy d-7 vs. MD-75: 68.6 ± 15.4 vs. 53 ± 
13.2 days, p = 0.44). Hence, the spleen is dispensible for marginal states of skin allograft 
acceptance. 
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The surprising result that the spleen was not necessary for the induction or the maintenance 
of allograft acceptance in the experimental model was further explored at a cellular and 
molecular level. Mice were treated with anti-CD154 + DST + Tac-75 and received either a 
C57BL/6 syngraft or a BALB/c allograft. On d50 post transplantation, leukocyte populations 
from spleen were analysed by flow cytometry. A panel of antibody-combinations was 
developed to analyse different leukocyte populations. Analyses of B cells, NK cells, DCs, 
MDSCs and macrophages did not display any significant differences between mice with a 
syngraft or mice with an allograft (Figure 46, gating strategy see Appendix).  
Figure 45: Splenectomy. (a) On d50 post transplantation MD-75 mice underwent splenectomy. As control 
group, allograft survival of MD-75 mice without further treatment is shown (historical control group). (b) Mice 
underwent splenectomy 7 days prior to transplantation and treatment with anti-CD154 + DST + Tac-75. Allograft 
acceptance was induced in non-surgically altered mice as control. n =  number of animals per group. Kaplan-
Meier-Survival plot. Statistical analysis: Log-rank test 
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The frequency of the CD8+ population was decreased in allografted mice, but not significantly 
(Figure 47a 35.1% ± 1.2 vs. 38.2% ± 3.6, p = 0.07). The percentage of CD4+ amongst CD3+ 
T cells was significantly higher in spleens of mice bearing an allograft (55% ± 1.3 vs. 51.4% ± 
4.3, p = 0.014). This finding indicates a possible shift in the effector or regulatory cell 
populations. Hence, subpopulations of CD4+ T cells were analysed. No significant changes 
were detected in either central or effector memory T cells; nor in the percentage of naïve or 
mature T cells (data not shown). Further, no significant difference in the frequency of CD25+ 
FoxP3+ regulatory T cells or CD25+ FoxP3- T cells was observed (Figure 47b: 1.4% ± 0.8 vs. 
1.2% ± 0.8, p = 0.6 and 4% ± 2.9 vs. 3.6% ± 1.7, p = 0.73, respectively). 
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Figure 47: Analysis of spleen Spleens from MD-75 mice with a syn- or an allograft were analysed on d50 post 
transplantation. (a+b) n = 9 per group. (c) n = 6 (syngraft) or 8 (allograft). Scatter plots show the mean and 
standard deviation. Statistical analysis: Mann-Whitney-Test, two-tailed (*: p < 0.05, ns: p > 0.05). 
  
Figure 46: Panel analysis of spleen. Spleens from MD-75 mice with a syn- or an allograft were analysed on 
d50 post transplantation. Column plots show the mean and standard deviation. n = 9 per group. Statistical 
analysis: Mann-Whitney-Test, two-tailed. 
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In concordance with the FACS data, quantitative RT-PCR analysis of relative foxp3 mRNA 
expression did not reveal any differences between mice with a syngraft and those with an 
allograft (Figure 47c: p = 0.49). In summary, no striking differences in the percentage of 
regulatory and effector cell populations were found in the spleens of mice with a syngraft and 
mice with an allograft. It was shown that the spleen is not necessary for the induction of 
allograft acceptance in our model and is even dispensable in the maintenance of allograft 
acceptance.  
 
Therefore, the graft draining LN (inguinal and axilliary) were examined by FACS, focussing 
on the T cell populations. The frequencies of both CD4+ and CD8+ amongst the CD3+ 
population were not different in mice with an allograft in comparison to mice with a syngraft 
(Figure 48a). Allografted mice seem to have slightly, yet not significantly, elevated 
percentages of CD25+ FoxP3+ cells in the draining LN (allo vs. syn: 7.6% ± 0.9 vs. 6.8% ± 
0.8, p = 0.12; Figure 48b). The percentages of the CD25+ FoxP3- cells were similar in both 
groups (Figure 48b: p = 0.69). Further, relative expression of foxp3 mRNA in whole dLN was 
comparable between mice with a syngraft and mice with an allograft (Figure 48c: p = 0.59).  
 
CD4+
CD8+
Syngraft Allograft
20
30
40
50
60
%
 
o
f C
D3
+
 
in
 
dL
N
0.0
2.5
5.0
7.5
10.0
%
 
o
f C
D4
+
 
in
 
dL
N
Syngraft Allograft
CD25+FoxP3-
CD25+FoxP3+
a b
ns
ns
ns
ns c ns
R
el
at
ive
 
fo
xp
3 
m
RN
A 
ex
pr
es
si
o
n
 
 
in
 
dL
N
Syngraft Allograft
0.0
0.5
1.0
1.5
%
 
o
f C
D3
+
 
in
 
dL
N
%
 
o
f C
D3
+
 
in
 
dL
N
%
 
o
f C
D4
+
 
in
 
dL
N
%
 
o
f C
D4
+
 
in
 
dL
N
%
 
o
f C
D4
+
 
in
 
dL
N
R
el
at
ive
 
fo
xp
3 
m
RN
A 
ex
pr
es
si
o
n
 
 
in
 
dL
N
R
el
at
ive
 
fo
xp
3 
m
RN
A 
ex
pr
es
si
o
n
 
 
in
 
dL
N
 
 
 
 
Animal experiments, as first done in Waldmann’s group [211], demonstrated that tolerance in 
transplantation is “infectious” and can be transferred by cell transfer. Thus, a cell transfer 
experiment was performed. Since cells from the spleen were not necessary for the 
maintenance of allograft acceptance in MD-75 mice, 1x106 total CD4+ and CD8+  T cells from 
the draining LNs of MD-75 mice were transferred on d50 into Rag 1-/- mice, which in general 
lack mature T and B lymphocytes [242]. Fourteen days after the cell transfer, mice 
underwent transplantation of both a B/c and a C3H skin allograft. The T cells originating from 
MD-75 mice will recognise B/c antigen as donor antigen and C3H antigen as third party 
antigen. As shown in Figure 49a, reconstituted Rag 1-/- mice rejected C3H grafts significantly 
earlier than the B/c grafts (MST C3H vs. B/c: 13 ± 0.4 vs. 19.5 ± 1.1 days, p < 0.001). This 
experiment was also done with T cells from dLN of MD-100 mice and again, the C3H grafts 
Figure 48: Analysis of dLNs Draining LNs from MD-75 mice with a syn- or an allograft were analysed on d50 
post transplantation. (a+b) n = 7 (syngraft) or 8 (allograft). (c) n = 13 (syngraft) or 20 (allograft). Scatter plots 
show the mean and standard deviation. Statistical analysis: Mann-Whitney-Test, two-tailed (ns: p > 0.05). 
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were rejected significantly earlier than the B/c grafts (Figure 49b: MST C3H vs. B/c: 15.5 ± 
1.9 vs. 47.8 ± 10 days, p < 0.001).  
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Thus, it seems that the allograft acceptance generated in our model can be transferred and 
the donor-specific regulatory cells are at least in part located in the dLN. As control, Rag 1-/- 
mice were reconstituted with T cells from the dLN from mice treated with either 75 mg/kg or 
100 mg/kg Tacrolimus for 50 days and received B/c and C3H transplants 14 days later. 
These experiments were still ongoing by the time of submission of this thesis. Therefore, the 
results obtained and described above have to be interpreted carefully and it must be 
conceded that they can give only indices, not proof.  
 
4.12.2 Regulators and effectors are also located in the graft 
After examination of spleen and dLN, another possible location of regulatory and effector cell 
populations was analysed, namely the skin graft itself. Indeed, an experiment previously 
done to generate an in vivo effector response (Figure 35) offered more read-out information. 
As already described, MD-75 mice received a second transplant (“challenge”) on d50 that 
was either a B/c or a C3H allograft. Figure 50 depicts allograft survival of both the first 
allograft, which is B/c in both groups, and of the second allograft, which is either B/c or C3H. 
The second allografts were rejected with similar kinetics, regardless whether they were donor 
(B/c) or third party (C3H) origin (MST second graft: B/c vs. C3H: 10.9 ± 1.6 vs. 13.3 ± 1.7 
days, p = 0.45). As shown before, application of a second graft from donor precipitates 
rejection of the first graft (Figure 35). Interestingly, despite rejection of a second B/c graft 
located next to the first B/c graft (Figure 50), the latter was rejected significantly later (MST 
days post-transplantation: first B/c graft vs. B/c challenge graft: 10.9 ± 1.6 vs. 20.7 ± 1.8 
Figure 49: T cell transfer from dLNs.  (a) On d50 post transplantation, 10 Rag1-/- mice received i.v. 1 x 106 T 
cells from MD-75 mice with an intact allograft on d50. (b) On d50 post transplantation, 8 Rag1-/- mice received 
i.v. 1 x 106 T cells from MD-100 mice with an intact allograft on d50.  14 days later, Rag1-/- mice received both a 
B/c (donor) or C3H (third party) transplant. n =  number of grafts per group. Kaplan-Meier-Survival plot. 
Statistical analysis: Log-rank test 
  
 Results  86 
days, p = 0.003, Figure 51). This hints at the presence of regulatory cells in the first allograft 
that suppressed the donor-specific effector cell enough to delay rejection. 
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To further examine regulatory and effector cells in the B/c grafts of B/6 mice treated with anti-
CD154 + DST + Tac-75, grafts were explanted on d50 and retransplanted onto Rag1-/- mice. 
After 14d, leukocytes from dLNs of these Rag1-/- mice were analysed by flow cytometry 
(Figure 52). Both CD25+ FoxP3+ and CD25+ FoxP3- CD4+ T cells were detected. Since Rag 
1-/- mice lack T cells, these cells must have come out of the graft and originate from the B/6 
recipient. 
Figure 50: Challenge.  On d50 post transplantation, MD-75 mice received a second transplant that was either 
B/c (donor) or C3H (third party). Allograft survival of first allograft (B/c) in both groups is compared with allograft 
survival of the second graft (B/c or C3H).  
  
Figure 51: Challenge graph.  On d50 post transplantation, MD-75 mice received a second transplant that was 
either B/c (donor) or C3H (third party). Allograft survival of first allograft (B/c) in both groups is compared with 
allograft survival of the second graft (B/c or C3H). n =  number of animals per group. Kaplan-Meier-Survival plot. 
Statistical analysis: Log-rank test, multiple comparisons with Holm-Sidak method 
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In a transfer experiment depicted in Figure 53, grafts from MD-75 mice were retransplanted 
onto Rag1-/- mice. In addition, the recipients also received a second transplant from a naïve 
B/c donor on the same day.  
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It was planned to reconstitute the Rag1-/- mice 14 days later with T cells from a B/6 wildtype 
animal and to assess graft survival in order to test the hypothesis that the regulatory cells in 
the graft from a MD-75 mouse will prevent rejection from occurring as early as in naïve B/c 
graft. Surprisingly, before the reconstitution could be done, the Rag 1-/- mice rejected the 
graft from a MD-75 mouse, and also the graft from a naïve B/c donor. Three “naïve” grafts 
showing signs of rejection (haemorrhagic spots, hardening) were analysed by flow cytometry 
(Figure 54). In these B/c grafts, the majority of leukocytes (CD45.2) detected was negative 
for H2-Kd (BALB/c MHC I) and positive for H2-Kb (C57BL/6 MHC I). This population 
Figure 52: Effector and regulatory T cells transferred with graft.  On d50 post transplantation, allografts 
from MD-75 mice were retransplanted onto Rag1-/- mice. 14 days later, dLNs from the Rag1-/- mice were 
analysed by flow cytometry. n =  5. Flow cytometry-plots  from one representative sample is shown. Gates and 
arrows indicate the gating strategy; numbers in the plots indicate percentages of the parent population. The 
scatter plot shows percentages of FoxP3- CD25+ FoxP3+ CD25+ of all five mice and the mean and SD. 
  
Figure 53: Experimental design retransplantation.  On d50 post transplantation, allografts from MD-75 mice 
were retransplanted onto Rag1-/- mice. Additionally, these Rag1-/- mice received a skin graft from a naïve B/c 
donor. 
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contained CD4+ T cells. The existence of H2-Kb positive cells in the “naïve” grafts of B/c 
origin can be only explained by migration.  
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Taken together, these data indicate that effector cells from the C57BL/6 mouse receiving a 
B/c graft under anti-CD154 + DST + Tac-75 must have migrated into the graft (the “MD-75 
graft”). Once the “MD-75 graft” was retransplanted onto a Rag1-/- mice together with a “naïve” 
B/c graft, these cells must have migrated to the “naïve” graft and then, they re-entered the 
“MD-75 graft” to cause allograft rejection.  
 
To avoid the rejection of the allografts as observed above, another transfer experiment was 
designed as follows: One group of Rag1-/- mice received a retransplanted 50d - graft from a 
MD-75 mouse, whereas a second group of Rag1-/- mice received a “naïve” B/c graft from 
untreated donors (Figure 55).  
 
Figure 54: FACS analysis Rag1-/- with double transplants.  One representative Flow cytometry plot shows 
the presence of T cells in the “naïve” graft undergoing rejection after the retransplanted graft had already been 
rejected.  T cell were found in all 3 analysed grafts. 
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After 14 days, the recipients were reconstituted with 1x106 T cells from untreated B/6 
wildtype mice. This precipitated allograft rejection in recipients with a “MD-75 graft” and in 
recipients with a “naïve” graft with similar kinetics (MST graft “MD-75” vs. “naïve”: 14.4 ± 1.5 
vs. 11.7 ± 1 days, p = 0.23; Figure 56). These results show that the regulation in the “MD-75 
graft” alone is not strong enough to keep the balance and prevent rejection in the new 
setting, the Rag1-/- mouse.  
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Further, the presence of regulatory T cells was examined on the molecular level by qPCR 
analysis of foxp3 mRNA in the skin graft. For this, skin grafts of MD-75 mice were pooled (at 
least 3 grafts / group) and CD45.2+ leukocytes were sorted. The control groups were mice 
that received a syngraft and the same treatment with anti-CD154 + DST + Tac-75. The foxp3 
expression in all samples from mice with a syngraft is given as the fold expression of the 
maximum dilution of the reference allograft pool that could be detected using the 
manufacturer’s instructions for the foxp3 primer. This was necessary, since the signal for 
Figure 55: Experimental design retransplantation and reconstitution. On d50 post transplantation, 
allografts from MD-75 mice were retransplanted onto Rag1-/- mice. A second group of Rag1-/- mice received a 
skin graft from a naïve B/c donor. After 14 days, recipients were reconstituted with 1x106 T cells from untreated 
B/6 wildtype mice. 
Figure 56: Transfer of regulation by retransplantation of the skin graft.  On d50 post transplantation, 
allografts from MD-75 mice were retransplanted onto Rag1-/- mice. A second group of Rag1-/- mice received a 
skin graft from a naïve B/c donor. After 14 days, recipients were reconstituted with 1x106 T cells from untreated 
B/6 wildtype mice. n =  number of animals per group. Kaplan-Meier-Survival plot. Statistical analysis: Log-rank 
test 
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foxp3 came up only at 35 cycles or not at all, with no congruent results in the triplicate 
measurements. In contrast to this, expression of foxp3 mRNA could be detected reliably in all 
pooled samples from mice with an allograft (mean relative expression in syngrafted mice vs. 
allografted mice:  0.12 ± 0 vs. 1.6 ± 0.5, p = 0.002, Figure 57). 
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In addition, it was possible to detect FoxP3+ cells in allografts of MD-75 on d50 or at the time 
point of rejection by immunohistochemical staining with anti-FoxP3 antibody (Figure 58). 
Judging from the phenotype of these cells (size, shape), they were 
lymphocytes.
100 µm
MD-75 (rejecting)
100 µm
MD-75 (d50)
 
Figure 58: Immunohistochemical FoxP3 staining. FoxP3+ cells were detected in skin sections of mice with a  
MD-75 allograft on d50 or a MD-75 allograft undergoing rejection od d61.  
 
In summary, graft transfer experiments indicated the presence of both regulatory and effector 
T cell populations in the grafts of MD-75 mice. This was further confirmed by cellular and 
molecular analyses of FoxP3, indicating the presence of regulatory T cells. In addition, the 
presence of effector cell populations was indicated by transfer experiments fortified by flow 
cytometry data. These results fit the expectation that a balanced mixture of effector and 
regulatory cells in our model should be detectable at the same sites. 
Figure 57: FoxP3- RT-PCR in skin grafts. Syn- and allografts from MD-75 mice were pooled on d50 post 
transplantation. RNA was isolated from CD45.2+ leukocytes and levels of FoxP3 were determined.  n = 5 pools 
per group, (at least 3 grafts / pool) . Scatter plots show the mean and standard deviation, FoxP3 expression in 
syngraft-pools was set according to the detection limit. Statistical analysis: One-sample T-Test, two-tailed (***: p 
< 0.005). 
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4.12.3 Analysis of myeloid cells in the graft 
The skin grafts of MD-75 mice after d50 after syn- or allotransplantation were further 
analysed for cell populations with effector or regulatory function. No significant difference 
was observed in the MDSC compartment of allogeneic or syngeneic skin grafts (Figure 59: 
MST CD11b+Gr1+: syngraft vs. allograft: 2.5% ± 1% vs. 3.2% ± 1.2%, p = 0.19).  
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Yet, the percentage of CD11b+ cells in allografts was significantly increased compared to the 
CD11b+ population in syngeneic grafts (Figure 59: MST CD11b+: syngraft vs. allograft: 34.5% 
± 4.2% vs. 51.5% ± 3.1%, p = 0.02). Therefore, this population was examined further. Using 
the cell surface markers CD11b and CD11c, five distinct populations were gated in the skin 
grafts (Figure 60): 1) CD11c+ CD11b++, 2) CD11c- CD11b++, 3) CD11c+ CD11b+, 4) CD11c- 
CD11b+ and 5) CD11c+ CD11b-.  
 
live
SS
C
Li
v
e-
D
ea
d
CD
11
b
FSC FSC CD11c
12
34
5
 
 
 
 
 
Figure 59: Myeloid cell analysis in skin grafts I. Syn- and allografts from MD-75 mice were analysed by Flow 
cytometry on d50 post transplantation. FACS plots showing gating information are representative examples. 
Column plots show the mean and standard deviation of CD11b+Gr1+ MDSCs and CD11b+ macrophages. 
Statistical analysis: Mann-Whitney-Test, two-tailed (*: p < 0.05, ns: p > 0.05). 
Figure 60: Myeloid cell analysis in skin grafts II. Syn- and allografts from MD-75 mice were analysed by Flow 
cytometry on d50 post transplantation. One representative plot is shown to demonstrate the gating strategy. . 
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The percentages of populations 1, 3 and 4 were significantly increased in allografts 
compared to syngrafts (Figure 61: p = 0.005, p < 0.001 and p = 0.0004, respectively). In 
contrast, the percentage of population 5 was significantly decreased in allografts (p < 0.001). 
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The populations in allografts were further characterised by flow cytometry. Population 1 
expressed high levels of Dectin-1 and F4/80, a marker of mature macrophages, whilst the 
expression of both markers in population 3 was low or absent (Figure 62). Expression of 
MHC class II and the costimulatory molecules CD80 and CD86 was absent in population 3, 
indicating a non-immunogenic phenotype. In contrast, population 1 showed a heterogenic 
expression of MHC class II and intermediate levels of CD80 with absent CD86 expression, 
thus indicating partially matured antigen-presenting cells. The macrophage-restricted 
receptor Sialoadhesin (CD169) was expressed in both populations 1 and 3. Mononuclear 
phagocytes in the mouse dermis have been described as Dectin-1 positive cells also 
expressing the mannose receptor (CD206) and the macrophage galactose-/N-
acetylgalactosamine-specificlectin (mMGL / CD301) [243]. Population 1 was negative for 
CD301 expression, as was population 3. Yet, in contrast to population 3, cells of population 1 
did express the mannose receptor.  
 
Figure 61: Myeloid cell analysis in skin grafts III. Skin grafts from MD-75 mice with a syn- or an allograft were 
analysed on d50 post transplantation.  n = 12 per group. Column plots show the mean and standard deviation in 
population 1 – 5, gating strategy as described above. Statistical analysis: Mann-Whitney-Test, two-tailed (**: p < 
0.01, ***: p < 0.001). 
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The above described expression profiles are indicative of population 3 harbouring immature 
macrophages whilst population 1 is consistent with partially or completely matured 
macrophages. In allografts, the ratio of population 3 to population 1 is significantly enhanced 
compared to syngrafts (Figure 63, p < 0.001), skewing towards more immature macrophages 
in the graft.  
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In addition, PD-L1 expression was detected in population 3 in contrast to population 1 
(Figure 62).  
 
Thus, non-immunogenic macrophages expressing PD-L1 might be a possible target for the 
anti-PD-L1 antibody treatment that precipitated rejection in MD-75 mice.     
Figure 62: Expression profile of Population 1 and 3. Histogram plots, black lines represent specific signals; 
red traces represent isotype controls. Data are representative profiles of allografted mice.  
Figure 63: Ratio of Population 1 and 3. Mean and SD are displayed for . Data are representative profiles of 
allografted mice.  
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4.13  The balance tips 
As indicated by previous data, allograft acceptance in MD-75 mice fails and grafts eventually 
undergo delayed acute rejection. In order to detect changes in the cellular compartment in 
MD-75 mice, effector and regulatory T cells were analysed further. As already mentioned and 
shown in Figure 21, on day 50 post transplantation, over 90% of MD-75 allografts are intact, 
but the grafts are rejected in the following weeks. Thus, effector and regulatory T cells in dLN 
from MD-75 mice on d50 were compared to dLN from MD-75 mice at a time point, where 
50% of the grafts in this experimental group were rejected or rejecting (day 94). A significant 
increase in the percentage of CD8+ T cells was observed comparing d50 mice with the “50% 
rejection” group (Figure 64a: d50 vs. “50% rejection”: 51.3% ± 3.3% vs. 55.1% ± 3.2%, p = 
0.015). The percentage of CD4+ T cells in dLN of “50% rejection” mice with both intact and 
rejecting/rejected grafts was significantly decreased compared to d50 mice (d50 vs. “50% 
rejection”: 43.3% ± 3.6% vs. 35.7% ± 2.1%, p = 0.002). The ratio of cytotoxic CD8+ T cells 
over CD4+ T cells was significantly increased in the “50% rejection” group compared to the 
d50 group (p = 0.002, Figure 64b). 
 
Surviving graft on d50
Surviving graft
Rejecting/Rejected graft
30
40
50
60
%
 
of
 
CD
3
CD8+ CD4+
d50 50% graft 
survival
d50 50% graft
survival
* ***
d50 50% graft
survival
0.0
0.5
1.0
1.5
2.0
ra
tio
 
CD
8+
 
/ C
D4
+
**
a b
 
 
 
 
 
In addition, the CD4+ T cell compartment was analysed for the percentages of CD25+FoxP3+ 
T regs and CD25+FoxP3- effector T cells. No significant changes were detected in the 
percentage of CD25+FoxP3+ amongst the CD4+ population (Figure 65a: d50 vs. 50% graft 
survival group: 8% ± 1% vs. 7.3% ± 1.2%, p = 0.26). In contrast to this, the percentage of 
CD25+FoxP3- amongst the CD4+ population was significantly increased in the 50% graft 
survival group (d50 vs. 50%  graft survival group: 3% ± 0.8% vs. 6.5% ± 1.4%, p < 0.001). 
The ratio of CD4+ effector cells over CD4+ regulatory was significantly increased in the “50% 
rejection” group compared to the d50 group (p < 0.001, Figure 65b). 
Figure 64: Analysis of CD4+ and CD8+ T cells in dLNs in MD-75 group with 50% rejection.  Draining LNs 
from a experimental group of  MD-75 mice with a syn- or an allograft were analysed when 50% of the mice had 
rejected the graft. Percentages of CD4+ and CD8+ of these mice were compared with data obtained from MD-75 
on d50 with intact allografts.  Scatter plots show the mean and standard deviation. Statistical analysis: Mann-
Whitney-Test, two-tailed (*: p < 0.05, **: p < 0.01, ***: p < 0.001). 
  
 Results  95 
a
Surviving graft on d50
Surviving graft
Rejecting/Rejected graft
0.0
2.5
5.0
7.5
10.0
CD25+FoxP3-
%
 
o
f C
D4
d50 50% graft 
survival
d50 50% graft
survival
CD25+FoxP3+
d50 50% graft
survival
0.0
0.5
1.0
1.5
2.0
ra
tio
 
CD
25
+
Fo
xP
3-
/ C
D2
5+
 
Fo
xP
3+
***
b
***
ns
 
 
 
 
 
 
Thus, the population of CD4+ effector T cells in the dLN increases over time and this increase 
is detectable in both mice undergoing rejection and mice with an intact allograft on d94. 
Nonetheless, it has to be mentioned that with these measurements, the whole polyclonal T 
cell pool is analysed and that therefore no conclusions can be made concerning the donor-
antigen-specific populations of effector and regulatory T cells.  
 
We then hypothesised that the late rejection that occurs in MD-75 mice is caused by donor-
reactive T cells that emigrate from the thymus after the treatment with anti-CD154 + DST.  
Therefore, allograft acceptance was induced in C57BL/6 mice after they had been 
thymectomised at 5-6 weeks of age, together with their littermates that did not undergo 
thymectomy. Both groups were treated in conformity with the standard protocol of anti-
CD154 + DST + Tac-75 and graft survival was monitored (Figure 66).  
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Figure 65: Analysis of dLNs in MD-75 group with 50% rejection.  Draining LNs from a experimental group of  
MD-75 mice with a syn- or an allograft were analysed when 50% of the mice had rejected the graft. Percentages 
of CD25+FoxP3- and CD25+FoxP3+ of these mice were compared with data obtained from MD-75 on d50 with 
intact allografts.  Scatter plots show the mean and standard deviation. Statistical analysis: Mann-Whitney-Test, 
two-tailed (***: p < 0.001). 
  
Figure 66: Thymectomy before induction therapy. Early thymectomised or untreated littermates were 
transplantated with a B/c graft and treated with anti-CD154 + DST + Tac-75 and graft survival was monitored.  
n =  number of animals per group. Kaplan-Meier-Survival plot. Statistical analysis: Log-rank test 
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The “conventional” MD-75 mice rejected with similar kinetics as previously observed with 
MD-75 treatment (MST: 78.8 ± 2.1 days, 50% of the mice had rejected, p = 0.007). In 
contrast to this, none of thymectomised mice rejected the graft up to date (d84). Thus, we 
conclude that late rejection in MD-75 mice is caused, in part, by recent thymic emigrants.  
 
4.14  Marginal states of allograft acceptance might be converted 
into operational tolerance 
A logical consequence that follows from our hypothesis and the previous data is the desire to 
tip the balance of effector and regulatory cells in favour of regulation. By enhancing the 
regulatory response, it might be possible to withdraw immunosuppression completely and to 
achieve stable long-term allograft survival, i.e. operational tolerance. Therefore, MD-75 on 
d50 post transplantation received a second weak regulation induction (anti-CD154 + DST) 
and Tacrolimus food was withdrawn. In comparison to the allograft survival time of previous 
Tacrolimus withdrawal groups (Figure 33), mice receiving this boost therapy did reject the 
allograft significantly later (Figure 67: MST withdrawal vs. boost: 61.4 ± 1.5 vs. 87.5 ± 6.4 
days,  p < 0.001).  
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These data indicate that it is feasible to achieve operational tolerance by boosting the 
regulatory response in marginal states, which is consistent with our hypothesis.  
 
 
 
 
Figure 67: Boost of marginal states. Starting on d50 post transplantation MD-75 mice received a DST 
together with 4 injections of anti-CD154. At the same time, Tacrolimus food was switched to normal diet 
(withdrawal of immunosuppression) Allograft survival was compared to a historical control group, where 
Tacrolimus food was withdrawn from MD-75 mice on d50. n =  number of animals per group. Kaplan-Meier-
Survival plot. Statistical analysis: Log-rank test 
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5 Discussion 
Tolerance in transplantation can be seen as the qualitative result of the balance of the 
effector and regulatory response. This further implies the existence of marginal states of 
allograft acceptance. In such marginal states, neither the effector nor the regulatory response 
is predominating, which leads to an unstable condition of non-rejection. In these cases, low-
dose immunosuppression might control a weak effector response or support a marginally 
exceeding regulatory response. A mouse skin transplant model of marginal states of allograft 
acceptance under low dose immunosuppression was established with this work. The 
existence of marginal states of allograft acceptance resulting from a balance between 
effector and regulatory response might have an influence on the development of new 
treatment strategies. 
 
Allogeneic skin transplantation in mice is a widely used method to conduct research on graft 
survival and tolerance inducing strategies [3,195]. This is due to various reasons: skin 
transplantation is a very stringent model, involving a primary non-vascular graft that is highly 
immunogenic. We established a low-dose Tacrolimus monotherapy that is subtherapeutic 
and a weak-regulation inducing protocol, that does not lead to permanent graft acceptance in 
a murine skin transplant model. By combining both subtherapeutic treatments, an 
experimental model of marginal states of allograft acceptance under immunosuppression 
was built. The weak-regulation inducing protocol was established as treatment with a donor-
specific transfusion (DST) of whole donor splenocytes in combination with a short course of 
anti-CD154 injections for costimulatory blockade or treatment with anti-CD154 alone.  
 
Using this experimental model, we formally show that marginal states of allograft acceptance 
under low-dose immunosuppression are dependent upon immunological regulation. This 
regulation is supported by low doses of the CNI Tacrolimus, as shown in vivo and in vitro; 
and mediated by regulatory T cells. Our data demonstrate that the late rejection that occurs 
in marginal states of allograft acceptance is of an acute type and mediated by thymic 
emigrants. Importantly, we could show that the boost of regulation in marginal states and 
thus further prolongation of allograft survival is achievable.   
 
 
5.1 Synergistic effect of Tacrolimus and regulation 
Depletion of alloreactive CD8+ T cells on the one side and the induction of regulatory T cells 
and hyporesponsiveness on the other side are not sufficient to induce tolerance with 
indefinite allograft survival in the full mismatch B/c-to-B/6 skin transplant model with anti-
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CD154 + DST. Therefore, and because the induced allograft survival was significantly 
reduced in comparison to the tolerance inducing protocol of triple costimulatory blockade, we 
consider treatment with anti-CD154 + DST as a weak tolerance inducing strategy in the 
stringent model of B/c-to-B/6 skin transplantation. 
 
The use of Tacrolimus monotherapy in the allogeneic skin transplant model showed that 
doses of 50, 75 and 100 mg per kg food had no or a small prolongation effect on allograft 
survival at the introduction time points tested. In contrast, doses of 150 mg/kg were found to 
be therapeutic when given before or at the time point of transplantation. Reflecting the 
clinical situation, therapeutic doses of Tacrolimus led to kidney damage, possibly due to viral 
infection. Yet, the inclusion bodies detected in mice treated with 150 mg/kg must still be 
identified, since histological staining for BK-virus, CMV and Adenovirus did not give positive 
results. Molecular analysis by virus-specific qPCR would be an approach to clarify the 
histopathological findings. Importantly, no or only mild kidney damage was observed after 
long-term treatment in mice under low-dose Tacrolimus (75 and 100 mg/kg, respectively), 
illustrating the benefit of CNI minimisation.  
 
Regarding the compatibility of CNIs and tolerance induction with costimulatory blockade, 
conflicting data have been published. Some groups reported antagonistic effects of CNI 
treatment; when combined with costimulatory blockade, this resulted in the abrogation of 
tolerance [244-246]. In contrast, there is also data showing neither beneficial or adverse 
effects of combined treatment with CNI and costimulatory blockade [246-248]. The 
combination of costimulatory blockade with CNI could also enhance prolongation of allograft 
survival. This was demonstrated with the combination of CTLA4-Ig and suboptimal CsA in a 
rat cardiac model [249] as well as the combination of ICOS and suboptimal Tacrolimus in a 
rat liver transplant model [250].  
 
Our data of Tacrolimus monotherapy and the data obtained when Tacrolimus at  high (150 
mg/kg) or low doses (75 mg/kg) was combined with the weak tolerance induction therapy 
show two modes of action of Tacrolimus. Interestingly, apart from the immunosuppressive 
feature, Tacrolimus also supports regulation in our allogeneic skin transplant model when 
given in low doses. Moreover, this synergistic effect was found to prolong allograft survival 
dose-dependently, comparing doses of 50, 75 and 100 mg/kg.  
 
This finding is unexpected in the light of previously published data. Tacrolimus as a 
Calcineurin inhibitor prevents the dephosphorylation of NF-AT, thus blocking the transcription 
of the IL-2 gene and therefore IL-2 production. This results in suppression of the activation, 
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differentiation and proliferation of naïve and memory effector CD4+ and CD8+ T cells 
[171,172], preventing rejection of allografts. But the production of IL-2 (mainly by CD4+CD25- 
T cells) is also necessary for the expansion and suppressive activity of CD4+CD25+ 
regulatory T cells [251,252]. In clinical studies, Tacrolimus levels were inversely correlated 
with T reg numbers [253] and patients under Tacrolimus treatment had lower numbers of 
circulating T regs than patients treated with Rapamycin [254]. Several studies, human or 
mouse, showed detrimental effects of Calcineurin inhibition on the generation and function of 
T regs [255-259]. On the basis of these data, it was concluded that CNI have a generally 
negative effect on regulatory T cells [260]. Yet, T regs from patients under CNI treatment 
were still capable of suppression in ex vivo cultures [257,261] and in lung transplant patients, 
the expansion of peripheral CD4+CD25+ T reg was not inhibited by CNI-based treatments 
[262]. 
  
We thus contemplated that T regs might be less susceptible to suppression by Tacrolimus in 
low doses than effector T cells. Therefore, we performed in vitro suppression assays in the 
presence of low doses of Tacrolimus to examine the in vivo observed regulation-supportive 
effect. Our in vitro data show an enhanced suppression of IFNγ expression in the presence 
of low doses of Tacrolimus in T reg suppression assays which might indicate a possible 
delayed impact on T reg function. It was described by Takada et al. that the distribution of 
Tacrolimus to the lymphatic circulation is extremely low (less than 0.2%) [263]. We can only 
speculate whether the Tacrolimus doses used in vitro (0.25 – 2 ng/ml) correspond effectively 
to the subtherapeutic Tacrolimus doses that further enhanced the allograft survival 
prolongation effect of anti-CD154 + DST in our in vivo model. Yet, under the assumption that 
they do, then the increased suppressive function of T regs is one probable reason for the 
beneficial effect of low-dose Tacrolimus on the weak tolerance inducing therapy in vivo.  
 
5.2 Breaking marginal states by disrupting regulation 
It follows from our hypothesis that in marginal states, a disturbance of either the regulation or 
the immunosuppression should tip the balance and lead to rejection of the graft. Our data 
show that by 1) withdrawing immunosuppression, 2) enhancing the effector response or 3) 
disrupting the regulatory response, allograft acceptance is abrogated.  
 
We have shown with several approaches that regulation is the basis for allograft acceptance 
in our model of marginal states under low-dose immunosuppression. As mentioned above 
the presence of regulatory T cells in transplanted animals treated with anti-CD154 + DST has 
been demonstrated by various groups and together with our in vitro data, this was the reason 
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for us to disrupt T reg mediated regulation. Yet, whilst murine T regs express CD25, 
treatment with depleting anti-CD25 antibody could not break allograft acceptance. This is 
possibly due to the fact that anti-CD25 does not specifically deplete T regs, but also activated 
effector cells that express CD25 [264].  
 
The transmembrane protein GITR is predominantly and highly expressed by T regs, yet its 
expression can be upregulated in activated CD4+ and CD8+ T cells. The suppression of 
CD4+CD25- T cells by CD4+CD25+ T regs has been shown to be dependent on GITR 
expression on the T regs [104]. Neutralisation of GITR signalling by agonistic anti-GITR 
antibody abrogated suppression in vitro and, in line with our findings, in vivo in transplant 
models [104,265]. 
 
PD-L1 and PD-1 are highly expressed on FoxP3+ T regs, but also on various other cell types 
[105]. PD-L1 blockade might thus be rather unspecific and not directly blocking regulatory T 
cells. Yet, it has been described in a cardiac transplant model that blockade of PD-L1 
promotes expansion of CD8+ and CD4+ effector cells, decreased the number of FoxP3+ T 
regs in the grafts and, as observed in our model, caused allograft rejection [266]. 
 
The depletion of regulatory CD4+ T cells in FoxP3-DTR mice by DT is highly specific, since 
FoxP3 expression is generally restricted to suppressive T cells [267]. In FoxP3-GFP-DTR 
mice, in contrast to C57BL/6 wildtype mice, allograft acceptance could not be established by 
combining anti-CD154 + DST with Tacrolimus at 75 mg/kg. This finding was unexpected, 
since the FoxP3-GFP-DTR mice were backcrossed to C57BL/6 background and the serum 
levels of Tacrolimus were comparable to wildtype C57BL/6 mice. The allograft survival curve 
of FoxP3-GFP-DTR mice treated with anti-CD154 + DST and Tacrolimus at 75 mg/kg and 
without DT-injections was similar to C57BL/6 mice treated with anti-CD154 + DST alone. 
Thus, we suspected that higher doses of immunosuppression were necessary to induce 
marginal states of allograft acceptance. Indeed, when the anti-CD154 + DST treatment in 
FoxP3-GFP-DTR mice was combined with Tacrolimus at 100 mg/kg, long-term allograft 
survival as observed in wildtype mice was induced. Depletion of T regs by DT-injections did 
abrogate allograft survival demonstrating that allograft survival in our model is dependent 
upon regulation mediated by T regs. 
 
We consider the fact that allograft acceptance in our model was abrogated by treatment with 
anti-TGFβ antibody as an indication for the involvement of induced T regs. The induction of T 
regs was described after treatment with anti-CD154 + DST [197]. TGFβ has not only been 
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shown as important for the induction of T regs but also as an inhibitor of effector T cell 
function [113,114].  
 
In line with data from Waldmann et al., we hypothesised that the regulation in our model of 
marginal states is transferrable [268]. However, classical skin transfer experiments onto T 
cell depleted mice (Rag1-/-) and subsequent reconstitution with T cells did not show 
transferrable regulation. Indeed, already before reconstitution, the balance between 
regulatory and effector response was skewed, presumably due to the loss of 
immunosuppression. Yet, our data from the dLN-cell transfer indicate that donor-specific 
regulatory T cells were present in MD-75 mice and could be transferred.  
 
Altogether, our data show that allograft acceptance under low-dose immunosuppression is 
dependent upon regulation.  
 
5.3 Collapse of marginal states 
In our experimental model of marginal states of allograft acceptance under low-dose 
Tacrolimus therapy, the balance between regulatory and effector response is skewed 
towards regulation and thus, long-term graft survival is achieved. However, whilst over 90% 
of the mice had an intact graft on day 50, rejection eventually occurred in 97% before 100 
days. This brings up the question, what causes the balance between effectors and regulators 
to tip towards rejection? Possible explanations may include:  1) (partial) loss of regulation, 2) 
increasing effector responses or 3) diminishing effect of immunosuppressive treatment.  
 
Our data comparing MD-75 mice with an intact graft on day 50 with a group of MD-75 mice 
with 50% rejecting/rejected and 50% intact surviving allografts did not show significant 
differences in the number of total FoxP3+ T regs in the dLNs. On the current evidence, it 
cannot be excluded that the number of allospecific FoxP3+ T regs was decreased, since 
allospecificity was not assessed in our system. Thus, the loss of allospecific T regs and thus 
regulation remains a possibility that could account for rejection in our model of marginal 
states. This will be tested in future experiments using MHC dexamers. 
 
Depletion of CD8+ T cells by depleting CD8-antibody [194] or DST [195,203] has been 
reported as necessary for the induction of long-term allograft survival in the skin transplant 
model. But in the stringent B/c-to-B/6-skin transplant model, CD8+ T cell depletion by 
combination of anti-CD154 + DST alone does not prevent rejection [195]. Also in our model 
of marginal states under low-dose immunosuppression, rejection occurs eventually. We 
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could show that thymectomy in adult mice prior to the induction therapy with anti-CD154 + 
DST + Tac-75 and allotransplantation significantly delayed rejection. This is in line with the 
findings of Rossini and colleagues, who have reported over 80% graft survival at d250 in 
thymectomised mice treated with anti-CD154 + DST without additional immunosuppression 
[198]. Thus our data are consistent with the conclusion that recent thymic CD8+ emigrants 
are responsible for late rejection in this model. In the group of MD-75 mice with 50% 
rejecting/rejected and 50% intact surviving allografts, the percentage of CD8+ T cells in the 
dLNs was significantly increased compared to MD-75 mice on d50. Together, these data 
indicate that recent CD8+ thymic emigrants enhancing the effector response might precipitate 
allograft rejection in our model of marginal states. One possibility to further examine this 
hypothesis would be to deplete CD8+ T cells on d50, which should lead to enhanced 
prolongation of the allograft survival.  
 
Iwakoshi et al. demonstrated that decline of anti-CD154 antibody in a transgenic 
costimulatory/DST – model in combination with increased numbers of alloreactive CD8+ T 
cells correlates with rejection. Specifically, they showed that anti-CD154 concentrations 
below 50 µg/ml could not prevent generation of T cell-responses in C57BL/6 mice and in 
transplanted transgenic CBA mice, this threshold level correlated with the initiation of 
rejection on d50 [269]. Yet, about 50% of those mice kept their graft for another 100 days. In 
the light of successful induction of indefinite allograft acceptance with anti-CD154, as 
mentioned above, it remains unclear whether the persistence of costimulatory blockade 
really is required for the maintenance of regulation and thus graft acceptance. We think it is 
possible that the decline of the anti-CD154 antibody means that CD4+ T cells receive 
adequate costimulation and that these activated CD4+ T cells provide critical help for CD8+ 
effector T cell responses.  
 
There is evidence for all three described mechanisms to contribute to the collapse of 
marginal states of allograft acceptance. Further work needs to be done to clarify the potential 
collaborative involvement to ultimately target these mechanisms in order to prevent late 
rejection in marginal states.  
 
A question that remains is whether the rejection that occurs in mice treated with anti-CD154 
+ DST + low-dose Tacrolimus is purely antigen-specific. In our model of marginal states 
characterised by the balance between effector and regulatory response, one can imagine 
that minor inflammatory conditions might add up to the effector response and thus tipping the 
balance and causing rejection. Mechanisms that could account for non-alloreactive 
fortification of the effector pool are bystander activation and heterologous immunity.  
 Discussion  103 
Bystander activation of T cells describes the TCR-independent, non-antigen specific 
activation of T cell responses by cytokines during an antigen-specific immune response     
[270]. Heterologous immunity refers to the reactivation of memory T cells generated during 
an earlier immune response by a second, unrelated immunogenic stimulus [271]. Here, the 
TCR of memory cells against antigen A cross-reactively recognizes an epitope of antigen B 
that is shared with antigen A or structurally similar to epitopes from antigen A.  
 
Bacterial infection with Listeria monocytogenes has been described to break allograft survival 
induced by anti-CD154 + DST in a murine cardiac transplant model due to IL-6 and IFNβ 
production [272]. In an allogeneic skin transplant model with anti-CD154 + DST treatment, 
infection with lymphocytic choriomeningitis virus abrogated allograft survival in contrast to 
syngraft survival [273]. However, the contribution of both bystander activation and 
heterologous immunity to the late rejection observed in our model remains speculative, since 
we did not perform any infection experiments to precipitate rejection. The animal husbandry 
during the experiments does not exclude the possibility of infections, as suggested by the 
finding of inclusion bodies in 150 mg/kg sentinel mice.  
 
5.4 Boost of marginal states 
We observed in our model that the balance between the effector and regulatory response 
tipped and skewed towards rejection. In order to boost the regulatory response, we treated 
mice after 50 days with a second round of induction therapy under withdrawal of Tacrolimus 
and thus achieved delayed allograft rejection. These data show that it is also possible to tip 
the balance towards stronger regulation and possibly eventually tolerance (i.e. allograft 
acceptance without immunosuppression). Data from a rat kidney transplant model shows 
that short-term low-dose CNI treatment in combination with the single administration of 
regulatory T cells could replace permanent immunosuppression by reducing circulating 
memory T cells [274]. The application of T reg or M reg in our skin transplant model is a 
promising approach to boost the regulation in marginal states to long-term allograft 
acceptance without immunosuppression, i.e. true tolerance.  
 
The feasibility to boost the regulatory response in marginal states is of importance with 
regard to the clinical situation, where there might be already patients under 
immunosuppression with regulatory responses just not sufficient to prevent rejection. If this 
regulation could be enforced, then operational tolerance seems an achievable goal.   
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6 Conclusion & Perspectives 
The objective of our project was to prove that marginal states of allograft acceptance exist. 
Therefore, we established a model combining weak regulation with low-dose Tacrolimus to 
achieve significantly prolonged allograft survival. Importantly, neither the low dose 
Tacrolimus therapy nor the weak regulation alone led to such a prolonged allograft survival. 
We proved our hypotheses that marginal states can be disrupted by withdrawing the 
immunosuppression, enhancing the effector response or disturbing the regulatory response, 
thus posing the following questions:  What information do we gain from the experimental 
model of marginal states in regard to clinical situations? Are these marginal states under low-
doses of CNI – immunosuppression desirable?  
 
With caution, we think that marginal states under low-doses of CNI – immunosuppression 
are desirable in the clinical situation. For the deliberate induction, it must be ensured that the 
balance will not be skewed towards rejection. Therefore, the underlying immune responses 
have to be identified, monitored and antagonised if necessary. Additionally, it must be kept in 
mind that any safe reduction of immunosuppression is of great benefit to the patient, if thus 
the adverse effects can be minimised and chronic allograft damage can be delayed or 
avoided. Importantly, the achievement of marginal states of allograft acceptance may be a 
potentially meaningful result of tolerance-inducing therapies and seems more immediately 
achievable than full operational tolerance. With regard to clinical therapy, it might be 
beneficial to use inductive prime-boost strategies in combination with low doses of 
immunosuppression which then will be extended to post-operative tolerance-promoting 
therapies. The idea to boost regulation at a later time point would be a novel therapeutic 
approach in the field of transplantation.  
 
The model system established in this thesis gives not only formal proof for the existence of 
marginal states of allograft acceptance, it further provides a foundation for: 1) determining 
biomarkers that reflect immunological regulation under immunosuppression, 2) 
understanding underlying immunological mechanisms of marginal states, 3) testing new 
therapeutic strategies that favour the induction of immune regulation, 4) understanding 
mechanisms of rejection in marginal states in order to antagonise them or 5) developing 
strategies to boost the regulatory response. 
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Figure 58 Immunohistochemical FoxP3 staining p. 90 
Figure 59 Myeloid cell analysis in skin grafts I p. 91 
Figure 60 Myeloid cell analysis in skin grafts II p. 91 
Figure 61 Myeloid cell analysis in skin grafts III p. 92 
Figure 62 Expression profile of Population 1 and 3 p. 93 
Figure 63 Ratio of Population 1 and 3 p. 93 
Figure 64 Analysis of CD4+ and CD8+ T cells in dLNs in MD-75 group with 50% 
rejection 
p. 94 
Figure 65 Analysis of dLNs in MD-75 group with 50% rejection p. 95 
Figure 66 Thymectomy before induction therapy p. 95 
Figure 67 Boost of marginal states p. 96 
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8.2 Supplementary figure 
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Supplementary figure I: Panel Gating strategy  
 Appendix  123 
8.3 Abbreviations 
 
°C Degree Celsius 
µ Micro 
µg Microgram 
µl Microliter 
ACK Ammonium-Chloride-Potassium 
ADCC Antibody dependent cellular toxicity 
Ag Antigen 
aH Armenian Hamster 
ANOVA Analysis of variance 
AP-1 Activator protein 1 
APC Antigen presenting cell 
APC Allophycocyanine 
APC-Cy7 Allophycocyanine-cyanine 7 
AUC Area under the curve 
BD Becton, Dickinson and Company 
BKV BK-virus 
BM Bone marrow 
BMDC Bone marrow derived cell 
BSA Bovine serum albumine 
c0 Trough level 
Ca2+ Calcium 
CCL Chemokine ligand 
CCR Chemokine receptor 
CD Cluster of differentiation 
CD40L CD40 ligand 
CFDA-SE Carboxyfluorescein diacetate N-succinimidyl ester 
CFSE Carboxyfluorescein succinimidyl ester 
cmax Maximum concentration  
cmin Minimum concentration 
CMV Cytomegalovirus 
CN Calcineurin 
d Day 
DAG Diacylglycerol kinase  
DC Dendritic cell 
dDC Donor-DC 
ddH2O Double-distilled water 
dil. Dilution 
dLN Draining LN 
DN Double negative 
DNA Desoxyribonucleic acid 
DST Donor-specific transfusion 
DT Diphtheria toxin 
DTH Delayed type hypersensitivity 
DTR Diphtheria toxin receptor 
e.g. Exempli gratia (for example) 
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EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
ERK Extracellular signal-regulated kinases 
et al. Et aliae (and others) 
EtOH Ethanol 
FACS Fluorescence activated cell sorting 
Fc Fragment crystallisable 
FCS Fetal calf serum 
FcγRIIA/C Fc-gamma-receptor II A/C 
Fig. Figure 
FITC Fluorescein isothiocyanate 
FK-506 Tacrolimus  
FKBP FK506 binding protein 
FoxP3 Forkhead box P3 
g Gram 
GFP Green fluorescent protein 
GITR Glucocorticoid-induced TNFR family related gene 
GM-CSF Granulocyte / macrophage colony-stimulating factor 
G-SCF Granulocyte-colony stimulating factor 
GVHD Graft-versus-host disease 
h Hour 
H&E Haematoxilin & Eosin 
HLA Human leukocyte antigen 
i.e. Id est (that is) 
i.p. Intraperitoneally 
i.v. Intravenously 
IFN Interferon 
Ig Immunoglobulin 
IL Interleukin 
IL-R Interleukin-receptor 
JAK Janus kinase 
JCV JC-virus 
k Kilo 
kg Kilogram 
l Liter 
Lck Lymphocyte-specific protein tyrosine kinase 
LD50 Lethal dose, 50% 
LN Lymph node 
Ly6C Lymphocyte antigen 6 C 
Ly6G Lymphocyte antigen 6 G 
m Milli 
m Meter 
M Molar 
M reg Regulatory Macrophage 
MACS Magnetic cell separation 
MAPK Mitogen-activated protein kinase 
MD-100 Treatment: anti-CD154 + DST + 100 mg/kg Tacrolimus 
MD-75 Treatment: anti-CD154 + DST + 75 mg/kg Tacrolimus 
MDSC Myeloid-derived suppressor cell 
mg Milligram 
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MHC Major Histocompatibility Complex 
min Minute 
ml Milliliter 
mRNA Messenger ribonucleic acid 
MST Mean survival time 
n Number 
n Nano 
ND Not determined 
NF-AT Nuclear factor of activated T cells 
NF-Atc Nuclear factor of activated T cells, cytosolic 
NF-Atn Nuclear factor of activated T cells, nuclear 
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B 
ng Nanogram 
NK Natural killer 
ns Not significant 
OD Optical density 
PBS Phosphate buffered saline 
PCR Polymerase-chain reaction 
PD Programmed death 
PD-L1 Programmed death-ligand 1 
PE Phycoerythrin 
PE-Cy 7 Phycoerythrin-cyanine 7 
PerCP Peridinin-chlorophyll-protein complex 
PerCP-
Cy5.5 Peridinin-chlorophyll-protein complex-cyanine 5.5 
pg Picogram 
PI3K Phosphatidylinositol 3-kinases 
PKC Proteine kinase C 
PLCγ Phospholipase C[gamma] 
qPCR Quantitative real-time PCR 
QT Quantitect 
R&D Reserach & diagnostics 
RA Retinoic acid 
RAG Recombination activation gene 
rcf Relative centrifugal force 
rDC Recipient-DC 
RNA Ribonucleic acid 
ROS Reactive oxgen species 
rpm Rounds per minute 
RPMI Roswell Park Memorial Institute 
RT Room temperature 
RT-PCR Real-time PCR 
SD Standard deviation 
SEM Standard error of the mean 
sH Syrian hamster 
STAT Signal transducers and activators of transcription 
SV-40 Simian virus 40 
T reg Regulatory T cell 
Tac Tacrolimus  
TBS Tris-buffered saline 
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TCR T cell receptor 
TGFβ  Transforming growth factor β  
Th T helper 
TNF Tumour necrosis factor 
Ts Suppressor T cell 
T-TBS TBS supplemented with 0.5 % (v/v) Triton-X 100 
USA United States of America 
v/v Volume/volume 
w/v Weight/volume 
ZAP70 Zeta-chain-associated protein kinase 70 
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